
From: sharyn.albrecht@tevausa.com
To: alisa.capreri@tevausa.com; anne.payne@tevausa.com; bonnie.canova@tevausa.com; bryan.bart@tevausa.com; christine.baeder@tevausa.com; cynthia.prediger@tevausa.com; darren.alkins@tevausa.com; dave_rekenthaler@ivax.com; david.lustig@teva.co.il; david.marshall@tevausa.com; elizabeth.stewart@tevausa.com; eyal.arieli@teva.co.il; fred.andrush@tevausa.com; gene.cioschi@tevausa.com; george.morabito@tevausa.com; gilad.shadur@teva.co.il; jeffrey.sipia@tevausa.com; jennifer.king@tevausa.com; joe.grotzinger@tevausa.com; john.blanke@tevausa.com; john.denman@tevausa.com; kevin.galownia@tevausa.com; kevin.green@tevausa.com; lance.kann@teva.co.il; madalen.renner@tevausa.com; maureen.cavanaugh@tevausa.com; menachem.weinberger@teva.co.il; michael.burton@tevausa.com; michael.altman@tevausa.com; mike.bondiskey@tevausa.com; nati.ahronov@teva.co.il; robert.hunsinger@tevausa.com; sara.barbera@tevausa.com; sarah.dougherty@tevausa.com; steve.denicola@tevausa.com; wayne.pusillo@tevausa.com; william.marth@tevausa.com; yatindra.joshi@tevausa.com; vanda.mosberg@tevausa.com
Sent: 11/18/2008 9:56:44 PM
Subject: NPA Market Share Report MAT 9-2008
Attachments: _; NPA Market Share Report MAT 9-08.pdf

Attached below is the Teva Market Share Report for MAT 9-2008.

Please keep in mind that the report is being distributed electronically and hard copies are no longer produced. If you prefer, you can print a hard copy of the report; however, keep in mind that this is a confidential report and it should not be copied and/or distributed. In addition, all of the Market Share Reports are available on the Market Research Website. Feel free to contact me if you have any questions.



NPA Market Share Report MAT 9-08.pdf

Sharyn Albrecht
Market Research Specialist
Market Research & Analysis
215-591-3004

PLAINTIFFS TRIAL
EXHIBIT
P-27980



TEVA PHARMACEUTICALS USA

INTER-OFFICE MEMORANDUM

Date: November 18, 2008
To: NAMS
From: John Denman
Subject: MARKET SHARE REPORT

You are being sent a Teva USA Market Share Report. This report is generated by Anne Payne and the Teva Market Research Department for internal support and your reference.

The Teva USA Market Share Reports are confidential internal reports and are not to be shared with anyone outside of Teva USA.

I am sure you will understand and respect the confidential nature of this information.

Regards,

John Denman
JD/vm



INTER-OFFICE MEMORANDUM

TEVA PHARMACEUTICALS USA

DATE: November 18, 2008 **COPIES TO:**
TO: Market Share Report Distribution List
FROM: Sharyn Albrecht
SUBJECT: September 2008 Market Share Data

Enclosed please find the September 2008 Market Share Reports. Please note the following:

- The reports for Cefadroxil Tablets, Cephalexin Tablets and Tetracycline Capsules reflect Teva as a generic competitor even though Teva is the RLD in the Orange Book.
- To give a more accurate report of newly launched products, weekly data was used for any product that was launched in 3Q2008. The weekly reports are located under a separate tab at the back of the report and reflect absolute numbers. The products that are reported using weekly data are: Divalproex Sodium Delayed-Release Tablets, Doxycycline for Oral Suspension and Lamotrigine Tablets. These three products are not included in the summary reports at the front of the Market Share Report.
- Due to low prescription volume, the following market is shown in absolute numbers: Megestrol Acetate Tablets.

Please call me at x3004 with any questions.

TRx Market Shares - IMS National Prescription Audit
MAT September 2008

257 Total Product Groups (by form including all strengths)*

# of Products Ranked	1st	2nd	3rd	Other
September 2008	119	62	38	38
June 2008	118	60	38	38
March 2008	112	66	36	40
December 2007	109	68	33	43

% of Products Ranked	1st	2nd	3rd	Other
September 2008	46.3%	24.1%	14.8%	14.8%
June 2008	46.5%	23.6%	15.0%	15.0%
March 2008	44.1%	26.0%	14.2%	15.7%
December 2007	43.1%	26.9%	13.0%	17.0%

*Not including new products reflecting weekly data (in market less than 3 months).



TEVA USA Product Growth - Top 10 Products in Market Over 24 Months

**NRx & TRx Market Shares - IMS National Prescription Audit (NPA) (including Mail Order)
MAT September 2008**

Evolution Index = $(1 + \text{Company Growth}) / (1 + \text{Total Market Growth})$

Product	Form	Strength(s)	TRx MAT Chg %	Evolut Index	TRx MAT (000s)	NRx MAT (000s)
Moexipril HCl	TAB	7.5 mg, 15 mg	+815.7	11.5	50	13
Trazodone HCl	TAB	50 mg, 100 mg	+713.4	7.9	893	373
Quinapril HCl	TAB	5 mg, 10 mg, 20 mg, 40 mg	+572.0	7.6	545	266
Sulfamethoxazole/Trimethoprim Susp	LIQ	200/40 mg/5ml	+342.3	4.1	388	350
Lorazepam	TAB	0.5 mg, 1 mg, 2 mg	+321.7	4.1	10	6
Hydrochlorothiazide	CAP	12.5 mg	+152.5	2.4	51	17
Clomipramine HCl	CAP	25 mg, 50 mg, 75 mg	+123.3	2.3	115	58
Indomethacin	CAP	25 mg, 50 mg	+118.1	2.2	258	174
Buspirone HCl	TAB	5 mg, 10 mg, 15 mg, 30 mg	+87.1	1.8	1,036	501
Cromolyn Sodium	OPHTH	4 %	+84.7	1.7	63	44

Notes:

Moexipril HCl - Picked up CVS.

Trazodone HCl - Picked up ESI and Omnicare.

Quinapril HCl - Picked up Walgreens.

Sulfamethoxazole/Trimethoprim Susp - Picked up CVS and RiteAid.

Lorazepam - Increase due to no customers in 2006. Sold to Cardinal, Kinray, Schnuck's and Quest in 2007. Sales in 2008 through September are only to Schnuck's.

Hydrochlorothiazide - Product was on backorder from December 2006 until April 2007, no sales during that period. Sales picked back up in May 2007.

Clomipramine HCl - Picked up Walgreens.

Indomethacin - Increase is due to the re-introduction of the Emcure product.

Buspirone HCl - Picked up WalMart, RiteAid, CVS, OneStop and ProGen.

Cromolyn Sodium - Picked up CVS, OneStop and ProGen.

TEVA USA Product Growth - Bottom 10 Products in Market Over 24 Months



NRx & TRx Market Shares - IMS National Prescription Audit (NPA) (including Mail Order) MAT September 2008

Evolution Index = (1 + Company Growth) / (1 + Total Market Growth)

Product	Form	Strength(s)	TRx MAT Chg %	Evolut Index	TRx MAT (000s)	NRx MAT (000s)
Omeprazole	MR CAP	10 mg, 20 mg	-97.0	0.0	95	33
Clobetasol Propionate	OINT	0.05 %	-92.7	0.1	3	2
Ethinyl Estradiol/Norgestimate/Norgestimate/Norge	TAB	0.035/0.18/0.215/0.25 mg	-85.2	0.2	74	19
Diclofenac Potassium	TAB	50 mg	-84.8	0.2	34	21
Ethinyl Estradiol/Norgestimate	TAB	0.035/0.25 mg	-84.6	0.2	17	4
Clobetasol Propionate	CRM	0.05 %	-82.3	0.2	39	29
Oxaprozin	TAB	600 mg	-74.8	0.3	27	11
Mercaptopurine	TAB	50 mg	-68.9	0.3	10	3
Albuterol Sulfate	INH SOL	0.5 %	-67.7	0.4	1	1
Clindamycin HCl	CAP	300 mg	-63.9	0.3	51	49

Notes:

Omeprazole - Teva had to leave the market temporarily and lost share as a result.

Clobetasol Propionate - Gave up RiteAid. Product is to be deleted.

Ethinyl Estradiol/Norgestimate/Norgestimate/Norgestimate - Gave up main customer, Brooks-Eckerd.

Diclofenac Potassium - Gave up RiteAid, Kroger, CVS, Cardinal, WalMart and Walgreens.

Ethinyl Estradiol/Norgestimate - Gave up main customer, Brooks-Eckerd.

Clobetasol Propionate - Gave up RiteAid, Walgreens and smaller accounts purchasing via wholesalers.

Oxaprozin - Lost RiteAid, CVS and Caremark awards.

Mercaptopurine - Gave up RiteAid.

Albuterol Sulfate - Gave up smaller customers purchasing via wholesalers.

Clindamycin HCl - Gave up RiteAid.

Top 20 Products by TRx



TRx Market Shares - IMS National Prescription Audit (NPA)
MAT September 2008

Rank	Product	Form	Strength(s)	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	TRx Mkt Share %	Evolution Index
1	Simvastatin	TAB	5 mg,10 mg, 20 mg, 40 mg, 80 mg	9,494	+18.6	27,620	+22.3	31.5	0.9
2	Hydrochlorothiazide	TAB	25 mg, 50 mg	7,808	+18.2	24,171	+29.7	64.8	1.3
3	Amoxicillin	CAP	250 mg, 500 mg	18,516	+3.7	19,804	+2.5	75.2	1.1
4	Metformin HCl	TAB	500 mg, 850 mg,1000 mg	5,704	-2.8	15,978	+1.8	38.4	1.0
5	Azithromycin	TAB	Tri-Pak 500 mg, Z-Pak 250 mg,250 mg, 500 mg, 600 mg	14,687	+6.4	15,197	+6.3	39.5	1.0
6	Cephalexin	CAP	250 mg, 500 mg	14,220	+0.3	14,936	+0.2	81.9	1.1
7	Lisinopril	TAB	2.5 mg, 5 mg,10 mg, 20 mg, 30 mg, 40 mg	4,416	-13.6	14,115	-14.2	19.6	0.8
8	Zolpidem Tartrate	TAB	5 mg,10 mg	6,671	+159.4	11,927	+199.1	42.2	2.4
9	Sertraline HCl	TAB	25 mg, 50 mg,100 mg	4,397	-10.5	11,299	-8.2	33.3	0.9
10	Clonazepam	TAB	0.5 mg, 1 mg, 2 mg	6,266	+13.7	10,921	+13.0	51.4	1.1
11	Acetaminophen/Codeine Phosphate	TAB	300mg/15 mg, 300mg/30 mg, 300mg/60 mg	8,718	-1.9	10,213	-2.0	80.4	1.0
12	Amlodipine Besylate/Benazepril HCl	CAP	2.5/10 mg, 5/10 mg, 5/20 mg,10/20 mg	2,949	+106.7	9,417	+186.4	76.9	3.1
13	Furosemide	TAB	20 mg, 40 mg	3,113	-6.4	8,168	-10.7	20.0	0.9
14	Atenolol	TAB	25 mg, 50 mg,100 mg	2,213	+55.4	7,520	+49.6	18.8	1.6
15	Amoxicillin	POS	125/5 mg/ml, 250/5 mg/ml	7,275	-6.6	7,404	-6.8	84.5	1.0
16	Gabapentin	CAP	100 mg, 300 mg, 400 mg	3,306	+11.1	7,061	+11.7	46.5	1.0
17	Fluconazole	TAB	50 mg,100 mg, 150 mg, 200 mg	5,744	+5.5	6,898	+5.0	55.7	1.0
18	Amoxicillin	POS	200/5 mg/ml, 400/5 mg/ml	6,764	+11.9	6,808	+11.8	68.5	1.1
19	Fluoxetine HCl	CAP	10 mg, 20 mg, 40 mg	2,739	-15.2	6,698	-12.4	31.6	0.9
20	Naproxen	TAB	250 mg, 375 mg, 500 mg	4,485	+11.0	6,604	+11.4	47.4	1.1

Evolution Index = (1 + Company Growth) / (1 + Total Market Growth)

IMS Health NPA data for 2008-Q3

TEVA USA Confidential - Do NOT Distribute

2008-11-12

TEVA USA TRx MARKET SHARE SUMMARY

IMS National Prescription Audit

September 2008

257 Total Product Groups

	TRx Q3/2008	TRx Q2/2008	TRx Variance	% CHG
Total Market (Brand & Generic)	373,990	374,984	-995	-0.30%
Generic Market (Generics Only)	364,698	360,399	4,299	1.19%
TEVA PHARMACEUTICA	113,223	112,471	752	0.67%

	TRx Q3/2008	TRx Q3/2007	TRx Variance	% CHG
Total Market (Brand & Generic)	373,990	361,827	12,163	3.36%
Generic Market (Generics Only)	364,698	333,778	30,920	9.26%
TEVA PHARMACEUTICA	113,223	104,114	9,110	8.75%

	TRx MAT 9/2008	TRx MAT 9/2007	TRx Variance	% CHG
Total Market (Brand & Generic)	1,513,786	1,470,431	43,355	2.95%
Generic Market (Generics Only)	1,446,519	1,297,570	148,949	11.48%
TEVA PHARMACEUTICA	452,705	418,847	33,858	8.08%

TEVA USA Market Share Data
Summary - Sept. 2008

CONFIDENTIAL - DO NOT DISTRIBUTE

11/12/2008



Teva Market Share Position (including Teva)

Date: 11/13/2008

Number and Percent of Products that are \geq 20%, 30% and 50%

Reporting Period: 2008-Q3

Number of Teva products that are equal to and greater than 20%, 30% and 50%.

# of Total Products	# of Products \geq 20%	# of Products \geq 30%	# of Products \geq 50%	# of All Other Products
257	182	149	88	75

Percent of Teva products that are equal to and greater than 20%, 30% and 50%.

% of Total Products	% of Products \geq 20%	% of Products \geq 30%	% of Products \geq 50%	% of All Other Products
100.0%	70.8%	58.0%	34.2%	29.2%



Teva Leadership Index (including Teva)

2008-11-13

Average Number of Players Within Teva's Markets

Reporting Period: 2008-Q3

Average Number of Players Within Teva's Markets

Total # of Products	Total # of Competitors	Average # of Competitors
257	148	6.8



Teva Leadership Index (including Teva)
Average Number of Players within Teva's Market Forms
Reporting Period: 2008-Q3

Date: 11/13/2008

Product Form	# of Products	Avg # of Competitors
ORAL SOLIDS	210	7.3
CAP	42	5.5
CHEW	5	2.8
GELCAP	1	5.0
MR CAP	2	8.0
MR TAB	16	5.3
ODT	2	7.0
TAB	142	8.3
SYSTEMIC ALL OTHERS	2	4.0
INH SOL BFS	2	4.0
SYSTEMIC ORAL LIQUID	24	5.2
LIQ	16	4.9
POS	8	5.9
TOPICAL DERMATOLOGICALS	17	4.3
CRM	5	4.0
GEL	1	4.0
LIQ	1	3.0
LOT	2	2.5
OINT	4	5.0
TOP	4	5.3
TOPICAL OPHTHALMIC	1	5.0
OPHTH	1	5.0
TOPICAL RECTAL	2	3.5
REC	2	3.5
TOPICAL UROLOGICAL	1	4.0
TOP	1	4.0



Teva Leadership Index (including Teva)
Average Number of Players Within All Generic Markets

2008-11-13

Reporting Period: 2008-Q3

Average Number of Players Within All Generic Markets

Total # of Products	Total # of Competitors	Average # of Competitors
913	276	4.6

Acetaminophen/Butalbital/Caffeine (Esgic Plus)
TAB, 500/50/40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	262	-6.5	450	-6.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	255	-6.1	435	-5.5												
1 WEST WARD	139	-0.8	244	-0.0	57.3	56.8	57.1	57.0	55.9	56.6	55.5	55.3	55.8	55.7	55.9	55.2
2 QUALITEST PRODUCTS	116	-11.2	189	-11.1	42.3	42.8	42.5	42.6	43.7	42.9	44.1	44.4	43.7	43.8	43.7	44.3
3 TEVA PHARMACEUT	0	-22.3	1	-29.8	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
4 INWOOD LABS	0	-60.5	1	-52.6	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.2	0.2	0.2	0.2
Brand	7	-20.2	14	-21.2												
1 FOREST PHARM	7	-20.2	14	-21.2	3.0	3.1	3.1	3.3	3.1	3.2	3.2	3.1	3.2	3.4	3.3	3.3
Generic Substitution %	97.5		96.8		97.0	96.9	96.9	96.7	96.9	96.8	96.8	96.9	96.8	96.6	96.7	96.7

Acetaminophen/Butalbital/Caffeine (Fioricet)
 TAB, 325mg/50mg/40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,162	+4.3	5,023	+3.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,083	+4.9	4,861	+3.8												
1 QUALITEST PRODUCTS	1,447	+14.5	2,161	+14.2	44.4	44.4	44.6	44.6	44.8	44.6	44.8	44.6	44.2	44.3	44.2	44.1
2 MIKART INC	608	+3.4	954	+2.9	19.6	19.6	19.8	19.5	19.5	19.6	19.5	19.7	19.4	19.6	19.8	19.8
3 WEST WARD	457	+8.9	809	+6.9	16.4	16.4	16.3	16.6	16.6	17.0	16.9	16.8	16.8	16.5	16.5	16.7
4 WATSON LABS	256	+3.9	442	+3.0	9.4	9.4	9.4	9.3	9.1	8.8	8.6	8.5	9.0	9.1	9.1	9.3
5 TEVA PHARMACEUT	279	-27.0	430	-28.8	8.6	8.7	8.5	8.6	8.7	8.8	8.9	9.2	9.2	9.1	9.1	8.8
6 MALLINCKRODT	24	+1.9	42	-1.3	1.1	1.1	1.0	0.9	0.8	0.8	0.7	0.8	0.7	0.7	0.7	0.8
7 MAJOR PHARM	8	-18.6	13	-13.9	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.4	0.4
8 FOREST PHARM	2	-15.9	5	-17.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
9 URL PHARMA	2	-37.4	3	-33.8	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10 EVERETT LABS	0	-17.2	1	-18.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	78	-14.2	162	-14.0												
1 WATSON LABS	78	-14.2	162	-14.0	3.0	3.2	3.2	3.3	3.3	3.2	3.1	3.1	3.1	3.5	3.4	3.4
Generic Substitution %	97.5		96.8		97.0	96.8	96.8	96.7	96.7	96.8	96.9	96.9	96.9	96.5	96.6	96.6

Acetaminophen/Codeine Phosphate ()
 TAB, 300mg/15 mg, 300mg/30 mg, 300mg/60 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	10,773	-5.0	12,868	-5.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	10,705	-4.9	12,764	-5.3												
1 TEVA PHARMACEUT	8,718	-1.9	10,213	-2.0	80.4	80.3	80.3	80.4	80.2	80.2	80.2	80.1	79.7	79.7	79.6	79.1
2 MALLINCKRODT	1,222	+7.4	1,569	+6.7	12.3	12.4	12.3	12.3	12.4	12.3	12.0	12.1	12.3	12.3	12.3	12.4
3 RANBAXY PHARM	416	-53.3	556	-51.9	3.2	3.6	3.9	4.0	4.0	4.2	4.3	4.5	4.7	4.9	5.2	5.7
4 QUALITEST PRODUCTS	218	+32.3	259	+32.1	2.7	2.4	2.2	2.1	2.1	2.0	2.0	2.0	1.9	1.8	1.7	1.7
5 BARR LABS	75	-21.7	95	-23.6	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.7	0.8	0.8
6 COREPHARMA	13	--	15	--	0.3	0.3	0.3	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
7 WATSON LABS	34	-23.8	44	-23.5	0.2	0.2	0.2	0.3	0.3	0.5	0.5	0.5	0.5	0.4	0.3	0.2
8 ACTAVIS	8	-75.8	10	-77.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
9 UNIT DOSE LABS	1	-38.9	2	-29.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	68	-23.3	103	-22.7												
1 MCNEIL PHARM	68	-23.3	103	-22.7	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9
Generic Substitution %	99.4		99.2		99.3	99.3	99.2	99.2	99.2	99.2	99.2	99.2	99.2	99.1	99.1	99.1

**Acetaminophen/Propoxyphene Napsylate (Darvocet-N)
TAB, 650/100 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	15,854	-3.6	21,504	-3.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	15,730	-3.4	21,309	-3.7												
1 QUALITEST PRODUCTS	9,028	+7.7	11,975	+7.5	54.4	54.5	54.6	54.7	55.6	55.9	56.2	56.5	57.0	56.9	57.6	59.9
2 TEVA PHARMACEUT	4,005	-11.8	5,409	-12.3	25.2	25.1	25.2	25.3	25.2	25.3	25.4	25.6	25.6	25.5	25.5	25.5
3 MALLINCKRODT	1,867	-11.0	2,598	-9.9	14.6	14.5	14.3	14.0	13.2	12.8	12.4	11.7	10.9	10.8	10.2	7.7
4 MYLAN	825	-34.6	1,319	-31.5	5.7	5.9	5.9	6.0	6.0	5.9	6.0	6.1	6.4	6.7	6.7	6.9
5 UNIT DOSE LABS	3	-26.4	5	-21.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
6 ABLE LABS	1	-67.6	1	-70.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
7 MCKESSON PKG SERV	0	-40.3	1	-39.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	124	-22.0	195	-21.2												
1 XANODYNE PHARMA	124	-22.0	195	-21.2	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
Generic Substitution %	99.2		99.1		99.2	99.1	99.1	99.1	99.1	99.1	99.1	99.1	99.1	99.0	99.0	99.0

Acetaminophen/Tramadol (Ultracet)
TAB, 37.5/325 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,176	-16.3	3,501	-15.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,136	-15.8	3,415	-14.3												
1 CARACO PHARM	1,050	+33.2	1,617	+39.0	42.8	44.9	46.4	46.5	46.9	47.7	48.9	49.9	49.2	48.6	48.4	47.7
2 TEVA PHARMACEUT	586	+12.3	988	+17.0	37.1	34.9	33.1	32.8	32.2	29.6	27.2	25.8	25.2	24.6	23.5	23.5
3 PAR PHARM	500	-59.2	809	-59.1	20.1	20.2	20.5	20.7	20.9	22.6	23.9	24.3	25.7	26.8	28.1	28.8
Brand	40	-38.0	87	-35.9												
1 MCNEIL PHARM	40	-38.0	87	-35.9	2.2	2.2	2.3	2.3	2.4	2.4	2.4	2.5	2.6	2.8	2.8	2.8
Generic Substitution %	98.2		97.5		97.8	97.8	97.7	97.7	97.6	97.6	97.6	97.5	97.4	97.2	97.2	97.2

Gain in Share: Picked up part of CVS/Caremark volume and Medco.

Acyclovir (Zovirax)
CAP, 200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	526	-2.3	1,001	-1.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	524	-2.1	995	-1.7												
1 TEVA PHARMACEUT	326	+4.9	612	+6.7	62.1	61.7	61.6	61.4	61.5	61.9	62.6	62.6	61.2	60.7	60.5	59.5
2 RANBAXY PHARM	64	+238.5	119	+211.9	20.7	20.4	20.0	19.4	18.2	15.2	11.3	6.4	3.7	3.5	3.3	3.4
3 WATSON LABS	105	-24.0	209	-23.0	10.7	11.3	12.0	13.0	14.7	17.7	21.4	26.4	30.4	30.9	30.6	30.6
4 APOTEX CORP	16	-55.3	32	-54.8	4.5	4.5	4.4	4.1	3.5	3.1	2.6	2.1	1.9	2.2	2.7	3.7
5 PAR PHARM	11	-61.6	22	-60.6	1.9	2.0	1.9	2.0	2.0	2.0	2.0	2.3	2.6	2.6	2.7	2.6
6 DAVA PHARM	0	-55.1	1	-56.1	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	2	-29.4	6	-27.6												
1 GSK PHARM	2	-29.4	6	-27.6	0.6	0.5	0.5	0.6	0.5	0.5	0.5	0.5	0.6	0.7	0.6	0.6
Generic Substitution %	99.6		99.4		99.4	99.5	99.5	99.4	99.5	99.5	99.5	99.5	99.4	99.3	99.4	99.4

Acyclovir (Zovirax)
 TAB, 400 mg, 800 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,277	+12.4	4,037	+10.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,274	+12.5	4,029	+10.1												
1 TEVA PHARMACEUT	1,406	+16.5	2,426	+13.1	60.6	60.6	60.5	60.2	60.1	60.0	61.2	61.3	60.0	59.5	59.3	59.2
2 RANBAXY PHARM	278	+352.4	497	+335.8	21.1	21.0	20.6	20.3	19.1	16.7	12.6	6.0	2.6	2.5	2.6	2.6
3 WATSON LABS	396	-21.5	749	-20.4	9.3	9.5	9.8	10.4	11.4	13.5	17.3	24.7	29.4	29.5	29.6	29.4
4 APOTEX CORP	140	-13.9	258	-14.2	7.0	6.8	6.8	6.7	7.1	7.6	6.7	5.5	5.2	5.7	5.7	5.8
5 PAR PHARM	50	-34.9	92	-34.1	2.0	2.1	2.2	2.2	2.2	2.0	2.1	2.3	2.6	2.6	2.6	2.7
6 DAVA PHARM	1	-53.1	2	-54.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1
7 MYLAN	1	-55.5	1	-58.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
8 ACTAVIS	1	-77.7	1	-81.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1
Brand	3	-23.8	8	-23.7												
1 GSK PHARM	3	-23.8	8	-23.7	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Generic Substitution %	99.9		99.8		99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8

Albuterol Sulfate (Proventil)
LIQ, 2 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,217	-8.3	1,294	-8.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,217	-8.3	1,294	-8.7												
1 TEVA PHARMACEUT	409	+15.9	432	+14.8	33.4	32.4	32.7	33.6	32.3	32.4	34.0	36.9	35.0	32.5	31.7	31.5
2 ACTAVIS	403	-10.4	427	-10.7	32.9	33.2	33.2	32.4	33.1	33.9	33.6	29.8	32.2	34.0	34.0	34.3
3 HI-TECH PHARMACAL	376	-26.7	403	-26.6	30.6	31.1	31.1	31.3	31.8	30.7	29.8	30.6	30.4	31.3	32.4	32.8
4 QUALITEST PRODUCTS	29	+142.1	31	+141.9	3.1	3.3	2.9	2.6	2.8	3.0	2.5	2.7	2.4	2.2	2.0	1.4
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Albuterol Sulfate (Ventolin)
INH SOL BFS, 0.5 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	303	-31.8	515	-27.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	212	-34.5	359	-30.5												
1 HI-TECH PHARMACAL	198	-18.5	335	-14.8	95.0	94.7	95.2	94.4	95.0	95.3	94.7	93.9	93.5	91.4	90.5	89.4
2 NEPHRON	5	+57.9	10	+34.4	4.0	4.3	3.7	4.2	3.3	2.6	2.2	2.1	2.4	2.4	2.3	2.2
3 WARRICK PHARM	8	-89.9	12	-89.2	0.4	0.5	0.7	1.1	1.4	1.8	2.5	3.3	3.7	5.5	6.6	7.6
4 TEVA PHARMACEUT	1	-66.9	1	-67.7	0.3	0.3	0.3	0.2	0.2	0.3	0.4	0.4	0.3	0.4	0.3	0.6
Brand	91	-24.7	155	-20.6												
1 BAUSCH & LOMB	91	-24.7	155	-20.6	32.9	30.7	28.9	29.4	29.8	29.4	28.4	31.6	31.7	30.2	29.9	29.0
Generic Substitution %	70.1		69.8		67.1	69.3	71.1	70.6	70.2	70.6	71.6	68.4	68.3	69.8	70.1	71.0

Alendronate Sodium ()
TAB, 35 mg, 70 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	5,765	+19.3	18,021	-0.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,258		9,960													
1 TEVA PHARMACEUT	1,772	--	4,873	--	57.9	57.5	56.9	50.8	38.8	38.1	39.5	39.3	50.0	0.0	0.0	0.0
2 BARR LABS	466	--	1,512	--	15.1	14.8	14.3	14.1	16.0	16.2	15.8	16.4	0.0	0.0	0.0	0.0
3 APOTEX CORP	75	--	256	--	14.5	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
4 WATSON LABS	942	--	3,309	--	12.0	25.4	28.9	35.0	45.2	45.6	44.7	44.3	50.0	0.0	0.0	0.0
5 COBALT LABS	2	--	5	--	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
6 MYLAN	1	--	4	--	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	2,507	-48.1	8,060	-55.3												
1 MERCK & COMPANY	2,507	-48.1	8,060	-55.3	9.5	8.8	9.8	9.9	18.8	20.7	22.6	54.7	100.0	100.0	100.0	100.0
Generic Substitution %	56.5		55.3		90.5	91.2	90.2	90.1	81.2	79.3	77.4	45.3	0.0	0.0	0.0	0.0

Alendronate Sodium (Fosamax)
TAB, 5 mg,10 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	96	-7.2	292	-19.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	43		120													
1 TEVA PHARMACEUT	42	--	118	--	93.0	98.6	100.0	100.0	100.0	100.0	100.0	100.0	0.0	0.0	0.0	0.0
2 APOTEX CORP	1	--	2	--	6.9	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	53	-48.8	172	-52.8												
1 MERCK & COMPANY	53	-48.8	172	-52.8	20.0	20.3	23.8	26.3	36.9	41.5	46.0	73.1	100.0	100.0	100.0	100.0
Generic Substitution %	44.8		41.0		80.0	79.7	76.2	73.7	63.1	58.5	54.0	26.9	0.0	0.0	0.0	0.0

Amiodarone HCl (
TAB, 200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,269	-1.7	3,604	-1.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,266	-1.6	3,593	-1.7												
1 SANDOZ	656	+2.5	1,875	+2.8	53.6	53.2	52.9	52.8	52.5	51.9	52.0	51.7	51.5	51.5	51.6	51.2
2 TEVA PHARMACEUT	285	-7.5	736	-9.1	19.6	20.4	20.5	20.3	20.2	20.4	20.4	20.5	20.7	20.7	21.0	21.2
3 TARO PHARM	118	+28.7	344	+31.7	9.5	9.7	9.7	9.6	9.6	9.6	9.6	9.5	9.5	9.7	9.6	9.4
4 UPSHER-SMITH	100	-18.6	300	-18.9	7.5	7.6	7.8	8.0	8.4	8.6	8.6	8.8	8.6	8.8	8.6	8.8
5 BARR LABS	67	+143.2	214	+129.2	7.5	6.6	6.2	6.1	5.9	5.8	5.7	5.6	5.8	5.7	5.3	5.2
6 PAR PHARM	18	-54.1	59	-52.2	1.4	1.5	1.5	1.5	1.5	1.6	1.6	1.7	1.7	1.8	1.9	2.3
7 AUROBINDO PHARM	19	-63.1	59	-62.8	0.9	1.0	1.2	1.5	1.8	2.1	2.0	2.0	1.9	1.8	1.9	1.7
8 UNIT DOSE LABS	3	-49.2	5	-56.9	0.0	0.0	0.2	0.2	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.2
Brand	3	-30.1	11	-29.7												
1 WYETH-AYERST	3	-30.1	11	-29.7	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Generic Substitution %	99.8		99.7		99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7

Amlodipine Besylate (Norvasc)
TAB, 2.5 mg, 5 mg,10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	14,620	+6.0	44,279	+10.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	14,090	+103.4	42,470	+140.4												
1 MYLAN	7,968	+78.9	23,241	+107.2	53.0	53.2	53.0	53.3	53.5	54.3	55.0	54.8	55.2	55.9	56.6	59.6
2 GREENSTONE LTD	3,973	+80.3	12,257	+115.9	27.4	27.5	27.6	27.2	27.7	29.2	29.3	29.8	30.4	29.7	30.2	30.8
3 ZYDUS PHARM	703	--	2,350	--	7.2	7.1	7.2	7.2	7.0	5.8	5.6	5.3	4.9	4.4	3.4	0.5
4 APOTEX CORP	965	+270.9	3,056	+311.6	7.1	7.1	7.3	7.3	7.2	6.9	6.7	6.8	6.8	7.7	7.7	7.9
5 ETHEX CORP	132	+80874.8	395	+96357.6	1.4	1.5	1.7	1.8	1.7	0.9	0.5	0.4	0.4	0.3	0.2	0.1
6 COBALT LABS	106	+2654025.0	342	+4279062.5	0.9	0.9	0.9	0.9	0.8	0.9	0.9	0.9	0.8	0.8	0.7	0.2
7 ACTAVIS	74	--	241	--	0.9	0.9	0.8	0.8	0.8	0.8	0.8	0.7	0.2	0.0	0.0	0.0
8 WOCKHARDT AMERICA	22	+1115400.0	70	+3500600.0	0.5	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.0
9 LUPIN PHARMA	60	+12360.1	237	+15318.5	0.4	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.5	0.3
10 AUROBINDO PHARM	6	--	21	--	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
11 UPSHER-SMITH	23	+7339.4	86	+6450.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
12 DR REDDY'S LAB	7	--	22	--	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 TEVA PHARMACEUT	4	+11745.5	13	+13039.6	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
14 ROXANE	15	+571.2	44	+810.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
15 SYNTHON PHARM	14	+254.4	46	+345.9	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
16 UNIT DOSE LABS	10	+378.2	27	+220.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
17 AMNEAL PHARM	3	--	8	--	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
18 CAMBER PHARM	2	--	6	--	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
19 BLU PHARM	0	--	1	--	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20 AMERICAN HLTH PKG	1	--	4	--	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	530	-92.3	1,809	-91.9												
1 PFIZER	530	-92.3	1,809	-91.9	2.8	2.9	3.0	3.1	3.3	3.5	3.8	4.1	4.8	5.7	6.0	6.5
Generic Substitution %	96.4		95.9		97.2	97.1	97.0	96.9	96.7	96.5	96.2	95.9	95.2	94.3	94.0	93.5

Amlodipine Besylate/Benazepril HCl (Lotrel)
CAP, 2.5/10 mg, 5/10 mg, 5/20 mg, 10/20 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,940	-17.4	13,109	-8.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,660	+132.5	12,063	+224.2												
1 TEVA PHARMACEUT	2,949	+106.7	9,417	+186.4	76.9	77.1	77.4	77.8	77.6	77.3	77.4	77.7	78.1	78.9	79.9	80.5
2 SANDOZ	711	+381.7	2,645	+511.8	23.1	22.9	22.6	22.2	22.4	22.7	22.6	22.3	21.9	21.1	20.1	19.5
Brand	280	-91.2	1,046	-90.1												
1 NOVARTIS RX	280	-91.2	1,046	-90.1	5.2	5.4	5.6	5.9	6.2	6.5	7.2	7.9	9.1	10.8	11.8	13.2
Generic Substitution %	92.9		92.0		94.8	94.6	94.4	94.1	93.8	93.5	92.8	92.1	90.9	89.2	88.2	86.8

Amoxicillin (Amoxil)
CAP, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	25,317	-7.8	27,226	-8.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	25,282	-7.7	27,186	-8.7												
1 TEVA PHARMACEUT	18,516	+3.7	19,804	+2.5	75.2	75.3	75.1	74.8	74.1	72.4	72.5	72.0	70.3	72.1	71.6	70.9
2 SANDOZ	3,584	-28.1	3,904	-28.0	12.0	11.8	12.1	12.5	13.3	15.0	15.2	15.4	16.2	15.0	15.7	16.1
3 RANBAXY PHARM	2,928	-31.9	3,200	-32.5	11.5	11.7	11.7	11.7	11.6	11.5	11.2	11.7	12.6	12.0	11.9	12.1
4 DAVA PHARM	230	+4.3	250	+2.6	1.1	1.0	1.0	1.0	0.9	1.0	1.0	0.9	0.9	0.8	0.8	0.7
5 WEST WARD	5	+57711.1	6	+50118.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
6 UNIT DOSE LABS	12	-54.2	13	-54.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1
7 AUROBINDO PHARM	2	--	3	--	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
8 AMERICAN HLTH PKG	4	+62.9	5	+60.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
9 ACTAVIS	1	+15.9	1	+15.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	36	-42.5	40	-44.0												
1 GSK PHARM	36	-42.5	40	-44.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2
Generic Substitution %	99.9		99.9		99.9	99.9	99.9	99.9	99.9	99.9	99.8	99.8	99.8	99.8	99.8	99.8

Amoxicillin (Amoxil)
CHEW, 125 mg, 250 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	493	-19.9	519	-20.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	493	-19.9	519	-20.1												
1 TEVA PHARMACEUT	374	-8.4	393	-8.7	77.3	77.4	77.9	77.3	76.8	77.1	75.8	76.0	75.3	74.6	73.7	72.5
2 RANBAXY PHARM	119	-42.6	126	-42.4	22.7	22.6	22.1	22.7	23.2	22.9	24.2	24.0	24.6	25.4	26.3	27.5
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Amoxicillin (Amoxil)
POS, 125/5 mg/ml, 250/5 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	8,819	-9.6	8,982	-9.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	8,554	-5.2	8,710	-5.5												
1 TEVA PHARMACEUT	7,275	-6.6	7,404	-6.8	84.5	85.4	85.4	85.5	85.6	85.2	85.0	84.7	84.6	85.2	85.0	84.7
2 SANDOZ	1,146	+12.9	1,171	+12.5	14.2	13.3	13.4	13.3	13.2	13.6	13.7	13.8	13.6	13.0	13.1	13.1
3 DAVA PHARM	77	-38.0	79	-38.2	0.9	0.9	0.9	0.8	0.8	0.8	0.8	0.8	0.9	1.0	1.2	1.1
4 WEST WARD	38	+59.4	38	+59.2	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5	0.6	0.5	0.5	0.7
5 PAR PHARM	17	-77.6	18	-77.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.3	0.4
Brand	265	-63.4	271	-63.4												
1 GSK PHARM	265	-63.4	271	-63.4	2.4	2.3	2.5	2.6	2.8	3.0	3.1	3.2	3.1	3.2	3.4	3.6
Generic Substitution %	97.0		97.0		97.6	97.7	97.5	97.4	97.2	97.0	96.9	96.8	96.9	96.8	96.6	96.4

Amoxicillin (Amoxil)
POS, 200/5 mg/ml, 400/5 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	9,824	+3.5	9,898	+3.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	9,814	+3.7	9,888	+3.6												
1 TEVA PHARMACEUT	6,764	+11.9	6,808	+11.8	68.5	68.9	69.0	69.4	69.4	68.8	68.7	68.3	68.8	69.6	68.9	68.2
2 RANBAXY PHARM	2,936	+0.7	2,964	+0.6	30.4	30.1	29.9	29.6	29.6	30.0	30.0	30.6	30.0	29.1	29.8	30.5
3 PAR PHARM	56	-88.8	56	-88.8	0.4	0.4	0.4	0.5	0.5	0.5	0.6	0.6	0.5	0.6	0.7	0.9
4 WEST WARD	50	+1313.1	50	+1317.3	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.6	0.7	0.6	0.4
5 SANDOZ	8	--	9	--	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0
Brand	11	-61.8	11	-62.2												
1 GSK PHARM	11	-61.8	11	-62.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
Generic Substitution %	99.9		99.9		99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.8

Amoxicillin (Amoxil)
TAB, 500 mg, 875 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	4,368	-2.0	4,455	-2.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	4,365	-1.7	4,452	-1.9												
1 RANBAXY PHARM	2,478	-4.1	2,528	-4.3	51.2	58.1	57.3	57.3	57.5	58.2	57.6	57.3	56.7	56.1	56.5	57.3
2 PAR PHARM	1,117	+46.9	1,135	+46.7	25.5	24.9	25.1	25.0	25.3	25.1	25.7	26.2	25.9	26.1	25.6	24.4
3 TEVA PHARMACEUT	674	-36.5	690	-36.6	21.3	14.8	14.9	15.0	14.7	14.6	14.7	14.6	15.2	15.5	15.6	16.1
4 SANDOZ	85	+250.7	87	+249.6	1.7	2.0	2.5	2.5	2.3	1.8	1.7	1.6	1.9	2.0	2.0	1.9
5 WEST WARD	10	+16.1	10	+17.0	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3
6 AUROBINDO PHARM	2	+369.4	2	+354.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	2	-87.4	3	-86.7												
1 GSK PHARM	2	-87.4	3	-86.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2
Generic Substitution %	99.9		99.9		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.9	99.9	99.9	99.8

Gain in Share: Walgreens is a new customer (sales commenced 8/2008).

Amoxicillin/Clavulanate Potassium (Augmentin)
CHEW, 200/28.5 , 400/57 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	236	-7.6	240	-7.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	236	-7.2	240	-7.2												
1 SANDOZ	102	-5.7	104	-5.6	43.5	42.7	43.0	43.1	43.4	43.3	43.4	44.1	43.1	42.7	42.9	42.3
2 TEVA PHARMACEUT	100	+13.6	102	+13.7	42.8	44.8	44.1	44.6	43.6	42.6	42.1	41.6	41.9	42.0	41.1	41.0
3 RANBAXY PHARM	27	-15.2	28	-15.6	13.2	11.9	11.5	11.0	11.1	11.7	11.3	11.3	11.6	11.2	11.2	11.3
4 PAR PHARM	7	-73.9	7	-74.0	0.5	0.7	1.4	1.3	1.9	2.5	3.2	3.0	3.4	4.0	4.8	5.4
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Amoxicillin/Clavulanate Potassium (Augmentin)
POS, 200/5 mg/ml, 400/5 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,669	+0.1	2,707	+0.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,665	+0.3	2,702	+0.2												
1 SANDOZ	1,475	-1.3	1,494	-1.6	56.6	57.1	57.3	56.3	55.6	55.0	54.9	54.6	54.7	54.3	54.6	55.3
2 TEVA PHARMACEUT	670	+30.8	678	+30.8	25.2	24.8	24.6	25.2	25.2	24.9	25.1	25.2	25.4	25.8	25.0	23.8
3 RANBAXY PHARM	390	+3.5	397	+3.9	14.9	14.5	14.2	14.2	14.3	14.9	15.0	15.2	14.9	14.4	14.6	14.6
4 PAR PHARM	112	-57.4	114	-57.4	2.5	2.8	3.2	3.5	4.0	4.4	4.3	4.4	4.3	4.7	5.1	5.7
5 WEST WARD	19	+60.9	19	+60.3	0.7	0.8	0.7	0.8	0.9	0.8	0.7	0.6	0.7	0.7	0.6	0.5
Brand	4	-46.2	4	-46.0												
1 GSK PHARM	4	-46.2	4	-46.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.3
Generic Substitution %	99.8		99.8		99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.8	99.7	99.7	99.7

Amoxicillin/Clavulanate Potassium (Augmentin)
TAB, 500mg/125 mg, 875mg/125 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	13,986	+5.4	14,393	+5.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	13,929	+5.4	14,331	+5.3												
1 SANDOZ	7,960	+5.8	8,164	+5.6	53.6	54.8	55.3	55.8	56.4	57.1	58.2	58.5	58.2	58.3	57.7	57.2
2 TEVA PHARMACEUT	4,334	+34.7	4,475	+34.0	32.4	32.4	32.5	32.2	31.7	30.9	30.8	30.3	30.4	31.1	30.9	30.3
3 RANBAXY PHARM	1,159	+11.3	1,204	+11.7	9.6	8.2	7.7	7.8	7.9	8.6	8.6	8.9	8.8	7.8	8.1	8.3
4 PAR PHARM	468	-67.0	481	-67.1	4.4	4.5	4.4	4.1	4.0	3.3	2.4	2.2	2.5	2.7	3.2	4.1
5 UNIT DOSE LABS	7	+16.9	8	+19.9	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
Brand	57	-7.0	62	-8.0												
1 GSK PHARM	57	-7.0	62	-8.0	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.5
Generic Substitution %	99.6		99.6		99.6	99.6	99.6	99.6	99.6	99.6	99.6	99.6	99.6	99.6	99.6	99.5

Amoxicillin/Clavulanate Potassium ES (Augmentin ES-600)
POS, 600 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,648	-2.4	3,705	-2.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,633	-2.2	3,689	-2.4												
1 TEVA PHARMACEUT	1,854	+10.3	1,883	+10.0	51.4	51.6	52.2	51.5	51.4	51.3	51.2	50.8	50.9	50.6	50.6	50.3
2 PAR PHARM	1,245	-36.9	1,264	-37.1	30.9	31.1	30.7	31.5	32.2	32.4	32.6	34.0	34.9	36.9	38.4	39.9
3 RANBAXY PHARM	431	+648.3	438	+652.1	14.3	13.5	13.2	13.1	12.6	12.7	12.8	12.0	11.0	10.4	10.1	9.7
4 SANDOZ	103	+788792.3	104	+801853.8	3.4	3.8	4.0	3.9	3.7	3.5	3.4	3.3	3.1	2.1	0.9	0.1
Brand	15	-35.0	15	-35.3												
1 GSK PHARM	15	-35.0	15	-35.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.4	0.4	0.5
Generic Substitution %	99.6		99.6		99.6	99.6	99.6	99.6	99.6	99.6	99.6	99.5	99.5	99.6	99.6	99.5

Anagrelide HCl (
CAP, 0.5 mg, 1 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	42	-5.2	128	-2.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	41	-2.9	123	+0.6												
1 TEVA PHARMACEUT	22	+1.3	63	+5.7	52.1	52.4	51.4	51.9	52.0	52.3	50.9	50.9	50.9	51.0	50.5	50.3
2 MYLAN	10	-6.1	32	-5.7	23.9	23.8	25.3	26.4	26.1	27.2	28.1	26.4	26.8	25.8	26.8	27.4
3 BARR LABS	6	+35.0	21	+36.8	22.4	21.9	20.9	18.9	17.9	15.4	14.6	14.9	14.5	14.3	13.4	13.6
4 SANDOZ	2	-56.3	6	-46.6	0.9	1.1	1.4	2.1	3.0	4.1	5.1	6.4	6.6	7.9	7.7	7.2
5 MALLINCKRODT	0	-44.5	1	-53.2	0.5	0.6	0.8	0.7	0.9	0.8	1.2	1.3	1.2	0.8	1.4	1.4
Brand	2	-41.5	5	-43.0												
1 SHIRE US INC	2	-41.5	5	-43.0	2.7	2.7	2.7	3.0	3.4	3.1	4.3	3.8	4.3	4.4	4.5	4.7
Generic Substitution %	96.4		96.3		97.3	97.3	97.3	97.0	96.6	96.9	95.7	96.2	95.7	95.6	95.5	95.3

Aspirin/Butalbital/Caffeine (Aspirin/Butalbital/Caffeine)
TAB, 325mg/50mg/40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	200	-11.8	369	-11.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	47	-25.1	85	-23.0												
1 ACTAVIS	39	-17.4	70	-14.9	83.6	83.5	82.7	83.4	83.9	84.3	83.8	83.2	83.4	83.3	83.3	80.5
2 QUALITEST PRODUCTS	6	-49.7	12	-48.2	13.4	14.1	15.2	14.0	13.4	12.7	13.6	13.6	13.5	13.6	13.2	16.1
3 TEVA PHARMACEUT	1	-24.9	1	-22.3	1.4	1.0	0.9	1.2	1.6	1.7	1.4	1.7	1.1	1.0	1.1	1.0
4 MAJOR PHARM	0	-21.6	1	-29.9	1.2	1.0	0.7	1.0	0.5	0.5	0.7	1.0	1.1	0.8	1.0	0.9
5 URL PHARMA	0	-72.1	1	-72.8	0.3	0.3	0.4	0.4	0.3	0.7	0.4	0.4	0.8	1.2	1.2	1.4
Brand	153	-6.8	284	-6.6												
1 WEST WARD	153	-6.8	284	-6.6	79.0	78.8	78.4	78.1	76.9	76.7	76.8	77.1	76.3	75.9	75.2	75.8
Generic Substitution %	23.3		23.0		21.0	21.2	21.6	21.9	23.1	23.3	23.2	22.9	23.7	24.1	24.8	24.2

Atenolol (Tenormin)
TAB, 25 mg, 50 mg,100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	12,303	-6.8	41,919	-6.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	12,247	-6.7	41,710	-6.9												
1 MYLAN	4,071	-9.6	13,084	-9.3	30.1	30.4	30.1	30.3	31.3	32.0	32.1	32.1	32.2	32.0	31.8	31.8
2 SANDOZ	2,587	-33.7	9,779	-31.4	23.2	23.5	24.1	23.7	23.0	22.6	22.5	22.8	23.5	23.9	24.1	24.3
3 TEVA PHARMACEUT	2,213	+55.4	7,520	+49.6	18.8	18.3	17.9	18.0	18.0	17.9	17.9	17.5	17.2	18.4	18.3	18.1
4 ZYDUS PHARM	1,399	+13.9	4,363	+13.9	10.8	10.4	10.4	10.5	10.5	10.6	10.4	10.7	10.8	9.9	10.2	10.4
5 MALLINCKRODT	1,151	+12.8	4,012	+13.9	8.8	9.1	9.4	9.5	9.5	9.5	9.6	9.7	10.2	10.1	9.9	9.8
6 RANBAXY PHARM	530	+1292.2	1,917	+1331.8	6.2	6.1	5.8	5.8	5.5	5.2	5.1	4.7	3.5	2.8	2.6	2.4
7 WATSON LABS	104	-64.3	342	-68.9	0.8	0.8	0.8	0.8	0.9	0.8	0.8	0.8	0.8	0.8	0.8	0.9
8 DAVA PHARM	65	-58.8	241	-59.3	0.6	0.6	0.7	0.6	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.7
9 MUTUAL PHARM	65	-79.0	230	-78.5	0.5	0.5	0.5	0.5	0.6	0.6	0.5	0.5	0.5	0.5	0.7	0.7
10 GENPHARM INC	43	-61.4	156	-59.3	0.1	0.1	0.1	0.2	0.2	0.3	0.3	0.4	0.6	0.7	0.7	0.7
11 UNIT DOSE LABS	11	-37.0	35	-41.2	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
12 MCKESSON PKG SERV	2	-70.7	10	-44.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 PAR PHARM	3	-97.4	12	-96.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
14 AMERICAN HLTH PKG	0	-24.2	1	-40.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15 MAJOR PHARM	1	-42.4	2	-42.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
16 LEDERLE SP	0	-41.5	1	-41.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
17 URL PHARMA	0	-86.9	1	-87.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	56	-18.0	209	-18.8												
1 ASTRAZENECA	56	-18.0	209	-18.8	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Generic Substitution %	99.5		99.5		99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5

Azithromycin (Zithromax)

TAB, Tri-Pak 500 mg, Z-Pak 250 mg, 250 mg, 500 mg, 600 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	39,449	+10.7	40,986	+10.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	39,161	+11.1	40,667	+11.0												
1 TEVA PHARMACEUT	14,687	+6.4	15,197	+6.3	39.5	39.5	38.8	38.4	38.6	37.3	36.5	36.4	36.6	36.4	37.1	36.9
2 GREENSTONE LTD	16,715	+3.4	17,401	+3.2	36.7	36.8	37.3	38.0	39.0	40.1	42.8	43.5	44.1	48.4	48.7	48.7
3 BARR LABS	4,412	+35.6	4,570	+35.8	11.7	11.9	12.2	11.9	11.5	12.8	11.3	11.1	11.2	10.4	10.1	9.7
4 SANDOZ	3,025	+48.8	3,164	+49.3	9.2	9.3	9.6	9.8	9.2	8.8	8.9	8.9	8.0	4.7	4.1	4.6
5 WOCKHARDT AMERICA	215	--	223	--	1.9	1.8	1.3	1.1	1.1	0.9	0.4	0.0	0.0	0.0	0.0	0.0
6 MYLAN	107	+5530.2	110	+5586.9	1.0	0.8	0.8	0.8	0.6	0.1	0.0	0.0	0.1	0.1	0.1	0.1
Brand	288	-20.6	319	-21.5												
1 PFIZER	288	-20.6	319	-21.5	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.9	0.8	0.9
Generic Substitution %	99.3		99.2		99.3	99.3	99.3	99.3	99.3	99.3	99.3	99.2	99.2	99.1	99.2	99.1

Baclofen (Lioresal)
TAB, 10 mg, 20 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,609	+7.5	3,892	+6.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,609	+7.5	3,892	+6.4												
1 TEVA PHARMACEUT	863	+16.0	2,027	+12.7	52.3	52.4	52.8	52.7	52.3	51.5	51.9	51.6	51.8	52.1	52.0	51.6
2 UPSHER-SMITH	426	+24.4	1,015	+25.5	32.0	31.6	30.8	29.8	28.0	24.1	22.7	22.7	22.6	22.8	22.8	22.7
3 QUALITEST PRODUCTS	114	-36.8	278	-32.6	6.9	7.0	7.2	7.3	7.1	7.2	7.1	7.0	7.2	7.2	7.1	7.2
4 CARACO PHARM	111	+159.7	326	+139.0	4.2	4.4	4.6	5.3	6.8	10.2	11.3	11.4	11.3	10.8	10.8	9.8
5 WATSON LABS	74	-46.2	189	-50.2	3.3	3.2	3.3	3.7	4.7	5.7	5.7	5.8	5.7	5.7	5.8	6.0
6 MYLAN	5	--	13	--	0.7	0.7	0.6	0.6	0.5	0.4	0.3	0.1	0.0	0.0	0.0	0.0
7 LANNETT	3	+1055.0	7	+933.6	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.1	0.1	0.0	0.0
8 GENPHARM INC	11	-74.9	31	-71.8	0.2	0.2	0.2	0.3	0.3	0.5	0.7	1.0	1.2	1.3	1.4	2.5
9 UNIT DOSE LABS	1	+77.0	2	+64.7	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0
10 MAJOR PHARM	0	-86.9	2	-75.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1
11 AMERICAN HLTH PKG	0	+34.7	1	-2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Benazepril HCl (Lotensin)

TAB, 5 mg,10 mg, 20 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,201	+3.2	7,114	+1.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,174	+3.8	7,011	+2.4												
1 TEVA PHARMACEUT	1,222	+11.9	3,604	+10.2	51.5	51.6	51.1	51.1	52.1	52.7	52.7	52.3	51.7	50.2	48.7	51.2
2 ETHEX CORP	427	+51.7	1,445	+51.4	21.5	21.2	21.8	21.8	20.9	20.2	19.9	19.7	19.9	20.5	21.7	18.5
3 SANDOZ	251	-21.5	1,003	-18.0	14.0	13.8	13.7	13.7	13.5	13.7	13.9	14.3	14.7	15.3	15.6	15.4
4 MYLAN	227	-19.2	784	-19.7	11.0	11.2	11.1	11.1	11.2	11.1	11.1	11.3	11.3	11.3	11.2	11.3
5 APOTEX CORP	30	-55.4	109	-48.1	1.5	1.7	1.7	1.6	1.6	1.6	1.5	1.5	1.4	1.4	1.3	1.8
6 RANBAXY PHARM	14	-70.8	54	-70.9	0.4	0.4	0.5	0.5	0.6	0.6	0.7	0.7	0.9	1.0	1.3	1.6
7 WATSON LABS	2	-59.2	9	-59.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2
8 UNIT DOSE LABS	0	+15.5	2	+3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	27	-28.0	103	-28.2												
1 NOVARTIS RX	27	-28.0	103	-28.2	1.2	1.3	1.3	1.3	1.4	1.4	1.5	1.5	1.5	1.7	1.6	1.7
Generic Substitution %	98.8		98.5		98.8	98.7	98.7	98.7	98.6	98.6	98.5	98.5	98.5	98.3	98.4	98.3

Benazepril HCl/HCTZ (Lotensin HCT)
TAB, 10/12.5 mg, 20/12.5 mg, 20/25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	635	-5.4	2,175	-1.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	624	-4.7	2,130	-0.5												
1 MYLAN	394	+10.4	1,300	+19.5	60.2	60.9	60.9	61.0	60.9	60.9	61.1	61.2	61.4	62.1	61.9	60.0
2 SANDOZ	176	+8.8	645	+9.1	30.5	29.4	29.5	29.5	29.6	29.9	29.8	30.2	30.9	31.6	31.6	30.9
3 TEVA PHARMACEUT	53	-59.7	181	-59.5	9.3	9.6	9.5	9.4	9.3	9.1	8.9	8.4	7.5	6.0	6.2	8.8
4 WATSON LABS	1	-62.2	3	-58.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.3
5 RANBAXY PHARM	0	-89.0	1	-87.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1
Brand	12	-33.8	46	-31.4												
1 NOVARTIS RX	12	-33.8	46	-31.4	1.7	1.8	1.9	1.9	2.0	2.1	2.1	2.2	2.2	2.4	2.5	2.6
Generic Substitution %	98.2		97.9		98.3	98.2	98.1	98.1	98.0	97.9	97.9	97.8	97.8	97.6	97.5	97.4

Benztropine Mesylate (Benztropine Mesylate (was Cogentin))

TAB, 0.5 mg, 1 mg, 2 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,633	+5.1	3,549	+4.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,075	+9.5	2,487	+8.5												
1 UPSHER-SMITH	606	+71.2	1,284	+59.3	52.0	52.1	51.3	50.7	50.7	51.4	51.7	52.5	52.6	52.1	51.6	50.9
2 BARR LABS	375	-34.5	1,007	-26.3	36.4	37.0	38.4	39.9	40.3	40.3	41.3	41.6	42.2	42.7	42.8	43.7
3 QUALITEST PRODUCTS	33	+41805.1	71	+66529.2	6.6	6.0	5.3	4.7	4.0	3.3	2.3	0.9	0.1	0.1	0.1	0.0
4 RISING PHARM	47	+20.8	88	+14.1	3.6	3.7	3.5	3.4	3.6	3.6	3.4	3.5	3.5	3.5	3.6	3.5
5 MAJOR PHARM	8	-14.8	16	-22.5	0.6	0.6	0.6	0.6	0.6	0.5	0.6	0.6	0.7	0.7	0.8	0.8
6 TEVA PHARMACEUT	2	-8.2	7	-2.9	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.3
7 UNIT DOSE LABS	3	+21.3	10	+4.6	0.2	0.3	0.3	0.3	0.4	0.3	0.4	0.4	0.5	0.5	0.6	0.5
8 MCKESSON PKG SERV	1	-46.8	3	-6.2	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	557	-2.4	1,063	-3.0												
1 PAR PHARM	557	-2.4	1,063	-3.0	28.7	28.7	28.8	28.7	28.7	29.4	29.8	31.0	31.6	31.3	31.4	31.3
Generic Substitution %	65.9		70.1		71.3	71.3	71.2	71.3	71.3	70.6	70.2	69.0	68.4	68.7	68.6	68.7

Betamethasone Dipropionate (Diprosone)
LOT, 0.05 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	81	-5.6	133	-5.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	81	-5.5	133	-5.4												
1 FOUGERA	59	-8.3	92	-9.3	69.2	69.7	69.6	69.3	68.5	69.4	68.9	68.5	69.3	68.3	69.1	70.9
2 TEVA PHARMACEUT	13	+8.1	21	+11.0	16.7	16.4	15.6	16.0	16.2	16.2	16.7	16.5	16.5	16.5	16.1	15.2
3 PERRIGO	9	-2.6	19	+0.2	14.0	13.9	14.7	14.7	15.3	14.3	14.3	14.8	14.0	15.0	14.5	13.7
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Betamethasone Valerate (Betamethasone Valerate)

CRM, 0.1 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	309	-1.8	432	-2.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	222	-3.2	307	-4.4												
1 TEVA PHARMACEUT	100	+24.0	138	+22.8	52.6	47.9	46.4	45.9	44.8	44.6	45.1	44.0	44.0	42.9	41.0	38.5
2 ACTAVIS	100	+1.3	136	+0.5	37.9	42.5	44.9	44.7	45.4	44.9	44.5	44.6	44.3	45.4	45.5	47.4
3 TARO PHARM	22	-55.6	33	-54.9	9.5	9.5	8.7	9.4	9.7	10.4	10.2	11.3	11.6	11.6	13.4	14.0
Brand	86	+2.2	125	+1.6												
1 FOUGERA	86	+2.2	125	+1.6	30.3	29.5	29.2	28.3	28.6	28.7	28.2	28.6	28.3	28.4	28.6	30.9
Generic Substitution %	72.0		71.0		69.7	70.5	70.8	71.7	71.4	71.3	71.8	71.4	71.7	71.6	71.4	69.1

Gain in Share: RiteAid and Walgreens are new customers.

Betamethasone Valerate (Betamethasone Valerate)
LOT, 0.10 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	96	-4.3	150	-4.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	96	-4.3	150	-4.7												
1 FOUGERA	59	-3.1	91	-3.7	60.3	61.1	61.2	61.4	61.7	61.5	60.7	61.6	61.5	60.5	59.3	60.7
2 TEVA PHARMACEUT	37	-6.1	58	-6.0	39.6	38.8	38.7	38.5	38.3	38.4	39.2	38.3	38.4	39.4	40.5	39.2
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Bisoprolol Fumarate (Zebeta)

TAB, 5 mg,10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	345	+12.4	1,071	+2.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	339	+13.3	1,048	+3.1												
1 SANDOZ	234	-5.9	745	-11.7	78.1	77.7	77.3	76.0	73.8	69.8	62.6	61.8	62.4	64.6	72.3	77.0
2 MYLAN	58	+47.6	196	+46.1	18.2	18.4	18.3	18.6	17.9	18.5	19.6	18.0	18.4	19.4	19.2	19.4
3 TEVA PHARMACEUT	8	-3.5	31	+6.9	2.8	2.8	2.9	2.9	3.2	3.5	2.8	2.9	2.9	2.8	3.0	2.8
4 AUROBINDO PHARM	38	+545185.7	72	+287344.0	0.6	0.8	1.3	2.2	4.8	7.8	14.4	16.9	15.7	12.7	5.0	0.2
5 MUTUAL PHARM	1	-61.0	4	-59.2	0.2	0.2	0.2	0.3	0.3	0.3	0.4	0.4	0.5	0.4	0.5	0.5
Brand	6	-22.7	23	-24.7												
1 BARR LABS	6	-22.7	23	-24.7	1.8	1.9	1.9	1.9	2.0	2.1	2.1	2.3	2.3	2.4	2.5	2.5
Generic Substitution %	98.2		97.9		98.2	98.1	98.1	98.1	98.0	97.9	97.9	97.7	97.7	97.6	97.5	97.5

Bumetanide (Bumex)

TAB, 0.5 mg, 1 mg, 2 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	771	+5.5	2,025	-1.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	769	+6.4	2,021	-0.2												
1 TEVA PHARMACEUT	438	+48.8	1,062	+31.9	59.9	58.9	57.3	56.9	56.6	55.9	54.9	53.4	50.7	46.0	40.8	39.3
2 MYLAN	174	-3.6	502	-5.3	24.6	24.8	24.8	24.8	24.5	24.3	24.5	24.5	25.0	25.5	25.1	25.7
3 SANDOZ	154	-37.0	449	-33.9	15.2	16.0	17.5	18.0	18.5	19.3	20.0	21.7	23.9	28.2	33.7	34.6
4 UNIT DOSE LABS	3	-9.0	8	-12.1	0.3	0.4	0.4	0.4	0.3	0.4	0.5	0.5	0.4	0.3	0.4	0.4
Brand	2	-78.3	4	-83.1												
1 ROCHE	2	-78.3	4	-83.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.3	0.4	0.4	0.6
Generic Substitution %	99.8		99.8		100.0	100.0	100.0	100.0	99.9	99.9	99.9	99.8	99.7	99.6	99.6	99.4

Gain in Share: Walgreens and Wal-Mart awarded the product to us. Usage at both customers is increasing.

Bupropion HCl (Wellbutrin)

TAB, 75 mg,100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	661	+3.6	1,424	+3.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	648	+3.6	1,396	+3.1												
1 TEVA PHARMACEUT	525	+12.2	1,102	+11.7	79.1	79.0	79.2	79.8	79.7	78.7	79.1	79.0	78.9	78.6	78.1	77.4
2 MYLAN	73	-37.4	189	-32.9	12.7	12.9	12.8	12.8	12.8	13.3	13.4	13.7	13.8	14.1	14.5	15.3
3 APOTEX CORP	35	+65.2	75	+61.5	6.1	6.0	6.0	5.3	5.4	5.8	5.4	5.1	5.0	4.6	4.7	4.5
4 SANDOZ	13	-21.6	27	-20.8	2.0	1.8	1.9	1.9	1.8	1.9	1.9	1.9	1.8	2.3	2.2	2.4
5 UNIT DOSE LABS	2	-32.9	4	-39.6	0.1	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.4	0.4	0.4	0.4
Brand	13	+2.3	28	+2.1												
1 GSK PHARM	13	+2.3	28	+2.1	1.9	1.9	1.9	2.0	1.9	1.9	2.0	1.9	1.9	2.0	2.0	1.9
Generic Substitution %	98.0		98.1		98.1	98.1	98.1	98.0	98.1	98.1	98.0	98.1	98.1	98.0	98.0	98.1

Bupropion HCl (Wellbutrin SR)
MR TAB, 100 mg, 150 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,648	-4.5	8,438	-3.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,556	-4.3	8,223	-3.5												
1 TEVA PHARMACEUT	1,855	+1.1	4,152	+1.4	48.5	49.2	49.1	49.9	50.1	49.4	50.2	50.9	51.1	51.7	52.7	52.9
2 SANDOZ	938	+14.0	2,162	+15.3	29.6	30.0	30.6	28.3	25.9	26.1	25.3	24.7	24.9	24.0	23.4	22.8
3 WATSON LABS	730	-31.0	1,827	-28.4	17.4	17.6	18.1	20.0	23.4	24.5	24.5	24.4	24.0	24.3	23.9	24.3
4 ACTAVIS	33	--	83	--	4.4	3.1	2.3	1.8	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	92	-12.4	215	-15.1												
1 GSK PHARM	92	-12.4	215	-15.1	2.5	2.5	2.4	2.5	2.5	2.5	2.5	2.6	2.6	2.7	2.7	2.7
Generic Substitution %	97.5		97.5		97.5	97.5	97.6	97.5	97.5	97.5	97.5	97.4	97.4	97.3	97.3	97.3

Bupropion HCl (Wellbutrin XL)

MR TAB, 150 mg, 300 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	5,859	-6.0	13,159	-3.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,692	+67.1	8,313	+76.6												
1 TEVA PHARMACEUT	2,554	+22.4	5,503	+24.6	65.0	64.4	65.9	66.2	59.9	65.6	66.8	68.0	68.1	68.7	69.0	69.7
2 ANCHEN PHARM	588	+1007.5	1,393	+1004.1	21.5	21.7	20.2	19.0	17.8	13.5	12.6	12.5	13.1	12.5	12.4	12.5
3 WATSON LABS	549	+685.5	1,417	+758.5	13.5	13.9	13.8	14.8	22.2	21.0	20.6	19.6	18.8	18.8	18.6	17.9
Brand	2,167	-46.2	4,845	-45.5												
1 GSK PHARM	2,167	-46.2	4,845	-45.5	11.7	12.4	13.6	19.6	47.0	46.9	47.5	48.9	49.0	49.0	49.7	50.0
Generic Substitution %	63.0		63.2		88.3	87.6	86.4	80.4	53.0	53.1	52.5	51.1	51.0	51.0	50.3	50.0

**Bupropion HCl (Zyban)
MR TAB, 150 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	69	-37.0	115	-36.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	66	-36.0	111	-35.3												
1 TEVA PHARMACEUT	47	-31.2	77	-31.0	71.3	71.1	68.8	68.9	68.8	69.6	69.9	70.5	69.8	67.8	68.6	66.6
2 WATSON LABS	18	-47.2	33	-44.7	25.8	27.4	29.9	30.3	30.4	29.8	29.5	29.0	29.9	32.0	31.4	33.4
Brand	3	-53.6	5	-55.2												
1 GSK PHARM	3	-53.6	5	-55.2	3.5	3.6	3.2	3.9	3.7	4.2	4.3	4.3	4.4	4.4	4.6	4.9
Generic Substitution %	95.8		95.9		96.5	96.4	96.8	96.1	96.3	95.8	95.7	95.7	95.6	95.6	95.4	95.1

Buspirone HCl (Buspar)
TAB, 5 mg,10 mg, 15 mg, 30 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,333	+4.6	5,099	+2.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,318	+4.8	5,060	+3.1												
1 MYLAN	1,080	+0.7	2,223	-0.3	44.1	44.2	43.7	43.8	43.8	43.7	43.9	44.0	44.0	43.9	44.0	44.0
2 TEVA PHARMACEUT	501	+94.5	1,036	+87.1	24.0	23.5	22.7	21.2	19.8	19.5	19.3	19.5	19.4	19.1	18.8	18.6
3 WATSON LABS	355	-24.7	832	-22.4	16.0	16.1	16.1	16.2	16.4	16.7	16.7	16.5	16.4	16.7	16.7	16.9
4 ETHEX CORP	249	+1.3	656	-0.3	10.6	10.9	11.8	13.0	13.5	13.7	13.8	13.6	13.6	13.7	13.7	13.6
5 PAR PHARM	99	-24.4	232	-24.8	4.8	4.7	4.6	4.5	4.5	4.5	4.5	4.5	4.6	4.6	4.6	4.7
6 ACTAVIS	29	+16.9	67	+13.8	0.4	0.5	0.8	1.0	1.7	1.6	1.6	1.6	1.6	1.6	1.8	1.8
7 UNIT DOSE LABS	4	-19.8	10	-30.4	0.1	0.2	0.1	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.3
8 MAJOR PHARM	1	-5.2	3	-27.5	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
9 AMERICAN HLTH PKG	0	-4.4	1	-11.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	15	-21.6	39	-21.1												
1 BRISTOL-M SQ US PH	15	-21.6	39	-21.1	0.7	0.7	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9
Generic Substitution %	99.4		99.2		99.3	99.3	99.3	99.3	99.2	99.2	99.2	99.2	99.2	99.1	99.1	99.1

Gain in Share: Both McKesson (OneStop) and ABC (ProGen) are new customers. Also gained several smaller customers.

Cabergoline (Dostinex)
TAB, 0.5 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	106	-0.2	330	+1.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	106	+3.2	329	+3.5												
1 PAR PHARM	90	-6.2	279	-6.1	82.9	84.2	84.2	84.8	84.5	85.0	85.3	84.9	85.3	85.0	85.1	85.7
2 TEVA PHARMACEUT	14	+209.2	45	+229.8	12.0	12.5	14.1	14.2	14.4	13.9	13.6	14.0	13.5	13.7	13.4	12.9
3 COBALT LABS	1	--	2	--	4.2	2.4	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
4 GREENSTONE LTD	1	-44.3	4	-50.4	0.9	0.9	1.0	0.9	1.1	1.1	1.1	1.1	1.2	1.3	1.5	1.4
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Calcitriol (Rocaltrol)
CAP, 0.25 mcg, 0.5 mcg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	515	+18.9	1,573	+19.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	511	+19.4	1,559	+20.1												
1 TEVA PHARMACEUT	452	+15.6	1,352	+15.4	85.9	86.2	85.9	86.0	86.1	86.3	86.5	87.2	87.1	87.6	88.3	87.7
2 ROXANE	59	+59.5	207	+64.3	14.1	13.8	14.1	14.0	13.9	13.7	13.5	12.8	12.9	12.4	11.7	12.3
Brand	4	-24.8	13	-27.5												
1 FONTUS PHARM	4	-24.8	13	-27.5	0.5	0.6	0.7	0.6	0.8	0.9	0.9	0.9	1.0	1.1	1.1	1.1
Generic Substitution %	99.3		99.2		99.5	99.4	99.3	99.4	99.2	99.1	99.1	99.1	99.0	98.9	98.9	98.9

Captopril (Capoten)

TAB, 12.5 mg, 25 mg, 50 mg, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	556	-22.2	1,813	-18.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	554	-20.3	1,804	-16.8												
1 WEST WARD	158	-21.5	578	-17.9	32.6	32.2	32.6	32.2	31.9	32.3	32.0	31.7	31.8	31.7	31.8	31.8
2 APOTEX CORP	132	+62.1	362	+149.1	20.9	20.8	20.5	20.6	20.5	20.6	20.5	20.5	19.8	19.2	18.9	18.7
3 TEVA PHARMACEUT	106	-11.3	349	-13.8	19.3	19.5	19.3	19.5	19.4	19.4	19.5	19.3	19.4	19.2	19.2	19.0
4 MYLAN	107	-54.2	352	-50.7	17.8	18.0	18.1	18.4	19.0	18.9	19.3	19.7	20.0	20.7	21.2	21.9
5 WOCKHARDT AMERICA	42	+93.8	135	+80.8	8.3	8.2	8.1	8.0	7.9	7.3	7.2	7.3	7.2	7.5	6.8	6.5
6 SANDOZ	7	-79.3	24	-79.5	1.0	1.1	1.2	1.0	1.1	1.2	1.3	1.3	1.4	1.5	1.7	1.8
7 UNIT DOSE LABS	1	-39.6	3	-42.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2
Brand	3	-86.9	8	-85.2												
1 PAR PHARM	3	-86.9	8	-85.2	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Generic Substitution %	99.5		99.5		99.6	99.6	99.6	99.6	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5

Captopril/HCTZ (Capozide)

TAB, 25mg/15 mg, 25mg/25 mg, 50mg/15 mg, 50mg/25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	55	-17.2	190	-15.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	54	-17.1	189	-15.6												
1 MYLAN	38	-21.1	134	-19.9	66.0	66.0	66.4	67.6	69.2	68.9	71.0	71.2	73.5	74.1	76.8	77.1
2 TEVA PHARMACEUT	16	-1.4	53	+2.3	33.2	33.2	32.8	31.3	29.9	30.0	28.0	27.5	25.3	24.5	21.9	21.5
3 SANDOZ	1	-57.6	2	-56.2	0.8	0.9	0.8	1.0	1.0	1.0	1.0	1.2	1.2	1.3	1.3	1.4
Brand	0	-31.2	1	-23.8												
1 PAR PHARM	0	-31.2	1	-23.8	0.6	0.8	0.7	0.6	0.9	0.7	0.8	0.8	0.8	0.9	0.8	0.8
Generic Substitution %	99.2		99.2		99.4	99.2	99.3	99.4	99.1	99.3	99.2	99.2	99.2	99.1	99.2	99.2

Gain in Share: We gained McKesson/OneStop.

Carbamazepine (Tegretol)
CHEW, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	219	-2.8	594	-4.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	206	-1.9	549	-3.6												
1 TEVA PHARMACEUT	143	-1.9	345	-3.0	57.1	61.6	63.2	63.3	63.5	63.5	63.3	63.4	64.2	63.3	64.2	63.9
2 TARO PHARM	48	-16.1	165	-15.0	25.2	23.4	25.5	30.5	32.0	32.3	32.3	32.0	31.7	32.4	31.5	32.2
3 CARACO PHARM	14	+129.7	37	+111.4	17.3	14.8	11.0	6.0	4.3	4.0	4.2	4.3	3.9	3.9	3.9	3.6
4 UNIT DOSE LABS	0	-6.9	1	-22.3	0.3	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Brand	13	-14.8	45	-16.6												
1 NOVARTIS RX	13	-14.8	45	-16.6	7.4	7.3	7.4	7.4	7.6	7.5	7.6	7.7	7.9	7.9	7.8	8.0
Generic Substitution %	94.0		92.4		92.6	92.7	92.6	92.6	92.4	92.5	92.4	92.3	92.1	92.1	92.2	92.0

Decline in Share: Gave up Wal-Mart.

Carbamazepine (Tegretol)
TAB, 200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	956	-3.4	2,681	-3.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	878	-2.6	2,394	-1.5												
1 TEVA PHARMACEUT	344	+4.3	902	+1.7	36.8	36.8	37.0	37.7	38.2	38.2	38.2	38.1	38.1	37.7	37.5	38.0
2 TARO PHARM	234	-27.2	731	-22.2	29.5	29.5	29.9	30.0	30.1	30.0	29.6	29.6	30.0	31.0	32.6	34.3
3 CARACO PHARM	258	+28.0	646	+43.3	28.1	28.2	28.1	27.7	27.6	27.6	27.9	27.6	27.1	26.4	25.0	22.8
4 APOTEX CORP	24	+66.1	63	+46.8	4.3	4.1	3.6	3.0	2.3	2.1	2.0	2.0	2.1	2.0	2.0	2.0
5 ACTAVIS	15	-48.4	46	-53.7	1.2	1.2	1.2	1.4	1.5	1.9	2.2	2.3	2.4	2.5	2.5	2.6
6 MCKESSON PKG SERV	0	-54.6	2	-25.7	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
7 UNIT DOSE LABS	1	-25.8	3	-39.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2
8 MAJOR PHARM	0	-35.7	2	-15.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1
9 INWOOD LABS	0	-80.6	1	-81.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	79	-11.5	287	-14.3												
1 NOVARTIS RX	79	-11.5	287	-14.3	9.9	10.2	10.2	10.4	10.6	10.7	10.7	10.8	11.1	11.3	11.2	11.4
Generic Substitution %	91.8		89.3		90.1	89.8	89.8	89.6	89.4	89.3	89.3	89.2	88.9	88.7	88.8	88.6

Carbidopa/Levodopa (Sinemet)

TAB, 10mg/100 mg, 25mg/100 mg, 25mg/250 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,104	+3.2	3,526	+2.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,092	+3.4	3,485	+2.5												
1 TEVA PHARMACEUT	585	-2.9	1,717	-3.7	51.6	51.2	50.9	50.4	49.4	48.0	45.4	47.5	48.2	47.6	50.1	50.7
2 ACTAVIS	479	+21.0	1,672	+17.7	47.0	47.2	47.4	47.7	48.5	49.9	52.2	49.6	48.5	48.3	45.4	44.4
3 ENDO GENERIC PROD	24	-53.8	82	-53.4	1.2	1.3	1.5	1.6	1.8	1.9	2.0	2.3	2.8	3.5	4.0	4.4
4 UNIT DOSE LABS	2	-44.4	9	-39.8	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.4	0.4	0.4	0.4	0.4
5 MAJOR PHARM	2	+65.8	3	+80.8	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
6 MCKESSON PKG SERV	0	-55.2	2	-27.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1
7 AMERICAN HLTH PKG	0	-39.9	1	-39.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	12	-10.6	41	-11.7												
1 DUPONT PHARM	12	-10.6	41	-11.7	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.3	1.3
Generic Substitution %	98.9		98.8		98.9	98.9	98.9	98.9	98.9	98.9	98.8	98.8	98.8	98.8	98.7	98.7

Carvedilol (Coreg)

TAB, 3.125 mg, 6.25 mg, 12.5 mg, 25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	4,895	+9.3	13,730	+3.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	4,676	+1461.7	12,930	+2501.3												
1 TEVA PHARMACEUT	1,388	+1150.0	3,537	+2562.3	28.8	28.6	28.5	28.0	27.4	26.9	26.9	26.7	26.6	26.3	26.3	26.3
2 MYLAN	775	+2172.5	2,240	+2389.4	17.5	17.6	17.3	17.4	17.4	17.1	17.2	17.3	17.3	17.4	17.3	17.1
3 APOTEX CORP	835	+1436.3	2,218	+2301.9	16.9	16.9	17.1	17.1	17.3	17.3	16.9	16.9	17.6	17.1	17.4	17.3
4 DR REDDY'S LAB	553	+1732.0	1,625	+2363.7	11.9	11.8	12.0	12.2	12.6	12.9	12.7	13.0	12.9	13.0	13.2	13.1
5 ZYDUS PHARM	327	+1706.4	1,092	+2739.9	8.6	8.5	8.3	8.3	8.2	8.2	8.2	8.0	8.2	9.1	9.0	9.0
6 SANDOZ	389	+961.5	957	+2351.6	6.9	7.1	7.3	7.3	7.5	7.8	7.9	7.6	7.3	7.1	7.1	7.9
7 AUROBINDO PHARM	285	+2449.0	892	+2864.4	6.4	6.5	6.5	6.6	6.5	7.0	7.1	7.2	7.4	7.4	7.4	7.1
8 CARACO PHARM	58	+3660.7	176	+5136.4	1.4	1.5	1.5	1.5	1.5	1.4	1.3	1.4	1.4	1.3	1.1	1.1
9 GLENMARK PHARMA	35	+2648.9	116	+3245.6	0.9	1.0	1.0	1.0	1.1	0.9	0.9	0.8	0.8	0.8	0.8	0.8
10 ACTAVIS	26	+2960.1	72	+4989.5	0.6	0.5	0.5	0.5	0.5	0.5	0.9	1.1	0.4	0.4	0.4	0.3
11 UNIT DOSE LABS	4	+5001.4	4	+6146.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	219	-94.8	801	-93.7												
1 GSK PHARM	219	-94.8	801	-93.7	2.6	2.8	3.2	3.7	4.1	4.5	5.1	5.8	7.0	8.7	10.4	13.8
Generic Substitution %	95.5		94.2		97.4	97.2	96.8	96.3	95.9	95.5	94.9	94.2	93.0	91.3	89.6	86.2

Cefaclor (Cefaclor (Previously Ceclor CD))
MR TAB, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	4	-34.7	5	-34.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	4	-33.2	4	-33.1												
1 TEVA PHARMACEUT	4	-33.2	4	-33.1	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Cefadroxil/Cefadroxil Monohydrate (Cefadroxil (Previously Duricef))

TAB, 1 g

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	17	-17.7	18	-16.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	17	-17.7	18	-16.7												
1 TEVA PHARMACEUT	12	-5.1	13	-4.5	69.4	72.7	73.1	72.5	72.9	71.0	69.5	68.8	69.1	70.2	64.0	67.2
2 RANBAXY PHARM	5	-37.2	6	-36.0	30.5	27.2	26.9	27.4	27.1	28.8	30.5	31.2	30.9	29.8	36.0	32.7
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Cefadroxil/Cefadroxil Monohydrate (Duricef & generics)
CAP, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	955	-9.0	1,023	-8.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	955	-9.0	1,023	-8.7												
1 TEVA PHARMACEUT	764	-15.6	818	-15.4	72.9	74.2	75.1	75.7	77.1	79.0	81.9	83.9	84.6	84.9	84.4	84.5
2 RANBAXY PHARM	98	+24.9	105	+25.2	11.5	11.2	11.4	11.5	11.1	10.3	9.6	9.0	9.7	9.3	9.5	9.7
3 ORCHID HEALTH	34	--	37	--	7.6	7.2	6.7	6.2	5.4	4.9	3.5	1.8	0.1	0.0	0.0	0.0
4 SANDOZ	39	-38.9	42	-38.7	3.7	3.5	3.2	3.4	3.5	3.5	3.9	4.3	4.8	5.2	5.3	5.3
5 AUROBINDO PHARM	12	--	13	--	2.8	2.9	2.6	2.4	2.1	1.4	0.3	0.3	0.1	0.1	0.0	0.0
6 WEST WARD	7	+554.3	8	+549.0	0.9	0.8	0.7	0.7	0.8	0.9	0.8	0.8	0.7	0.6	0.6	0.5
7 LUPIN PHARMA	1	--	1	--	0.5	0.3	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Decline in Share: Gave up Cardinal source programs and McKesson OneStop.

**Cefdinir (Omnicef)
CAP, 300 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,244	-14.1	3,318	-14.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,156	+238.0	3,225	+238.1												
1 DAVA PHARM	581	+180.8	596	+180.1	37.1	34.3	24.0	13.1	14.7	15.1	14.8	14.9	15.9	15.9	15.7	18.2
2 TEVA PHARMACEUT	1,089	+321.0	1,112	+320.5	33.7	33.2	33.6	34.4	34.1	33.6	34.4	34.9	35.0	35.5	35.1	34.7
3 SANDOZ	1,042	+193.6	1,061	+194.6	11.2	14.8	24.8	35.8	36.1	36.5	36.3	36.3	36.4	36.5	37.4	37.8
4 LUPIN PHARMA	298	+164.5	307	+163.7	9.9	10.4	11.0	10.9	9.9	9.8	10.0	9.7	9.1	8.8	8.5	7.7
5 ORCHID HEALTH	139	+355305.1	143	+365653.8	6.5	6.2	6.3	5.9	5.3	4.9	4.6	4.2	3.6	3.3	3.2	1.6
6 AUROBINDO PHARM	6	--	6	--	1.6	1.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	88	-96.9	93	-96.8												
1 ABBOTT PHARM PRODS	88	-96.9	93	-96.8	1.1	1.3	1.5	1.7	1.7	1.8	2.1	2.4	3.7	4.3	4.9	5.3
Generic Substitution %	97.3		97.2		98.9	98.7	98.5	98.3	98.3	98.2	97.9	97.6	96.3	95.7	95.1	94.7

Cefdinir (Omnicef)

POS, 125 mg/5ml, 250 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	5,648	-1.9	5,711	-2.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	5,307	+325.5	5,365	+325.7												
1 DAVA PHARM	835	+280.0	844	+279.4	37.4	34.5	25.0	10.1	11.5	12.4	12.1	12.5	12.8	12.7	12.9	15.0
2 TEVA PHARMACEUT	1,806	+317.6	1,823	+317.7	33.3	32.7	33.3	33.9	33.4	32.8	33.3	34.0	34.5	35.7	34.9	34.5
3 SANDOZ	2,060	+273.1	2,083	+273.7	13.9	18.0	26.6	42.2	42.7	43.0	42.6	41.9	42.2	42.0	43.3	44.3
4 LUPIN PHARMA	426	+887.9	432	+880.3	10.2	9.9	10.3	9.3	8.4	8.2	8.5	8.3	7.5	6.9	6.5	5.3
5 ORCHID HEALTH	177	--	180	--	4.7	4.6	4.6	4.4	4.1	3.6	3.5	3.3	3.1	2.6	2.4	0.8
6 AUROBINDO PHARM	3	--	3	--	0.4	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	341	-92.4	345	-92.4												
1 ABBOTT PHARM PRODS	341	-92.4	345	-92.4	1.3	1.6	2.2	2.8	2.9	3.0	3.7	4.4	9.1	10.5	11.2	12.0
Generic Substitution %	94.0		94.0		98.7	98.4	97.8	97.2	97.1	97.0	96.3	95.6	90.9	89.5	88.8	88.0

Cefprozil (Cefzil)

POS, 125 mg/5ml, 250 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,063	-6.9	1,076	-7.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,055	-5.6	1,067	-5.8												
1 LUPIN PHARMA	583	+213.7	590	+211.3	65.4	66.6	66.5	65.4	65.2	64.8	62.5	59.9	56.4	49.0	32.1	25.4
2 TEVA PHARMACEUT	264	-51.4	267	-51.5	12.5	12.8	14.6	18.2	19.2	19.2	20.2	21.9	24.2	28.6	43.7	49.1
3 SANDOZ	111	-3.6	112	-3.6	10.5	10.3	9.7	10.4	10.7	10.7	11.3	11.0	10.7	10.4	10.0	9.3
4 AUROBINDO PHARM	13	--	13	--	8.1	6.7	4.9	1.8	0.4	0.2	0.1	0.0	0.1	0.0	0.0	0.0
5 RANBAXY PHARM	26	+107.1	26	+105.2	2.2	2.3	2.6	2.6	2.7	2.8	2.8	2.9	2.5	2.2	1.9	1.8
6 ORCHID HEALTH	5	--	5	--	0.7	0.7	0.9	0.7	0.6	0.6	0.7	0.4	0.2	0.2	0.1	0.0
7 PAR PHARM	54	-79.3	55	-79.3	0.6	0.7	0.8	1.0	1.2	1.6	2.4	3.8	5.8	9.5	12.3	14.4
Brand	8	-66.4	8	-66.6												
1 BRISTOL-M SQ US PH	8	-66.4	8	-66.6	0.2	0.3	0.4	0.4	0.5	0.9	0.8	0.9	0.9	1.0	1.1	1.1
Generic Substitution %	99.2		99.2		99.8	99.7	99.6	99.6	99.5	99.1	99.2	99.1	99.1	99.0	98.9	98.9

Decline in Share: Gave up RiteAid, Wal-Mart, Walgreens and, recently, McKesson/OneStop.

Cefprozil (Cefzil)
TAB, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	680	-5.9	696	-6.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	675	-4.0	692	-4.3												
1 LUPIN PHARMA	218	+68.1	223	+66.1	38.6	38.9	38.3	36.9	37.3	37.1	36.1	34.1	31.4	26.8	19.1	19.8
2 TEVA PHARMACEUT	181	-40.3	186	-40.3	16.4	16.3	18.3	20.6	21.6	22.2	23.5	24.9	27.7	33.1	42.4	43.0
3 WOCKHARDT AMERICA	70	--	71	--	14.6	17.4	20.3	21.0	20.0	17.9	15.0	9.9	2.8	0.4	0.1	0.0
4 SANDOZ	78	+1.6	80	+1.5	11.7	12.6	12.4	13.0	12.5	12.8	12.2	11.7	11.1	11.0	9.9	8.8
5 APOTEX CORP	5	--	6	--	8.2	3.7	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
6 AUROBINDO PHARM	5	--	6	--	5.3	4.3	2.7	1.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
7 PAR PHARM	104	-45.8	107	-45.9	2.6	3.9	4.6	4.9	5.9	7.6	10.8	17.1	25.1	27.2	27.4	27.5
8 RANBAXY PHARM	13	+488.3	13	+462.0	2.3	2.5	2.4	2.2	2.3	2.2	2.1	2.1	1.8	1.5	1.1	1.0
9 ORCHID HEALTH	1	--	1	--	0.4	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.1	0.0	0.0	0.0
Brand	4	-77.2	5	-76.4												
1 BRISTOL-M SQ US PH	4	-77.2	5	-76.4	0.2	0.4	0.5	0.6	0.6	0.6	0.6	0.6	0.8	0.9	0.9	1.0
Generic Substitution %	99.4		99.3		99.8	99.6	99.5	99.4	99.4	99.4	99.4	99.4	99.2	99.1	99.1	99.0

Decline in Share: Gave up Walgreens, RiteAid and, recently, McKesson/OneStop.

Cephalexin (Cephalexin (Previously Keflet))
TAB, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	10	-10.8	11	-10.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	10	-10.8	11	-10.8												
1 TEVA PHARMACEUT	10	-10.8	11	-10.8	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

**Cephalexin (Keflex)
CAP, 250 mg, 500 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	17,928	-5.7	18,903	-5.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	17,908	-5.7	18,880	-5.8												
1 TEVA PHARMACEUT	14,220	+0.3	14,936	+0.2	81.9	81.9	81.4	81.4	80.7	79.2	78.7	77.7	76.8	76.7	76.7	76.2
2 RANBAXY PHARM	2,680	-22.1	2,877	-22.0	12.4	13.1	13.8	13.8	14.4	15.8	16.0	16.1	16.5	16.7	17.0	17.3
3 LUPIN PHARMA	438	+29.7	467	+30.0	1.8	1.3	1.3	1.5	2.0	2.3	2.3	3.1	3.6	3.7	3.4	3.5
4 KARALEX PHARM	76	--	80	--	1.6	1.4	1.1	0.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5 AUROBINDO PHARM	245	+0.5	257	+0.3	1.3	1.3	1.3	1.4	1.5	1.5	1.5	1.5	1.3	1.2	1.2	1.3
6 WEST WARD	149	+336.3	156	+337.8	0.7	0.7	0.8	0.8	0.8	0.8	0.9	1.0	1.0	1.0	0.8	0.6
7 UNIT DOSE LABS	43	-38.3	46	-37.8	0.1	0.2	0.1	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3
8 DAVA PHARM	23	-82.1	24	-82.5	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2
9 PAR PHARM	29	-94.6	31	-94.5	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.4	0.6
10 AMERICAN HLTH PKG	3	-26.2	3	-25.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
11 WORLD GEN LLC	1	-66.8	1	-66.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	20	-29.5	23	-29.3												
1 MIDDLEBROOK PHARM	20	-29.5	23	-29.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	99.9		99.9		99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9

Gain in Share: RiteAid, Kroger, McKesson/OneStop, Walgreens demand is increasing. Also smaller accounts are growing.

Cephalexin (Keflex)
POS, 125/5 mg/ml, 250/5 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,496	-0.7	2,563	-0.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,496	-0.7	2,563	-0.8												
1 TEVA PHARMACEUT	2,036	-5.0	2,086	-5.2	80.6	81.1	81.1	81.0	81.3	81.9	82.5	81.5	81.0	81.6	81.6	81.4
2 RANBAXY PHARM	360	+20.6	375	+20.4	12.3	12.8	13.4	13.7	13.9	15.0	15.2	15.8	16.0	15.5	15.8	15.5
3 KARALEX PHARM	39	--	39	--	4.4	3.9	3.5	3.3	2.9	1.0	0.0	0.0	0.0	0.0	0.0	0.0
4 LUPIN PHARMA	55	-4.6	56	-4.6	2.5	1.9	1.8	1.7	1.7	1.9	2.0	2.5	2.7	2.5	2.4	2.7
5 PAR PHARM	3	+697.8	3	+697.6	0.1	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.2
6 DAVA PHARM	3	-79.4	3	-79.5	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Cetirizine Dihydrochloride (Zyrtec)
LIQ, 5 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	798	-62.9	1,474	-62.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	45		59													
1 TEVA PHARMACEUT	45	--	59	--	100.0	100.0	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	753	-64.9	1,415	-63.9												
1 PFIZER	753	-64.9	1,415	-63.9	12.7	17.1	32.7	87.4	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Generic Substitution %	5.6		4.0		87.3	82.9	67.3	12.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Chlorzoxazone (Parafon)
TAB, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	323	-9.4	502	-7.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	321	-9.2	498	-7.5												
1 BARR LABS	165	-8.1	262	-6.4	54.0	53.6	53.5	53.3	52.6	52.6	52.1	51.8	51.3	51.6	52.1	52.5
2 TEVA PHARMACEUT	156	-10.4	236	-8.6	45.9	46.2	46.4	46.5	47.3	47.3	47.8	48.0	48.6	48.3	47.8	47.4
Brand	2	-25.5	4	-20.9												
1 MCNEIL PHARM	2	-25.5	4	-20.9	0.8	0.8	0.7	0.9	0.8	0.9	0.9	0.9	0.8	1.0	0.9	0.9
Generic Substitution %	99.4		99.1		99.2	99.2	99.3	99.1	99.2	99.1	99.1	99.1	99.2	99.0	99.1	99.1

Ciclopirox (Penlac Nail Lac)

TOP, 8 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	391	-7.4	537	-11.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	364	+9700.9	488	+10590.2												
1 APOTEX CORP	158	+6177.6	213	+6512.9	39.8	40.4	41.9	43.3	42.9	43.6	44.9	44.9	45.3	45.3	45.6	48.0
2 PERRIGO	112	+16558.7	145	+19940.4	30.8	29.2	29.9	30.1	30.1	30.4	29.9	30.5	29.7	29.7	29.3	27.4
3 G & W LABS	26	+33303.8	36	+40742.7	9.0	9.2	8.8	8.3	7.7	7.1	6.7	6.4	6.3	6.6	6.3	5.8
4 HI-TECH PHARMACAL	17	+13463.4	24	+16835.7	6.0	5.6	5.4	4.5	5.4	4.8	4.6	4.7	4.6	4.3	4.3	3.6
5 SANDOZ	18	+17759.2	25	+19630.7	5.7	5.7	5.2	4.7	4.8	4.8	4.8	4.8	5.2	4.8	5.1	6.2
6 WATSON LABS	12	+409300.0	18	+592000.0	3.3	3.9	3.2	3.3	3.2	3.3	3.8	3.7	4.0	4.3	4.1	4.1
7 JSJ PHARMACEUTICAL	5	--	5	--	2.3	2.4	2.2	2.1	1.7	1.0	0.1	0.0	0.0	0.0	0.0	0.0
8 ACTAVIS	10	+6480.3	14	+7659.3	1.6	1.9	2.0	2.2	2.9	3.5	3.7	3.6	3.5	3.6	3.6	3.5
9 TEVA PHARMACEUT	4	+5873.8	5	+6743.4	1.0	1.2	1.0	1.0	0.9	1.0	1.1	1.1	1.0	1.1	1.3	1.2
10 HARRIS PHARM	1	+45350.0	1	+63950.0	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.1
11 TARO PHARM	1	--	1	--	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.2	0.2
Brand	28	-93.4	50	-91.7												
1 DERMIK	28	-93.4	50	-91.7	3.6	4.2	4.9	5.0	5.2	6.7	8.1	9.7	12.3	14.0	15.5	23.6
Generic Substitution %	92.9		90.8		96.4	95.8	95.1	95.0	94.8	93.3	91.9	90.3	87.7	86.0	84.5	76.4

Cilostazol (Pletal)
TAB, 50 mg,100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	524	-0.8	1,590	-2.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	519	+0.1	1,573	-1.8												
1 TEVA PHARMACEUT	264	+13.3	804	+19.9	46.2	46.0	46.2	46.0	46.1	46.6	48.0	51.5	58.1	59.7	59.5	58.5
2 ROXANE	73	+2436.1	156	+1704.3	16.3	16.3	15.8	15.5	15.0	14.2	12.4	8.6	2.6	0.9	0.9	0.9
3 PRASCO LABS	54	-31.5	177	-32.2	10.7	10.8	11.0	11.0	11.3	11.4	11.5	11.4	11.2	11.6	11.6	11.7
4 COREPHARMA	34	+107.8	132	+116.5	9.0	9.0	9.0	8.6	8.5	8.4	8.3	8.2	8.1	7.9	7.8	7.6
5 APOTEX CORP	46	-1.3	153	-5.0	8.6	8.4	8.4	8.7	9.4	10.0	10.5	10.9	10.4	10.3	10.2	10.7
6 SANDOZ	31	-73.5	105	-72.0	7.7	7.8	7.4	7.1	6.5	6.0	6.0	6.0	6.1	6.2	6.6	7.0
7 WATSON LABS	13	-25.4	35	-26.7	0.9	1.1	1.6	2.4	2.4	2.5	2.6	2.6	2.8	2.6	2.7	2.8
8 ACTAVIS	2	-0.1	8	+0.8	0.3	0.4	0.4	0.6	0.7	0.6	0.6	0.6	0.6	0.6	0.5	0.5
9 MYLAN	0	-50.4	2	-40.8	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10 MUTUAL PHARM	0	-81.2	1	-80.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1
Brand	5	-48.1	17	-45.2												
1 OTSUKA AMERICA PH	5	-48.1	17	-45.2	0.9	1.0	0.9	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.3
Generic Substitution %	99.0		98.9		99.1	99.0	99.1	99.0	99.0	99.0	99.0	99.0	98.8	98.8	98.8	98.7

Decline in Share: Gave up Walgreens.

Cimetidine (Tagamet)
TAB, 300 mg, 400 mg, 800 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	416	-17.0	948	-15.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	416	-16.9	948	-15.3												
1 TEVA PHARMACEUT	252	-14.4	562	-10.3	61.6	61.3	60.7	60.1	59.6	59.3	59.2	59.3	58.9	57.8	57.7	57.3
2 APOTEX CORP	123	-2.2	285	-5.1	30.7	30.6	30.4	30.8	30.9	30.7	30.1	29.3	29.4	29.3	29.0	29.6
3 MYLAN	24	-47.8	57	-45.2	5.4	5.4	5.6	5.6	5.9	5.9	6.2	6.5	6.3	6.5	6.5	6.4
4 BARR LABS	15	-40.7	39	-39.5	2.2	2.4	2.9	3.1	3.2	3.6	4.0	4.4	4.9	5.9	6.3	6.0
5 SANDOZ	1	-83.1	3	-83.6	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.5
6 DAVA PHARM	0	-69.8	1	-71.6	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Cimetidine HCl (Tagamet)
LIQ, 300 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	43	-8.8	61	-10.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	43	-8.8	61	-10.7												
1 HI-TECH PHARMACAL	28	-5.7	39	-6.9	60.8	62.8	66.2	66.1	63.1	64.8	65.7	65.3	64.0	62.8	64.5	64.3
2 MORTON GROVE PHARM	7	-34.1	11	-35.8	19.8	19.8	17.4	16.4	16.7	16.9	17.1	18.2	18.9	19.9	20.1	20.4
3 TEVA PHARMACEUT	5	+37.1	7	+38.1	11.8	11.1	11.0	11.7	13.5	11.4	10.7	10.1	11.3	11.0	9.5	9.5
4 PHARMACEUT ASSOC	2	+26.0	4	+26.5	7.4	6.0	5.2	5.4	6.4	6.6	6.0	6.2	5.2	5.8	5.1	4.8
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Ciprofloxacin HCl (Cipro)
TAB, 250 mg, 500 mg, 750 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	18,792	+4.0	19,728	+3.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	18,741	+4.2	19,670	+4.1												
1 RANBAXY PHARM	5,644	+15.1	5,927	+14.8	29.8	29.7	30.0	29.9	29.7	29.6	28.8	28.7	30.9	31.5	31.5	31.5
2 COBALT LABS	4,659	+306.8	4,826	+313.9	25.0	25.2	25.0	24.9	25.0	24.7	24.6	24.6	24.1	24.3	23.8	23.3
3 DR REDDY'S LAB	3,685	-30.0	3,911	-29.7	16.5	16.6	17.2	17.6	18.3	19.6	21.0	22.3	22.2	22.3	22.5	22.5
4 TEVA PHARMACEUT	3,137	-43.2	3,295	-43.0	16.2	16.3	16.3	16.3	16.4	16.5	16.7	16.5	17.1	17.3	17.5	17.9
5 APOTEX CORP	1,295	+137.5	1,361	+137.7	11.1	10.7	10.0	9.7	8.9	7.7	7.0	6.0	3.7	2.7	2.6	2.7
6 WEST WARD	152	-33.7	161	-34.0	0.8	0.7	0.7	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	1.0
7 ACTAVIS	69	-27.7	82	-20.2	0.3	0.4	0.4	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
8 SANDOZ	27	-25.4	29	-25.7	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
9 AMERICAN HLTH PKG	17	+33.8	18	+32.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10 PAR PHARM	33	-82.4	35	-82.3	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.3	0.3	0.4
11 UNIT DOSE LABS	14	-48.4	15	-48.8	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
12 BARR LABS	5	-62.3	6	-63.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 TARO PHARM	2	-62.5	2	-63.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
14 MYLAN	1	-59.4	1	-59.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15 LANNETT	1	-45.9	1	-47.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	51	-33.8	58	-33.5												
1 SCHERING	51	-33.8	58	-33.5	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4
Generic Substitution %	99.7		99.7		99.8	99.8	99.8	99.7	99.7	99.7	99.7	99.7	99.7	99.6	99.6	99.6

Citalopram Hydrobromide (Celexa)

TAB, 10 mg, 20 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	8,688	+22.6	21,289	+25.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	8,612	+23.2	21,076	+25.9												
1 AUROBINDO PHARM	2,492	+24.5	5,445	+36.7	25.6	25.8	25.5	25.5	25.7	25.9	25.7	25.8	25.8	25.7	26.5	26.8
2 APOTEX CORP	1,745	+107.6	4,573	+93.8	20.2	20.4	21.0	21.2	21.5	22.5	22.6	22.2	22.1	22.6	22.4	22.1
3 TORRENT PHARM	643	--	1,527	--	15.6	15.6	15.5	14.0	12.1	6.4	1.1	0.8	0.6	0.5	0.1	0.0
4 DR REDDY'S LAB	1,167	-9.7	2,959	-6.6	15.4	14.9	14.3	15.1	14.9	13.7	13.5	13.3	13.2	13.2	13.2	13.2
5 TEVA PHARMACEUT	584	+4.7	1,683	+8.4	7.9	7.9	7.8	8.0	8.0	8.1	8.2	8.1	8.0	8.2	7.9	7.9
6 WATSON LABS	518	+4.6	1,250	+3.6	5.9	6.0	6.2	6.0	6.1	6.0	6.0	6.0	6.2	5.4	5.5	5.8
7 CARACO PHARM	1,159	+0.2	2,876	+3.1	5.9	6.0	6.3	6.6	8.1	13.8	19.4	20.1	20.4	20.6	20.6	20.5
8 COREPHARMA	85	+188.6	195	+234.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	0.9	0.9	0.9	0.9	0.8
9 CAMBER PHARM	40	--	111	--	0.8	0.8	0.8	0.7	0.7	0.6	0.4	0.4	0.4	0.3	0.2	0.0
10 PERRIGO	56	+29.9	129	+25.6	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
11 SANDOZ	54	-21.4	144	-25.8	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.7	0.7	0.8	0.8	0.8
12 INWOOD LABS	57	-87.9	152	-87.8	0.4	0.4	0.4	0.5	0.6	0.7	0.8	0.8	0.9	1.0	1.1	1.2
13 WOCKHARDT AMERICA	5	-56.8	12	-53.6	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
14 ACTAVIS	7	-67.1	17	-67.8	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
Brand	76	-23.4	214	-25.2												
1 FOREST PHARM	76	-23.4	214	-25.2	0.8	0.8	0.9	0.9	0.9	1.0	1.0	1.0	1.1	1.2	1.2	1.3
Generic Substitution %	99.1		99.0		99.2	99.2	99.1	99.1	99.1	99.0	99.0	99.0	98.9	98.8	98.8	98.7

Clarithromycin (Biaxin)
TAB, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,967	+18.8	3,119	+18.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,956	+19.2	3,105	+18.5												
1 TEVA PHARMACEUT	790	+50.5	826	+49.7	35.4	24.0	24.0	24.2	24.1	24.5	25.6	25.0	25.5	26.9	29.3	31.3
2 RANBAXY PHARM	1,031	+89.4	1,079	+85.0	22.4	34.1	34.5	34.8	36.8	39.0	38.9	40.4	41.8	39.1	23.6	19.6
3 DAVA PHARM	448	-23.7	476	-23.9	14.8	15.5	15.4	15.4	14.8	15.0	15.2	14.2	14.0	16.2	17.6	17.1
4 APOTEX CORP	264	+6602375.0	277	+6914075.0	13.8	13.2	12.9	12.8	12.1	10.3	11.5	11.7	8.6	2.1	1.1	0.2
5 ROXANE	179	-22.5	187	-23.2	6.7	6.5	6.2	6.3	5.9	5.9	5.7	6.1	5.8	6.0	5.9	5.9
6 SANDOZ	214	-63.5	229	-62.5	5.7	5.5	5.7	5.4	5.1	4.4	2.6	2.2	3.6	8.5	20.7	24.5
7 MYLAN	12	--	14	--	1.2	1.2	1.3	1.1	1.0	0.7	0.3	0.1	0.0	0.0	0.0	0.0
8 WOCKHARDT AMERICA	17	+223.8	18	+227.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.6	1.3	1.8	1.4
Brand	11	-34.4	13	-34.0												
1 ABBOTT PHARM PRODS	11	-34.4	13	-34.0	0.4	0.4	0.4	0.5	0.4	0.4	0.4	0.3	0.4	0.5	0.5	0.5
Generic Substitution %	99.6		99.6		99.6	99.6	99.6	99.5	99.6	99.6	99.6	99.7	99.6	99.5	99.5	99.5

Clarithromycin (Biaxin XL)

MR TAB, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,299	-39.5	1,353	-39.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,111	-23.8	1,151	-23.4												
1 TEVA PHARMACEUT	821	+41.4	849	+41.6	64.6	64.5	64.4	63.8	63.0	58.9	52.4	65.1	85.9	97.9	97.7	97.2
2 WATSON LABS	268	--	278	--	33.8	33.8	34.0	34.6	35.2	39.2	45.6	32.7	11.7	0.0	0.0	0.0
3 SANDOZ	23	-97.4	24	-97.4	1.6	1.6	1.5	1.6	1.8	1.9	2.0	2.2	2.4	2.1	2.3	2.8
Brand	188	-72.7	202	-72.1												
1 ABBOTT PHARM PRODS	188	-72.7	202	-72.1	3.7	4.6	5.1	5.1	5.3	6.0	8.9	10.6	18.8	27.1	27.7	29.5
Generic Substitution %	85.5		85.1		96.3	95.4	94.9	94.9	94.7	94.0	91.1	89.4	81.2	72.9	72.3	70.5

Decline in Share: Gave up ANDA, Kroger, Wal-Mart, Publix and smaller customers.

Clemastine Fumarate (Tavist)
LIQ, 0.5 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	20	-17.5	27	-17.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	20	-17.5	27	-17.0												
1 TEVA PHARMACEUT	19	-16.8	25	-15.9	94.4	93.8	92.7	93.7	94.5	94.5	95.7	96.2	94.7	94.3	96.1	93.8
2 QUALITEST PRODUCTS	1	-6.2	1	-16.6	4.6	4.7	6.7	5.6	4.8	4.9	3.8	3.0	4.4	4.7	2.9	5.2
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Clemastine Fumarate (Tavist)
TAB, 2.68 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	30	-12.8	65	-10.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	30	-12.8	65	-10.1												
1 TEVA PHARMACEUT	21	+1.9	44	+6.8	73.3	72.5	72.2	71.8	71.4	71.3	69.6	67.3	66.0	64.6	63.1	61.6
2 SANDOZ	8	-36.0	20	-33.1	26.7	27.5	27.8	28.2	28.6	28.7	30.4	32.7	34.0	35.4	36.9	38.4
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: Both Premier Group and OneStop usage is increasing.

Clindamycin HCl (Cleocin)
CAP, 150 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,833	-3.4	4,079	-4.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,831	-3.4	4,077	-4.4												
1 RANBAXY PHARM	1,720	+3.2	1,814	+2.8	33.7	44.1	45.3	45.2	45.7	46.1	45.9	46.1	45.8	46.0	45.1	44.9
2 GREENSTONE LTD	538	-1.1	581	-3.0	25.2	14.7	14.3	14.1	13.6	12.9	12.7	12.5	12.8	12.5	12.8	13.2
3 TEVA PHARMACEUT	813	-14.9	863	-16.2	20.7	20.9	20.9	21.4	21.2	21.2	21.5	21.3	21.3	21.2	21.3	21.2
4 WATSON LABS	462	-3.0	494	-4.2	13.2	13.0	12.0	11.9	11.8	11.9	11.7	11.9	12.0	11.8	12.1	12.1
5 SANDOZ	294	-7.1	319	-8.0	7.1	7.2	7.3	7.3	7.6	7.9	8.0	8.0	8.0	8.4	8.6	8.5
6 LANNETT	3	-30.4	3	-32.8	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
7 UNIT DOSE LABS	1	-41.5	2	-40.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1
Brand	2	-26.1	3	-27.1												
1 PFIZER	2	-26.1	3	-27.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	99.9		99.9		100.0	99.9	99.9	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9

Clindamycin HCl (Cleocin)
CAP, 300 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,138	+8.5	3,289	+7.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,136	+8.5	3,287	+7.6												
1 RANBAXY PHARM	2,609	+14.6	2,727	+13.9	76.3	82.5	83.5	83.7	84.2	84.8	84.5	84.5	83.7	83.3	82.8	82.0
2 GREENSTONE LTD	214	+20.9	226	+18.1	13.4	8.0	7.5	7.3	6.7	5.9	5.8	5.5	5.5	5.2	5.4	5.9
3 SANDOZ	203	-5.8	218	-6.7	6.0	5.9	5.8	5.9	6.0	6.2	6.7	6.9	7.4	7.6	7.7	7.7
4 WATSON LABS	40	-25.8	42	-26.6	2.0	1.6	1.2	1.1	1.1	1.0	1.1	1.2	1.2	1.2	1.2	1.3
5 TEVA PHARMACEUT	49	-62.9	51	-63.9	2.0	1.7	1.6	1.6	1.6	1.6	1.4	1.3	1.3	1.3	1.5	1.6
6 LANNETT	17	-42.9	18	-42.7	0.2	0.2	0.3	0.3	0.4	0.3	0.3	0.4	0.7	1.2	1.2	1.2
7 MARTEC PHARM	6	-12.8	6	-13.9	0.2	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3
Brand	1	-37.5	2	-39.3												
1 PFIZER	1	-37.5	2	-39.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.1
Generic Substitution %	100.0		99.9		100.0	100.0	100.0	100.0	99.9	100.0	99.9	100.0	100.0	100.0	99.9	99.9

Clobetasol Propionate (Temovate)
CRM, 0.05 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,058	+7.9	1,460	+8.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,055	+8.1	1,457	+8.2												
1 TARO PHARM	625	+10.1	874	+9.9	56.6	57.0	57.0	57.7	58.0	60.5	62.1	62.6	63.0	62.8	62.8	62.1
2 FOUGERA	395	+68.4	535	+66.3	37.6	40.0	40.5	40.1	39.6	37.0	35.2	34.5	33.9	33.7	33.4	33.4
3 GLENMARK PHARMA	4	--	6	--	3.3	0.7	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
4 TEVA PHARMACEUT	29	-82.7	39	-82.3	2.5	2.2	2.0	2.0	2.2	2.3	2.5	2.7	2.9	3.2	3.6	4.3
5 ACTAVIS	1	-65.6	2	-67.8	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2
Brand	2	-41.1	4	-39.9												
1 PHARMADERM	2	-41.1	4	-39.9	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.3	0.4	0.3	0.3
Generic Substitution %	99.8		99.8		99.8	99.8	99.8	99.8	99.8	99.7	99.8	99.8	99.7	99.6	99.7	99.7

Clobetasol Propionate (Temovate)
OINT, 0.05 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	783	+9.1	1,128	+8.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	781	+9.3	1,126	+8.6												
1 TARO PHARM	480	+9.1	699	+7.9	59.0	58.6	57.9	58.8	59.9	62.4	64.7	64.8	65.0	64.8	64.6	64.4
2 FOUGERA	294	+21.8	418	+22.7	37.3	40.1	41.6	40.9	39.9	37.3	34.9	34.7	34.3	34.5	34.6	34.5
3 GLENMARK PHARMA	3	--	4	--	3.3	1.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
4 TEVA PHARMACEUT	2	-93.0	3	-92.7	0.2	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.3	0.4	0.6	0.7
5 ACTAVIS	1	-69.2	1	-68.4	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.2
Brand	2	-41.1	2	-40.0												
1 PHARMADERM	2	-41.1	2	-40.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.3
Generic Substitution %	99.8		99.8		99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.7	99.8	99.7

Clomiphene Citrate (Clomid)
TAB, 50 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	586	-1.2	755	-0.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	579	-0.9	746	-0.4												
1 WATSON LABS	305	-0.8	390	+0.0	56.5	56.6	55.4	55.2	55.3	54.7	53.1	50.1	46.4	43.3	47.4	53.3
2 TEVA PHARMACEUT	224	+16.7	288	+16.6	36.3	36.1	37.1	37.1	36.2	36.5	37.8	40.2	43.4	46.4	42.3	35.9
3 PAR PHARM	49	-40.5	65	-39.3	7.0	7.1	7.4	7.6	8.3	8.7	8.9	9.4	10.0	10.1	10.1	10.6
4 EMD SERONO	1	-46.5	2	-46.7	0.2	0.1	0.2	0.2	0.2	0.1	0.2	0.2	0.3	0.3	0.2	0.3
Brand	7	-23.3	9	-23.1												
1 SANOFI AVENTIS PHR	7	-23.3	9	-23.1	1.0	1.2	1.1	1.1	1.1	1.1	1.1	1.2	1.3	1.2	1.4	1.4
Generic Substitution %	98.8		98.8		99.0	98.8	98.9	98.9	98.9	98.9	98.9	98.8	98.7	98.8	98.6	98.6

Clomipramine HCl (Anafranil)

CAP, 25 mg, 50 mg, 75 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	196	-0.6	435	-1.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	194	-0.3	429	-1.6												
1 TARO PHARM	110	-14.7	256	-11.5	59.2	58.1	58.0	57.2	56.8	59.1	59.6	60.0	59.0	60.5	62.9	64.0
2 TEVA PHARMACEUT	58	+137.8	115	+123.3	28.5	28.8	28.5	28.5	28.6	27.4	27.0	26.3	26.2	25.3	23.8	21.9
3 MYLAN	15	-49.3	34	-48.7	6.6	7.3	7.8	8.4	8.7	7.8	7.7	8.1	8.7	8.5	8.0	8.7
4 SANDOZ	11	-6.4	24	-14.2	5.7	5.7	5.6	5.9	5.8	5.7	5.6	5.6	6.1	5.5	5.3	5.4
Brand	3	-15.8	6	-21.3												
1 MALLINCKRODT	3	-15.8	6	-21.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.3	1.4	1.5	1.5	1.6
Generic Substitution %	98.7		98.6		98.7	98.7	98.6	98.6	98.6	98.6	98.6	98.7	98.6	98.5	98.5	98.4

Gain in Share: Growth in smaller accounts and chains purchasing through the wholesalers.

Clonazepam (Klonopin)
TAB, 0.5 mg, 1 mg, 2 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	12,607	+6.5	22,160	+6.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	12,446	+6.7	21,868	+6.7												
1 TEVA PHARMACEUT	6,266	+13.7	10,921	+13.0	51.4	51.2	51.3	51.4	50.7	49.7	49.6	49.1	48.8	48.4	48.7	48.9
2 CARACO PHARM	3,600	+4.1	5,950	+7.3	27.4	27.4	27.1	26.6	27.3	28.0	28.1	28.1	27.5	26.8	25.4	26.7
3 ACTAVIS	1,251	-7.3	2,372	-9.6	9.8	9.9	10.0	10.0	10.1	10.2	10.4	10.7	11.4	12.4	13.4	12.1
4 SANDOZ	841	+6.4	1,748	+6.7	8.1	8.1	8.0	8.0	7.8	8.0	7.9	7.9	8.0	8.0	8.1	8.1
5 MYLAN	186	-12.2	327	-17.6	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.5
6 QUALITEST PRODUCTS	82	+136.6	142	+140.0	0.8	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.5
7 WATSON LABS	168	-32.3	316	-30.0	0.7	1.0	1.1	1.4	1.5	1.4	1.4	1.7	1.8	1.8	1.8	1.9
8 APOTEX CORP	43	-1.5	79	-11.3	0.2	0.3	0.3	0.4	0.4	0.5	0.5	0.5	0.4	0.4	0.4	0.2
9 UNIT DOSE LABS	5	-16.3	7	-25.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 MCKESSON PKG SERV	2	-71.4	5	-68.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
11 DISPENSEXPRESS	0	+107.5	1	+229.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	161	-9.5	292	-9.9												
1 ROCHE	161	-9.5	292	-9.9	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
Generic Substitution %	98.7		98.7		98.8	98.8	98.7	98.7	98.7	98.7	98.7	98.7	98.6	98.6	98.6	98.6

Clotrimazole Soln (Lotrimin & Mycelex)

TOP, 1 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	84	+9.9	113	+13.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	83	+12.1	113	+15.4												
1 TARO PHARM	50	+24.7	68	+27.5	62.0	62.5	61.6	62.2	61.6	61.9	61.1	62.0	60.5	60.9	58.6	55.3
2 TEVA PHARMACEUT	33	-2.9	44	+0.7	38.0	37.5	38.4	37.8	38.4	38.1	38.9	38.0	39.5	39.1	41.4	44.7
Brand	1	-70.1	1	-69.2												
1 SCHERING	1	-70.1	1	-69.2	0.5	0.4	0.5	0.4	0.4	0.4	0.4	0.9	0.7	0.5	0.9	0.8
Generic Substitution %	99.3		99.4		99.5	99.6	99.5	99.6	99.6	99.6	99.6	99.1	99.3	99.5	99.1	99.2

Decline in Share: Cardinal sell out decreasing.

Clozapine (Clozaril)

TAB, 25 mg, 50 mg,100 mg, 200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	544	+1.9	1,561	+2.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	504	+4.2	1,458	+4.0												
1 TEVA PHARMACEUT	341	-0.7	1,073	+0.9	73.6	73.5	74.4	74.3	73.5	74.0	73.0	72.8	73.0	73.3	73.2	74.2
2 MYLAN	120	+4.7	293	+2.8	18.5	19.2	19.0	19.0	19.7	20.0	20.8	21.1	21.0	21.0	21.3	20.5
3 CARACO PHARM	40	+70.4	87	+76.4	7.7	7.0	6.3	6.5	6.5	5.7	5.6	5.4	5.5	5.3	5.1	4.9
4 PAR PHARM	2	+42.7	5	+24.4	0.1	0.1	0.1	0.2	0.2	0.3	0.5	0.5	0.5	0.4	0.4	0.4
5 UNIT DOSE LABS	0	+23.3	1	+33.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
Brand	40	-20.3	103	-19.5												
1 NOVARTIS RX	40	-20.3	103	-19.5	5.9	6.2	6.3	6.5	6.4	6.4	6.7	6.7	6.8	6.9	7.2	7.1
Generic Substitution %	92.6		93.4		94.1	93.8	93.7	93.5	93.6	93.6	93.3	93.3	93.2	93.1	92.8	92.9

Cromolyn Sodium (Opticrom)
OPTH, 4 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	129	+8.4	187	+9.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	129	+8.4	186	+9.9												
1 TEVA PHARMACEUT	44	+88.2	63	+84.7	41.7	41.1	35.4	37.8	38.4	35.8	32.2	30.6	28.6	26.0	22.8	19.7
2 FALCON PHARM	47	-16.6	70	-14.5	39.9	38.0	38.6	33.7	27.8	31.3	36.7	39.2	43.0	45.3	47.3	49.6
3 AKORN, INC	36	+0.3	49	+2.4	16.4	19.2	24.0	27.0	31.7	30.8	28.8	27.6	25.8	25.0	26.2	27.3
4 PACIFIC PHARM	2	-36.0	3	-28.5	1.4	1.0	0.7	0.7	1.3	1.3	1.6	1.8	2.0	2.8	2.8	2.4
5 BAUSCH & LOMB	1	-24.8	1	-18.6	0.4	0.6	0.8	0.6	0.5	0.4	0.5	0.5	0.4	0.6	0.7	0.6
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: CVS and ABC/ProGen are new customers.

Cromolyn Sodium Soln (Intal)
INH SOL BFS, 10 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	21	-32.0	39	-35.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	20	-34.4	38	-37.9												
1 TEVA PHARMACEUT	14	-28.2	25	-30.5	74.6	74.3	76.8	70.6	69.9	66.6	62.9	64.6	65.8	65.8	68.4	67.6
2 DEY LABS INC	6	-38.5	12	-43.4	20.9	20.8	21.5	27.3	27.6	31.1	35.0	33.2	32.0	31.7	30.0	30.4
Brand	1	+428.1	1	+312.8												
1 KING PHARM	1	+428.1	1	+312.8	6.9	8.3	12.7	16.3	12.3	7.8	1.5	0.3	0.5	0.4	0.3	0.8
Generic Substitution %	95.9		96.4		93.1	91.7	87.3	83.7	87.7	92.2	98.5	99.7	99.5	99.6	99.7	99.2

Gain in Share: Teva is last generic in market, we recently relaunched the product.

Cyclobenzaprine HCl (Flexeril)
 TAB, 10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	12,481	+3.2	17,568	+3.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	12,422	+3.3	17,459	+3.7												
1 BARR LABS	5,020	-2.3	6,676	-3.2	36.2	36.9	37.1	36.7	37.4	38.9	39.2	39.8	39.9	39.3	39.1	38.6
2 MYLAN	3,922	-4.6	5,476	-3.9	30.4	28.7	28.5	31.4	31.6	31.6	32.0	32.5	32.8	32.3	32.2	32.5
3 WATSON LABS	2,466	+4.6	3,691	+4.4	20.7	22.1	22.8	20.5	20.2	19.8	21.4	21.5	21.2	21.1	21.2	21.2
4 BRECKENRIDGE	429	+261.9	642	+264.7	4.4	4.4	3.9	4.0	3.9	3.5	3.3	2.8	2.5	3.6	4.1	3.8
5 CADISTA PHARM	238	+963.8	389	+732.6	4.4	4.3	4.1	4.1	3.7	2.9	0.9	0.3	0.4	0.6	0.4	0.5
6 QUALITEST PRODUCTS	81	+418.2	124	+433.3	1.2	1.0	1.0	0.7	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.4
7 SANDOZ	100	-8.2	203	-8.1	1.1	1.1	1.1	1.2	1.1	1.1	1.2	1.1	1.1	1.2	1.2	1.3
8 AMNEAL PHARM	18	+108123.5	27	+158729.4	0.8	0.6	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
9 MUTUAL PHARM	84	-1.7	129	+0.5	0.5	0.5	0.5	0.5	0.6	0.8	0.8	0.9	1.0	1.0	1.0	0.9
10 ACTAVIS	51	+4.4	80	+6.8	0.2	0.3	0.5	0.7	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.6
11 UNIT DOSE LABS	3	-31.9	6	-31.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 MAJOR PHARM	6	+183.7	9	+143.8	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0
13 URL PHARMA	3	-77.8	6	-75.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0
14 TEVA PHARMACEUT	1	-51.8	1	-56.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	59	-15.5	108	-11.2												
1 MCNEIL CONS & SPEC	59	-15.5	108	-11.2	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.7
Generic Substitution %	99.5		99.4		99.5	99.4	99.4	99.4	99.4	99.4	99.4	99.4	99.4	99.3	99.3	99.3

Cyclosporine (Neoral)
GELCAP, 25 mg, 50 mg, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	197	-6.2	649	-4.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	131	-5.3	393	-1.6												
1 ABBOTT PHARM PRODS	42	-9.3	156	-7.7	37.4	37.3	38.7	39.4	39.3	39.3	39.7	40.8	40.7	40.8	41.0	41.2
2 BARR LABS	38	+8.4	108	+9.6	27.4	27.7	27.6	27.2	27.0	26.9	26.9	26.6	27.4	28.6	28.0	27.1
3 TEVA PHARMACEUT	38	-0.8	94	+9.5	25.9	25.8	24.7	24.4	24.6	24.5	24.2	24.1	23.1	21.9	22.4	22.4
4 SANDOZ	13	-31.0	35	-24.5	9.2	9.1	9.0	8.8	8.9	9.1	9.1	8.4	8.8	8.7	8.6	9.2
Brand	67	-8.0	255	-9.3												
1 NOVARTIS RX	67	-8.0	255	-9.3	39.3	39.4	39.0	39.3	39.0	39.3	39.1	39.0	39.5	39.6	39.8	39.9
Generic Substitution %	66.2		60.6		60.7	60.6	61.0	60.7	61.0	60.7	60.9	61.0	60.5	60.4	60.2	60.1

Cyclosporine (Neoral)
LIQ, 100 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	7	-2.6	17	-5.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	4	-1.0	8	+2.0												
1 BARR LABS	2	-8.2	3	-6.9	44.9	41.0	46.3	42.5	39.2	44.4	40.3	36.6	39.5	41.6	41.6	45.6
2 ABBOTT PHARM PRODS	1	-13.5	3	-7.0	35.4	37.6	38.1	40.9	41.7	36.3	41.0	46.4	43.0	39.4	45.0	40.6
3 TEVA PHARMACEUT	0	+45.1	1	+29.9	11.3	11.8	8.8	8.8	9.2	9.4	9.8	9.3	11.7	13.0	9.3	10.0
4 APOTEX CORP	0	+319.7	1	+381.4	8.4	9.6	6.7	7.8	9.8	9.9	8.9	7.7	5.8	5.9	4.1	3.9
Brand	3	-4.4	10	-9.9												
1 NOVARTIS RX	3	-4.4	10	-9.9	56.3	54.3	53.9	51.3	55.4	53.9	54.0	58.6	56.7	59.2	57.4	56.8
Generic Substitution %	53.6		44.4		43.7	45.7	46.1	48.7	44.6	46.1	46.0	41.4	43.3	40.8	42.6	43.2

Cyproheptadine HCl (Cyproheptadine (was Periactin))
 TAB, 4 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	538	-0.8	993	-0.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	537	-0.8	993	-0.7												
1 TEVA PHARMACEUT	195	-2.4	379	-4.2	38.2	38.1	38.3	38.2	38.0	37.9	37.9	37.9	38.2	38.4	38.5	38.1
2 BARR LABS	210	-3.0	353	-1.1	34.5	34.5	34.9	35.3	35.6	35.8	36.2	36.4	36.3	36.0	36.1	35.8
3 PAR PHARM	57	-22.7	122	-20.3	12.3	12.4	12.4	12.2	12.1	12.3	12.2	11.9	12.2	12.4	12.1	12.7
4 CYPRESS PHARM	56	+55.5	104	+56.3	11.4	11.1	10.8	10.8	10.8	10.5	10.3	10.2	10.0	9.8	10.0	10.0
5 RISING PHARM	18	+27.4	34	+29.6	3.6	3.8	3.6	3.4	3.4	3.5	3.4	3.4	3.2	3.3	3.3	3.3
6 MAJOR PHARM	0	-39.7	1	-51.5	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Desmopressin Acetate (DDAVP)
TAB, 0.1 mg, 0.2 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	430	-3.5	947	-1.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	419	-2.0	917	+0.3												
1 TEVA PHARMACEUT	206	+11.9	417	+14.2	52.6	52.1	52.1	51.2	50.7	49.7	48.0	45.5	41.0	36.2	33.6	33.8
2 BARR LABS	163	+11.0	393	+12.8	45.4	45.6	45.0	45.2	45.1	44.8	44.7	44.1	42.5	40.0	36.8	35.5
3 APOTEX CORP	50	-48.4	107	-46.7	1.9	2.3	2.9	3.6	4.2	5.5	7.3	10.4	16.5	23.8	29.7	30.7
Brand	12	-37.1	30	-37.8												
1 SANOFI AVENTIS PHR	12	-37.1	30	-37.8	2.8	2.8	2.7	2.8	2.9	3.0	3.3	3.4	3.4	3.4	3.5	3.5
Generic Substitution %	97.2		96.9		97.2	97.2	97.3	97.2	97.1	97.0	96.7	96.6	96.6	96.6	96.5	96.5

Gain in Share: CVS is new customer.

Dexmethylphenidate HCl (Focalin)
TAB, 2.5 mg, 5 mg,10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	521	+9.1	522	+9.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	283	+458.9	283	+458.9												
1 TEVA PHARMACEUT	283	+458.9	283	+458.9	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Brand	238	-44.3	239	-44.2												
1 NOVARTIS RX	238	-44.3	239	-44.2	38.6	44.7	51.5	51.4	49.3	49.4	57.2	54.6	42.3	35.5	36.1	40.4
Generic Substitution %	54.3		54.3		61.4	55.3	48.5	48.6	50.7	50.6	42.8	45.4	57.7	64.5	63.9	59.6

Diazepam (Valium)
 TAB, 2 mg, 5 mg, 10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	9,441	+2.1	13,623	+1.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	9,228	+2.5	13,280	+2.0												
1 MYLAN	5,273	+1.5	7,357	+0.8	53.7	54.0	54.1	54.6	55.2	55.9	56.2	56.3	56.4	56.4	56.3	55.8
2 TEVA PHARMACEUT	2,346	+21.2	3,406	+21.1	27.5	27.0	27.0	26.8	26.0	25.4	25.1	24.7	24.7	24.6	24.4	24.4
3 WATSON LABS	1,338	-15.3	2,103	-14.7	15.6	15.7	15.7	15.7	15.9	15.9	15.7	15.8	15.7	15.8	16.0	16.5
4 QUALITEST PRODUCTS	115	+70.0	172	+68.8	1.8	1.8	1.7	1.4	1.2	1.1	1.1	1.1	1.1	1.1	1.1	1.0
5 BARR LABS	150	-27.7	232	-27.0	1.4	1.4	1.5	1.5	1.6	1.6	1.7	1.9	2.0	2.0	2.1	2.2
6 UNIT DOSE LABS	2	-1.5	4	+2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
7 ACTAVIS	4	-74.7	6	-74.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.1
Brand	213	-14.2	344	-13.8												
1 ROCHE	213	-14.2	344	-13.8	2.3	2.3	2.4	2.4	2.5	2.5	2.5	2.5	2.6	2.8	2.7	2.7
Generic Substitution %	97.7		97.5		97.7	97.7	97.6	97.6	97.5	97.5	97.5	97.5	97.4	97.2	97.3	97.3

Diclofenac Potassium (Cataflam)

TAB, 50 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	372	-6.9	535	-7.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	369	-6.9	530	-7.2												
1 SANDOZ	173	+66.0	246	+55.0	47.9	47.7	47.8	47.1	46.2	46.0	46.5	46.2	46.6	45.3	45.2	44.7
2 MYLAN	141	+24.3	201	+23.1	38.2	38.2	37.8	38.5	38.9	38.5	38.2	38.0	37.6	38.3	37.4	36.3
3 APOTEX CORP	34	+102.9	48	+101.2	9.5	9.3	9.8	9.5	9.5	9.8	9.2	9.5	8.6	8.4	8.4	8.2
4 TEVA PHARMACEUT	21	-86.8	34	-84.8	4.4	4.7	4.7	4.9	5.4	5.6	6.1	6.3	7.3	7.9	9.0	10.8
Brand	2	-15.7	6	-15.6												
1 NOVARTIS RX	2	-15.7	6	-15.6	0.9	0.9	1.0	1.1	1.0	1.0	1.1	1.0	1.1	1.2	1.1	1.0
Generic Substitution %	99.4		99.0		99.1	99.1	99.0	98.9	99.0	99.0	98.9	99.0	98.9	98.8	98.9	99.0

Decline in Share: Gave up smaller accounts purchasing through the wholesalers. Also ANDA purchases declining and gave up smaller direct accounts.

Diclofenac Sodium (Voltaren XR)

MR TAB, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	320	-4.3	621	-5.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	315	-4.0	609	-4.9												
1 ACTAVIS	104	-1.9	194	-2.6	31.7	31.2	32.3	32.0	32.1	32.0	32.3	32.3	31.7	31.5	31.4	31.1
2 TEVA PHARMACEUT	89	-14.8	161	-16.2	25.4	26.2	25.7	25.9	26.2	26.3	26.3	26.4	27.0	26.6	27.2	27.6
3 SANDOZ	37	-18.8	81	-17.0	17.9	16.7	15.3	13.4	11.5	11.3	12.0	12.1	11.9	12.2	12.3	12.6
4 MYLAN	42	+55.5	81	+55.8	13.7	13.8	13.4	13.6	13.6	13.7	13.1	13.0	13.1	12.8	12.7	12.2
5 WATSON LABS	43	-5.0	93	-7.3	11.3	12.0	13.3	15.2	16.6	16.7	16.3	16.2	16.3	17.0	16.4	16.4
Brand	4	-20.3	11	-18.8												
1 NOVARTIS RX	4	-20.3	11	-18.8	1.7	1.7	1.6	1.7	1.7	1.7	1.8	1.6	1.9	2.1	2.2	1.9
Generic Substitution %	98.6		98.2		98.3	98.3	98.4	98.3	98.3	98.3	98.2	98.4	98.1	97.9	97.8	98.1

Dicloxacillin Sodium (Dicloxacillin Sodium)
CAP, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	430	-10.2	460	-10.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	323	-5.2	343	-5.2												
1 TEVA PHARMACEUT	323	-5.2	343	-5.2	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Brand	107	-22.4	117	-22.0												
1 SANDOZ	107	-22.4	117	-22.0	24.4	24.4	25.4	24.9	24.6	25.7	25.3	25.3	26.2	25.2	26.0	26.5
Generic Substitution %	75.1		74.6		75.6	75.6	74.6	75.1	75.4	74.3	74.7	74.7	73.8	74.8	74.0	73.5

Diflunisal (Dolobid)
TAB, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	208	-12.1	314	-11.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	208	-12.1	314	-11.6												
1 TEVA PHARMACEUT	208	-12.1	314	-11.6	100.0	100.0	100.0	100.0	100.0	99.9	99.9	99.8	99.9	99.9	99.9	99.9
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Diltiazem HCl (Cardizem)

TAB, 30 mg, 60 mg, 90 mg, 120 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	427	+14.9	1,077	+11.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	424	+15.2	1,068	+11.4												
1 MYLAN	328	+17.0	830	+12.8	77.8	77.5	77.0	76.6	77.3	77.6	79.1	80.5	78.7	76.0	76.6	76.8
2 TEVA PHARMACEUT	89	+11.8	222	+9.3	21.3	21.6	21.7	21.8	21.2	20.9	19.2	17.6	19.3	22.1	21.6	21.4
3 UNIT DOSE LABS	6	+18.7	15	+4.4	0.7	0.7	1.1	1.4	1.3	1.4	1.5	1.7	1.8	1.7	1.5	1.5
4 WATSON LABS	1	-74.6	1	-77.9	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3
Brand	3	-13.6	9	-16.5												
1 BIOVAIL PHARMACEUT	3	-13.6	9	-16.5	0.7	0.7	0.8	0.8	0.8	0.8	0.9	0.9	0.9	1.0	0.9	1.0
Generic Substitution %	99.3		99.2		99.3	99.3	99.2	99.2	99.2	99.2	99.1	99.1	99.1	99.0	99.1	99.0

Diltiazem HCl (Cardizem CD)

MR CAP, 120 mg, 180 mg, 240 mg, 300 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,956	-4.2	9,880	-4.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,913	-3.7	9,723	-3.8												
1 WATSON LABS	1,785	+0.0	5,770	+2.0	55.5	56.0	56.5	59.1	61.2	60.6	60.5	60.7	60.6	60.2	60.3	60.5
2 ACTAVIS	633	-5.0	2,156	-7.7	22.4	22.1	22.8	21.3	21.2	21.8	22.0	22.1	22.6	22.7	22.6	22.3
3 TEVA PHARMACEUT	373	-8.9	1,441	-8.3	15.4	15.4	15.3	15.0	14.9	15.0	14.8	14.5	14.4	14.3	14.5	14.4
4 APOTEX CORP	112	-24.7	326	-34.1	6.5	6.3	5.1	4.3	2.4	2.4	2.3	2.3	2.0	2.3	2.3	2.3
5 AMERICAN HLTH PKG	9	-35.5	30	-39.0	0.2	0.2	0.2	0.2	0.2	0.3	0.4	0.4	0.4	0.4	0.4	0.4
6 MCKESSON PKG SERV	0	-81.3	1	-83.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	43	-29.9	157	-29.0												
1 BIOVAIL PHARMACEUT	43	-29.9	157	-29.0	1.4	1.4	1.4	1.4	1.5	1.5	1.6	1.6	1.7	1.8	1.8	1.9
Generic Substitution %	98.6		98.4		98.6	98.6	98.6	98.6	98.5	98.5	98.4	98.4	98.3	98.2	98.2	98.1

Diphenhydramine HCl (Diphenhydramine HCL)
CAP, 25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	182	+9.6	308	+7.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	181	+9.6	308	+7.5												
1 TEVA PHARMACEUT	181	+9.7	307	+7.7	99.7	99.7	99.6	99.7	99.6	99.7	99.7	99.7	99.6	99.5	99.5	99.3
2 URL PHARMA	1	-18.0	1	-22.6	0.2	0.2	0.3	0.2	0.3	0.2	0.2	0.3	0.3	0.3	0.4	0.4
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

**Disopyramide Phosphate (Norpace)
CAP, 100 mg, 150 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	15	-8.0	50	-10.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	14	-7.6	47	-9.8												
1 WATSON LABS	13	-8.8	42	-12.3	85.9	86.8	88.6	87.8	88.7	88.6	88.6	87.8	88.6	87.2	87.5	87.6
2 TEVA PHARMACEUT	1	+3.8	6	+13.9	14.1	13.2	11.4	12.2	11.3	11.4	11.4	12.2	11.4	12.8	12.5	12.4
Brand	1	-14.9	2	-20.8												
1 PFIZER	1	-14.9	2	-20.8	4.2	4.1	4.5	4.3	4.4	4.3	4.2	5.3	4.6	4.9	4.8	5.3
Generic Substitution %	95.4		95.4		95.8	95.9	95.5	95.7	95.6	95.7	95.8	94.7	95.4	95.1	95.2	94.7

Doxazosin Mesylate (Cardura)

TAB, 1 mg, 2 mg, 4 mg, 8 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,817	-6.1	5,966	-4.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,797	-5.7	5,892	-3.9												
1 APOTEX CORP	998	+80.6	3,176	+89.7	58.9	57.8	56.6	55.1	54.0	53.4	52.8	52.6	52.2	52.1	51.6	50.3
2 TEVA PHARMACEUT	507	-3.8	1,736	-4.6	29.2	29.5	29.3	29.4	29.5	29.1	29.5	29.5	29.8	29.9	29.5	29.4
3 ETHEX CORP	260	-38.0	888	-40.7	11.0	11.7	13.1	14.5	15.4	16.2	16.4	16.3	16.3	16.1	16.5	17.1
4 MYLAN	7	-35.8	23	-40.0	0.4	0.4	0.4	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.5
5 BARR LABS	18	-94.9	47	-95.3	0.3	0.4	0.4	0.4	0.5	0.6	0.7	0.8	0.9	1.1	1.4	2.2
6 ACTAVIS	3	-88.3	8	-87.8	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2
7 UNIT DOSE LABS	2	-23.8	5	-36.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
8 PAR PHARM	2	-66.1	5	-68.9	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
9 MAJOR PHARM	1	-8.1	3	+10.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.1	0.0
10 DAVA PHARM	0	-91.4	1	-88.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	19	-30.1	74	-27.0												
1 PFIZER	19	-30.1	74	-27.0	1.1	1.1	1.1	1.2	1.2	1.2	1.3	1.2	1.3	1.4	1.4	1.4
Generic Substitution %	98.9		98.8		98.9	98.9	98.9	98.8	98.8	98.8	98.7	98.8	98.7	98.6	98.6	98.6

Doxepin HCl Conc (Sinequan)
LIQ, 10 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	9	+5.5	17	+5.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	9	+5.5	17	+5.2												
1 MORTON GROVE PHARM	5	-11.3	10	-10.6	50.8	52.8	53.0	53.1	54.2	55.8	56.2	55.7	55.3	60.7	61.5	66.8
2 TEVA PHARMACEUT	4	+39.4	7	+36.9	47.1	45.9	45.9	45.0	43.7	42.1	42.4	43.2	42.8	37.5	37.3	31.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: Increasing sales from smaller accounts purchasing through the wholesalers.

Doxycycline Hyclate (Periostat)

TAB, 20 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	228	-10.9	511	-10.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	224	-9.3	500	-9.0												
1 LANNETT	78	+368.0	183	+362.0	39.0	39.6	39.0	39.0	38.7	37.8	37.3	36.8	36.5	34.1	32.4	30.2
2 MUTUAL PHARM	75	-0.1	182	+1.5	34.4	34.4	34.6	34.7	34.8	35.8	36.3	37.1	36.8	37.5	39.9	38.8
3 TEVA PHARMACEUT	61	-42.4	115	-53.1	25.0	24.8	25.3	25.2	25.2	25.0	24.4	23.6	23.4	22.1	19.0	13.5
4 SANDOZ	10	-79.1	21	-76.1	1.6	1.2	1.1	1.1	1.2	1.4	2.0	2.5	3.3	6.3	8.8	17.5
Brand	4	-56.2	11	-55.2												
1 GALDERMA LABS	4	-56.2	11	-55.2	1.5	1.5	1.6	1.7	1.7	1.9	2.1	2.1	2.4	2.6	2.7	2.7
Generic Substitution %	98.3		97.9		98.5	98.5	98.4	98.3	98.3	98.1	97.9	97.9	97.6	97.4	97.3	97.3

Gain in Share: Walgreens is a new customer. Greater sales from smaller accounts purchasing through wholesalers. Increasing sales by Supervalu and Heartland.

Doxycycline Hyclate (Vibra-Tabs)
TAB, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,395	+2.0	2,966	+1.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,395	+2.0	2,965	+1.9												
1 WEST WARD	759	+217.9	911	+227.3	29.6	29.7	30.2	30.0	31.7	31.6	30.9	31.3	31.0	31.4	31.1	29.6
2 MUTUAL PHARM	504	+105.4	632	+103.8	25.4	24.7	24.4	24.0	21.6	20.7	20.7	20.4	19.6	19.0	18.6	17.7
3 TEVA PHARMACEUT	532	+3.0	681	+3.7	22.5	22.8	22.7	22.8	22.4	22.6	23.0	23.1	23.7	23.2	23.3	23.3
4 WATSON LABS	568	-50.4	702	-50.4	22.0	22.4	22.0	22.4	23.3	23.9	24.2	23.7	23.9	24.5	24.7	26.5
5 URL PHARMA	29	-85.7	36	-85.5	0.4	0.4	0.5	0.7	0.8	1.0	1.0	1.3	1.6	1.8	2.1	2.8
6 MAJOR PHARM	3	+83.0	4	+81.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.1
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Doxycycline Hyclate (Vibramycin)

CAP, 50 mg,100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	6,885	+6.4	8,232	+6.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	6,884	+6.4	8,230	+6.0												
1 WEST WARD	3,000	+235.4	3,539	+235.8	44.6	44.0	45.1	45.7	44.9	43.8	42.9	41.5	41.7	41.4	41.5	39.7
2 WATSON LABS	2,902	-34.8	3,449	-35.1	39.3	39.6	38.9	39.0	40.4	41.3	42.3	43.8	44.0	44.2	44.1	45.3
3 TEVA PHARMACEUT	323	-26.6	440	-21.0	8.3	8.2	7.6	7.1	6.0	4.6	3.7	3.6	3.8	3.8	3.9	4.4
4 MUTUAL PHARM	592	+7.8	722	+5.6	7.1	7.5	7.5	7.4	7.9	9.4	10.1	10.1	9.5	9.6	9.4	9.2
5 QUALITEST PRODUCTS	40	-29.7	47	-30.1	0.5	0.5	0.6	0.6	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.8
6 MAJOR PHARM	11	-21.4	13	-18.6	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.1	0.2	0.2	0.2	0.3
7 URL PHARMA	13	-77.8	16	-76.5	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.4
8 AMNEAL PHARM	3	+36.0	3	+29.6	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	1	-12.6	2	-10.0												
1 PFIZER	1	-12.6	2	-10.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Enalapril Maleate (Vasotec)

TAB, 2.5 mg, 5 mg,10 mg, 20 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	4,260	-4.3	13,342	-5.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	4,219	-4.1	13,196	-4.8												
1 MYLAN	1,709	-1.7	5,049	-1.5	38.3	38.7	38.5	38.4	38.5	38.3	38.5	38.3	38.3	38.0	37.8	37.4
2 WOCKHARDT AMERICA	1,097	+40.4	3,621	+35.8	32.9	30.5	27.6	26.3	26.5	26.9	26.7	26.5	26.3	26.4	26.5	26.6
3 TEVA PHARMACEUT	735	-17.8	2,211	-16.4	16.2	16.1	16.3	16.5	16.5	16.7	16.8	17.0	17.2	16.9	17.3	17.6
4 RANBAXY PHARM	409	+2.7	1,412	+4.5	6.4	8.4	10.9	11.9	11.5	11.2	11.2	11.0	11.1	11.5	11.4	11.4
5 TARO PHARM	82	-64.2	286	-65.8	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.3	2.3	2.4	2.2	2.2
6 APOTEX CORP	39	+61627.0	110	+59769.9	1.5	1.4	1.4	1.3	1.2	0.8	0.7	0.6	0.5	0.4	0.2	0.1
7 SANDOZ	54	-60.2	187	-58.6	1.2	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.5	1.5	1.6	1.7
8 PAR PHARM	57	-32.4	187	-34.7	0.9	1.0	1.1	1.2	1.5	1.5	1.5	1.6	1.6	1.6	1.7	1.7
9 WATSON LABS	30	-76.5	114	-76.1	0.4	0.5	0.6	0.7	0.8	0.9	1.0	1.0	1.0	1.1	1.1	1.1
10 UNIT DOSE LABS	7	-12.9	16	-39.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2
11 MAJOR PHARM	1	+13.0	4	+42.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	41	-24.5	146	-26.2												
1 BIOVAIL PHARMACEUT	41	-24.5	146	-26.2	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.2	1.2	1.2	1.2
Generic Substitution %	99.0		98.9		99.0	99.0	99.0	99.0	99.0	98.9	98.9	98.9	98.8	98.8	98.8	98.8

Enalapril Maleate/HCTZ (Vaseretic)

TAB, 5mg/12.5 mg,10mg/25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	347	-4.2	1,125	-4.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	342	-3.6	1,106	-3.9												
1 TARO PHARM	133	-4.2	440	-5.3	37.1	36.6	37.6	38.3	40.0	41.4	41.3	41.8	42.0	40.3	40.3	40.4
2 MYLAN	104	+1.0	351	+1.2	31.1	31.7	31.8	32.3	31.9	31.9	31.9	31.3	30.7	32.1	32.1	31.8
3 TEVA PHARMACEUT	89	-10.3	254	-11.8	23.1	23.4	22.6	22.6	22.3	22.4	23.1	23.2	23.5	23.0	23.1	22.9
4 APOTEX CORP	3	+6077.6	13	+4292.8	2.9	2.0	1.8	1.5	1.4	1.2	0.8	0.9	0.7	0.6	0.5	0.4
5 PAR PHARM	5	-10.1	16	+3.2	2.9	2.9	2.5	1.3	0.9	0.9	0.9	0.9	1.0	0.9	1.0	1.1
6 DR REDDY'S LAB	7	+21.6	24	+7.7	2.2	2.6	2.9	3.2	2.8	1.6	1.2	1.2	1.4	2.3	2.3	2.5
7 SANDOZ	2	-41.2	8	-43.0	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.8
Brand	5	-33.6	19	-33.1												
1 BIOVAIL PHARMACEUT	5	-33.6	19	-33.1	1.4	1.5	1.6	1.6	1.5	1.6	1.7	1.7	1.8	1.9	1.9	1.9
Generic Substitution %	98.6		98.3		98.6	98.5	98.4	98.4	98.5	98.4	98.3	98.3	98.2	98.1	98.1	98.1

Estazolam (Prosom)

TAB, 1 mg, 2 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	84	-15.8	169	-14.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	83	-13.3	168	-11.5												
1 TEVA PHARMACEUT	52	-22.9	105	-20.2	54.4	57.1	57.4	58.1	60.0	60.6	62.1	63.0	66.3	68.4	70.0	69.0
2 WATSON LABS	18	-21.2	38	-22.8	27.5	26.4	25.8	26.0	23.5	23.4	22.0	20.7	19.2	17.9	17.2	20.3
3 PAR PHARM	13	+138.4	26	+160.5	18.1	16.6	16.8	15.9	16.4	16.0	15.9	16.2	14.5	13.6	12.8	10.6
Brand	0	-86.8	1	-88.6												
1 ABBOTT PHARM PRODS	0	-86.8	1	-88.6	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.4	0.8	1.3	2.0
Generic Substitution %	99.5		99.5		99.9	99.9	99.9	99.9	99.8	99.8	99.8	99.7	99.6	99.2	98.7	98.0

Decline in Share: Gave up McKesson/OneStop and ABC/Progen. Walgreens, CVS and Wal-Mart usage declining.

Ethinyl Estradiol/Norgestimate (Ortho Cyclen-28)

TAB, 0.035/0.25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	982	+11.6	3,144	+1.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	929	+15.3	2,946	+4.2												
1 BARR LABS	546	-12.4	1,871	-13.4	53.3	53.2	53.3	53.2	53.2	53.9	58.7	74.2	78.4	78.4	78.0	77.8
2 WATSON LABS	378	+146.4	1,059	+89.1	46.2	46.4	46.3	46.5	46.4	45.7	40.9	25.4	21.0	20.8	21.0	21.0
3 TEVA PHARMACEUT	4	-85.2	17	-84.6	0.5	0.4	0.4	0.3	0.3	0.4	0.4	0.5	0.6	0.9	1.0	1.1
Brand	53	-28.6	197	-30.8												
1 ORTHO PHARM	53	-28.6	197	-30.8	5.2	5.5	5.8	5.9	6.2	6.2	6.2	6.4	6.6	7.0	7.1	7.5
Generic Substitution %	94.6		93.7		94.8	94.5	94.2	94.1	93.8	93.8	93.8	93.6	93.4	93.0	92.9	92.5

Ethinyl Estradiol/Norgestimate/Norgestimate/Norgestimate (Ortho Tricyclen-28)

TAB, 0.035/0.18/0.215/0.25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,239	-6.7	11,454	-7.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,994	-3.4	10,554	-4.1												
1 WATSON LABS	1,726	-3.2	5,882	-2.2	56.0	56.0	55.8	55.6	55.7	55.6	55.4	55.8	55.9	55.6	55.7	55.7
2 BARR LABS	1,249	+4.7	4,598	+2.4	43.2	43.2	43.5	43.7	43.8	44.0	44.1	43.6	43.5	43.5	43.3	43.3
3 TEVA PHARMACEUT	19	-84.9	74	-85.2	0.7	0.7	0.7	0.7	0.5	0.5	0.5	0.5	0.6	0.9	1.0	1.1
Brand	246	-33.8	900	-35.0												
1 ORTHO PHARM	246	-33.8	900	-35.0	6.9	7.0	7.2	7.4	7.5	7.6	7.8	8.0	8.1	8.7	8.8	9.1
Generic Substitution %	92.4		92.1		93.1	93.0	92.8	92.6	92.5	92.4	92.2	92.0	91.9	91.3	91.2	90.9

Ethosuximide (Zarontin)
LIQ, 250 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	15	+6.4	45	+6.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	14	+12.0	39	+11.4												
1 TEVA PHARMACEUT	10	+41.0	29	+46.3	79.5	80.3	79.9	78.5	77.0	76.7	73.4	72.5	70.5	68.0	62.2	57.7
2 PHARMACEUT ASSOC	3	-31.5	10	-32.5	20.5	19.6	19.9	21.4	22.9	23.2	26.5	27.3	29.3	31.9	37.5	42.1
Brand	2	-23.6	5	-20.9												
1 PFIZER	2	-23.6	5	-20.9	10.8	10.8	11.3	11.3	12.3	12.0	11.5	13.1	12.3	12.8	13.0	13.6
Generic Substitution %	88.7		88.0		89.2	89.2	88.7	88.7	87.7	88.0	88.5	86.9	87.7	87.2	87.0	86.4

Gain in Share: Walgreens and McKesson OneStop usage increasing. Chains purchasing more through the wholesalers.

**Etodolac (Lodine)
CAP, 300 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	119	-16.1	205	-15.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	119	-16.1	205	-15.5												
1 TARO PHARM	53	-21.8	97	-21.6	47.0	46.4	46.2	46.8	45.9	44.9	45.2	46.8	47.0	48.3	49.4	51.2
2 TEVA PHARMACEUT	57	-13.7	91	-13.1	42.9	43.8	43.4	43.3	43.9	45.1	45.9	45.4	46.5	45.5	44.6	43.4
3 APOTEX CORP	8	+33.9	16	+46.8	9.9	9.5	10.1	9.5	10.0	9.7	8.5	7.4	6.0	5.7	5.4	4.8
4 MYLAN	0	-70.6	1	-73.9	0.3	0.2	0.2	0.4	0.2	0.2	0.4	0.4	0.4	0.4	0.5	0.6
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

**Etodolac (Lodine)
TAB, 400 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,043	-8.1	1,673	-7.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,043	-8.1	1,673	-7.5												
1 APOTEX CORP	441	+100.5	660	+115.8	43.8	43.6	43.1	42.2	41.0	39.0	38.0	37.8	37.5	36.3	36.2	35.5
2 TARO PHARM	267	-15.4	450	-16.2	23.3	23.8	24.1	24.4	25.6	27.7	28.7	28.8	28.9	28.8	28.9	29.3
3 ACTAVIS	142	-59.8	247	-56.2	14.2	14.2	14.2	14.8	14.5	14.5	14.6	14.6	14.9	15.5	15.4	15.7
4 SANDOZ	95	-10.0	169	-8.5	10.2	10.1	10.1	10.2	10.3	10.2	10.0	10.0	9.9	10.2	10.1	10.1
5 TEVA PHARMACEUT	97	-30.0	146	-31.3	8.4	8.3	8.4	8.4	8.6	8.7	8.7	8.8	8.7	9.1	9.3	9.3
6 MYLAN	1	-74.6	1	-76.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Etodolac (Lodine XL)

MR TAB, 400 mg, 500 mg, 600 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	287	-20.7	532	-18.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	286	-20.6	532	-18.4												
1 TEVA PHARMACEUT	203	-23.2	382	-20.2	73.0	72.9	72.5	72.2	71.7	71.4	71.2	71.0	71.4	71.3	71.5	71.8
2 TARO PHARM	83	-12.9	150	-12.4	27.0	27.0	27.4	27.8	28.2	28.5	28.7	28.9	28.5	28.6	28.4	28.1
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Famciclovir (Famvir)
TAB, 125 mg, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	658	-5.4	1,001	-1.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	591	+2183.4	878	+2697.3												
1 TEVA PHARMACEUT	591	+2183.4	878	+2697.3	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Brand	68	-89.9	123	-87.6												
1 NOVARTIS RX	68	-89.9	123	-87.6	6.5	7.0	7.5	8.9	9.7	10.1	10.2	11.4	14.2	16.8	18.0	25.1
Generic Substitution %	89.7		87.7		93.5	93.0	92.5	91.1	90.3	89.9	89.8	88.6	85.8	83.2	82.0	74.9

Famotidine (Pepcid)
TAB, 20 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,181	-0.3	5,221	-0.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,173	-0.2	5,195	-0.6												
1 TEVA PHARMACEUT	1,469	+0.9	3,217	+0.2	61.3	61.7	61.8	62.2	62.4	62.1	62.4	62.0	62.1	61.9	61.9	61.2
2 WOCKHARDT AMERICA	213	+26.8	671	+22.9	16.6	15.6	14.1	13.2	12.8	12.7	12.4	12.0	11.5	11.4	11.3	11.5
3 PAR PHARM	303	-9.8	812	-8.8	12.9	13.5	14.8	15.5	15.6	15.9	15.8	16.2	16.5	17.0	16.8	17.0
4 WATSON LABS	88	-11.7	222	-13.8	4.2	4.1	4.2	4.1	4.2	4.3	4.3	4.4	4.5	4.1	4.4	4.6
5 DR REDDY'S LAB	44	+10.5	123	+5.7	2.6	2.5	2.4	2.4	2.3	2.3	2.3	2.3	2.2	2.3	2.4	2.4
6 MYLAN	50	-25.5	132	-25.3	2.3	2.4	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.7	2.7
7 UNIT DOSE LABS	2	-72.9	8	-68.9	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2
8 MAJOR PHARM	3	+65.0	3	+59.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
9 AMERICAN HLTH PKG	1	+27000.0	6	+194966.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.3	0.3	0.1
Brand	8	-28.1	26	-23.2												
1 MERCK & COMPANY	8	-28.1	26	-23.2	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.5	0.5
Generic Substitution %	99.6		99.5		99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.4	99.5	99.5

Fexofenadine HCl (Allegra)
TAB, 30 mg, 60 mg,180 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	7,288	-13.4	18,336	-6.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	7,126	-12.2	17,858	-4.5												
1 DR REDDY'S LAB	3,591	+63.4	8,477	+98.5	47.2	47.0	46.3	46.9	47.9	48.2	48.1	47.7	47.7	47.4	47.5	47.5
2 TEVA PHARMACEUT	2,028	-35.4	5,319	-27.7	28.3	29.6	30.2	30.7	30.4	30.1	29.6	29.5	29.7	29.6	29.7	29.8
3 PRASCO LABS	1,465	-47.3	3,945	-44.2	22.3	22.2	22.5	21.8	21.2	21.2	21.9	22.4	22.2	22.6	22.6	22.5
4 MYLAN	42	+2298.2	117	+2373.1	2.2	1.1	0.9	0.6	0.5	0.5	0.4	0.4	0.5	0.4	0.2	0.1
5 UNIT DOSE LABS	0	+141.5	1	+179.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	162	-44.4	478	-43.3												
1 SANOFI AVENTIS PHR	162	-44.4	478	-43.3	2.1	2.1	2.2	2.2	2.3	2.4	2.6	2.7	3.0	3.2	3.2	3.2
Generic Substitution %	97.8		97.4		97.9	97.9	97.8	97.8	97.7	97.6	97.4	97.3	97.0	96.8	96.8	96.8

Finasteride (Proscar)
TAB, 5 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,293	+11.5	4,331	+16.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,261	+15.4	4,212	+21.9												
1 TEVA PHARMACEUT	481	-28.8	1,493	-26.2	36.2	36.0	36.2	36.0	35.9	35.6	35.6	35.7	35.5	33.6	34.3	34.7
2 DR REDDY'S LAB	243	+6.3	849	+5.4	21.8	21.3	19.6	17.9	18.1	18.9	19.2	20.0	20.4	21.1	21.6	22.1
3 ACTAVIS	167	+778.1	583	+943.6	15.9	15.8	15.3	15.2	15.3	14.7	14.2	13.4	12.6	11.7	10.9	10.3
4 MYLAN	219	+95.0	757	+100.1	13.7	14.4	16.4	18.0	18.1	18.3	18.5	18.5	19.1	20.8	20.5	20.2
5 AUROBINDO PHARM	30	--	98	--	11.1	9.8	5.3	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
6 BARR LABS	120	+113.8	430	+125.5	1.3	2.6	7.0	12.4	12.6	12.5	12.5	12.4	12.5	12.7	12.8	12.6
7 UNIT DOSE LABS	1	--	1	--	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	32	-52.3	119	-54.8												
1 MERCK & COMPANY	32	-52.3	119	-54.8	2.0	2.1	2.1	2.2	2.3	2.4	2.5	2.8	3.2	3.8	3.8	4.0
Generic Substitution %	97.5		97.3		98.0	97.9	97.9	97.8	97.7	97.6	97.5	97.2	96.8	96.2	96.2	96.0

Fluconazole (Diflucan)

TAB, 50 mg,100 mg, 150 mg, 200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	10,548	+2.4	12,817	+1.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	10,481	+2.6	12,723	+2.2												
1 TEVA PHARMACEUT	5,744	+5.5	6,898	+5.0	55.7	55.7	55.6	55.1	54.5	53.9	53.7	53.7	53.7	53.3	53.0	52.8
2 GLENMARK PHARMA	3,768	+43.2	4,605	+44.2	36.8	36.7	36.6	36.8	36.5	36.1	36.1	36.0	35.7	36.0	35.8	35.3
3 GREENSTONE LTD	744	-26.1	936	-26.0	5.7	5.8	5.9	6.1	7.0	7.8	8.0	8.1	8.4	8.4	8.5	8.6
4 RANBAXY PHARM	155	-70.2	196	-70.8	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.5	1.5	1.4	1.5	1.7
5 PAR PHARM	26	-78.2	33	-77.5	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.3	0.4	0.6	0.9
6 APOTEX CORP	17	-28.8	21	-29.3	0.0	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
7 DR REDDY'S LAB	13	-97.0	16	-96.9	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3
8 MYLAN	2	-48.5	2	-48.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
9 TARO PHARM	6	-75.6	7	-75.9	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10 UNIT DOSE LABS	3	+0.4	3	-2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
11 SANDOZ	2	-87.1	2	-88.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 PHYSICIAN PARTNER	0	+917.5	1	+1041.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 BARR LABS	1	-44.8	1	-46.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
14 ROXANE	2	-79.6	2	-79.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	67	-25.2	94	-26.3												
1 PFIZER	67	-25.2	94	-26.3	0.6	0.6	0.6	0.7	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.8
Generic Substitution %	99.4		99.3		99.4	99.4	99.4	99.3	99.3	99.3	99.2	99.2	99.2	99.2	99.2	99.2

**Fluocinonide (Lidex)
CRM, 0.05 %**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,111	+1.4	1,550	+1.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,111	+1.7	1,549	+1.4												
1 TARO PHARM	777	-10.2	1,087	-10.5	65.3	66.1	67.0	67.7	69.3	71.5	73.6	73.4	73.0	72.2	72.2	72.0
2 TEVA PHARMACEUT	277	+73.8	378	+75.3	28.5	28.0	27.4	26.9	25.9	24.5	23.0	22.6	21.8	21.5	20.9	21.0
3 FOUGERA	56	-15.7	83	-14.0	6.2	5.9	5.6	5.3	4.8	4.0	3.4	3.9	5.2	6.3	6.8	6.9
Brand	1	-80.3	1	-83.8												
1 MEDICIS DERM	1	-80.3	1	-83.8	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	99.9		99.9		100.0	100.0	100.0	100.0	99.9	100.0	99.9	99.9	99.9	99.9	99.9	99.9

Gain in Share: ABC/ProGen is a new customer. RiteAid usage increasing.

**Fluocinonide (Lidex)
GEL, 0.05 %**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	88	-0.7	119	-0.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	88	+1.0	118	+1.2												
1 FOUGERA	38	+10.7	50	+11.9	43.2	42.8	43.1	43.0	42.8	43.3	40.7	41.2	41.8	40.9	42.3	41.0
2 TEVA PHARMACEUT	27	-9.3	37	-9.0	31.1	30.7	31.0	32.1	30.5	30.9	31.5	31.5	30.1	31.2	31.0	32.8
3 TARO PHARM	22	-0.4	31	-1.0	25.7	26.5	25.9	24.8	26.6	25.9	27.8	27.4	28.1	27.9	26.7	26.2
Brand	1	-65.7	1	-69.8												
1 MEDICIS DERM	1	-65.7	1	-69.8	1.7	0.4	0.4	0.6	0.5	0.5	0.5	0.6	0.7	0.8	0.6	0.6
Generic Substitution %	99.1		99.3		98.3	99.6	99.6	99.4	99.5	99.5	99.5	99.4	99.3	99.2	99.4	99.4

Fluocinonide (Lidex)
LIQ, 0.05 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	253	+3.8	387	+3.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	253	+4.0	387	+3.2												
1 TEVA PHARMACEUT	135	-4.7	207	-5.9	58.4	55.2	53.8	54.3	53.1	51.9	52.4	52.8	52.6	52.3	52.2	52.3
2 FOUGERA	96	+35.0	146	+36.1	35.9	39.4	41.2	40.0	39.9	39.1	37.4	36.3	36.0	36.0	36.2	36.2
3 TARO PHARM	21	-28.4	34	-29.0	5.6	5.5	5.0	5.6	7.0	9.0	10.1	10.9	11.4	11.6	11.6	11.5
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: ABC/Progen and Wal-Mart are new customers. McKesson/OneStop usage is increasing.

**Fluocinonide (Lidex)
OINT, 0.05 %**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	460	+0.7	651	+0.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	460	+1.1	650	+0.8												
1 FOUGERA	170	+18.2	243	+18.5	41.0	40.0	39.8	39.7	38.4	36.9	36.0	35.6	35.6	35.6	35.6	34.9
2 TEVA PHARMACEUT	189	+2.8	262	+2.2	39.3	40.6	40.1	39.8	40.4	40.1	40.1	40.4	40.3	40.5	40.5	41.1
3 TARO PHARM	101	-20.7	145	-20.9	19.8	19.4	20.1	20.5	21.2	23.0	23.9	24.0	24.1	23.9	24.0	24.1
Brand	1	-76.8	1	-77.1												
1 MEDICIS DERM	1	-76.8	1	-77.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.3
Generic Substitution %	99.9		99.9		99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.8	99.7	99.7	99.7

Fluocinonide (Lidex-E)
CRM, 0.05 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	75	-28.7	105	-28.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	75	-26.5	104	-26.1												
1 TARO PHARM	44	-15.1	61	-15.7	53.3	53.7	54.7	55.0	56.8	59.8	62.2	61.9	60.6	61.2	64.1	62.7
2 TEVA PHARMACEUT	31	+5.6	43	+4.9	46.7	46.3	45.3	45.0	43.2	40.2	37.8	38.0	39.4	38.8	35.9	37.3
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: ABC/ProGen is a new customer.

Fluoxetine HCl (Prozac)
CAP, 10 mg, 20 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	8,540	-2.7	21,289	+0.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	8,393	-2.4	20,901	+0.5												
1 SANDOZ	2,783	+59.8	6,560	+84.5	32.7	32.9	33.0	32.9	32.2	31.0	30.7	30.5	30.2	30.1	30.2	30.3
2 TEVA PHARMACEUT	2,739	-15.2	6,698	-12.4	31.6	32.0	31.9	32.0	32.4	32.5	32.6	32.6	32.6	31.9	31.4	31.1
3 BARR LABS	2,219	-7.0	5,913	-8.4	26.8	26.9	26.8	27.1	27.6	28.6	29.1	29.1	29.2	29.4	29.4	29.6
4 DR REDDY'S LAB	244	+67.5	674	+67.2	3.6	3.7	4.0	4.0	3.8	3.5	2.7	2.4	2.5	2.9	2.9	2.8
5 PAR PHARM	215	-75.2	563	-73.5	2.7	2.1	2.0	1.8	1.7	1.9	2.6	3.0	3.2	3.5	3.8	4.0
6 MALLINCKRODT	98	-26.7	259	-27.3	1.2	1.1	1.1	1.1	1.2	1.4	1.2	1.2	1.3	1.3	1.3	1.3
7 MYLAN	77	+43.9	188	+43.3	1.0	1.0	1.0	1.0	1.0	1.0	0.9	0.9	0.7	0.8	0.8	0.8
8 RANBAXY PHARM	14	-55.5	35	-64.2	0.4	0.3	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.1	0.1
9 UNIT DOSE LABS	3	-51.6	7	-43.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1
10 WATSON LABS	1	-62.9	3	-68.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
11 MCKESSON PKG SERV	0	-31.7	1	-21.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	147	-16.3	388	-17.5												
1 LILLY	147	-16.3	388	-17.5	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.9	2.0	2.0	2.0
Generic Substitution %	98.3		98.2		98.3	98.3	98.3	98.2	98.2	98.2	98.2	98.2	98.1	98.0	98.0	98.0

Fluoxetine HCl (Prozac)
LIQ, 20 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	90	+3.6	192	+4.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	89	+4.4	188	+5.1												
1 APOTEX CORP	44	+61.9	84	+68.2	40.9	45.1	47.0	46.6	46.6	46.9	45.4	44.4	42.8	43.0	42.9	41.6
2 MORTON GROVE PHARM	15	-41.9	41	-32.6	27.3	23.0	20.9	20.6	20.7	20.7	21.6	21.2	21.8	21.0	21.4	22.0
3 TEVA PHARMACEUT	17	+51.4	37	+43.1	20.9	20.6	20.9	21.0	20.4	19.7	19.3	19.6	19.3	18.4	18.1	18.0
4 PHARMACEUTCL ASSOC	8	-5.0	18	-2.6	7.4	7.7	7.4	8.4	8.6	8.8	9.5	10.6	11.5	12.1	12.1	11.9
5 MALLINCKRODT	2	-44.3	4	-49.1	2.2	2.0	2.2	2.0	2.3	2.3	2.3	2.3	2.3	2.5	2.5	3.0
6 PAR PHARM	2	-74.8	4	-75.4	1.1	1.4	1.4	1.3	1.4	1.5	1.9	2.0	2.3	2.9	2.9	3.6
Brand	2	-24.8	4	-22.2												
1 LILLY	2	-24.8	4	-22.2	2.1	2.0	2.0	2.2	2.1	2.1	2.2	2.3	2.3	2.5	2.3	2.6
Generic Substitution %	98.0		97.8		97.9	98.0	98.0	97.8	97.9	97.9	97.8	97.7	97.7	97.5	97.7	97.4

Fluoxetine HCl (Prozac)
TAB, 10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	427	-15.9	877	-17.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	427	-15.9	876	-17.1												
1 PAR PHARM	296	-15.6	643	-17.4	70.4	70.6	71.5	72.5	73.7	76.6	84.3	82.9	72.3	68.3	68.9	70.0
2 TEVA PHARMACEUT	131	-16.5	233	-16.2	29.6	29.4	28.5	27.5	26.3	23.4	15.7	17.1	27.7	31.7	31.1	30.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

**Fluoxetine HCl (Sarafem)
CAP, 10 mg, 20 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	51	-45.6	126	-49.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	9		14													
1 TEVA PHARMACEUT	9	--	14	--	100.0	100.0	100.0	100.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	42	-55.2	111	-54.7												
1 WARNER-CHILCOTT	42	-55.2	111	-54.7	15.7	16.6	21.6	38.7	98.1	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Generic Substitution %	17.7		11.3		84.3	83.4	78.4	61.3	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Flurbiprofen (Ansaid)
TAB, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	129	-11.4	206	-12.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	128	-10.9	205	-11.5												
1 TEVA PHARMACEUT	47	-4.3	78	-5.3	40.0	39.6	39.8	39.1	36.7	37.3	36.7	37.6	37.5	36.6	37.2	35.6
2 MYLAN	45	-15.6	72	-15.9	33.0	33.3	33.6	34.2	36.1	34.8	35.6	35.3	34.8	35.5	36.3	35.7
3 CARACO PHARM	35	-8.0	54	-8.3	26.3	26.6	26.0	25.9	26.2	26.7	26.5	25.7	26.0	26.1	24.5	26.5
4 GREENSTONE LTD	1	-61.1	3	-60.7	0.6	0.5	0.6	0.7	1.0	1.2	1.2	1.3	1.6	1.8	2.0	2.2
Brand	1	-57.5	1	-78.6												
1 PFIZER	1	-57.5	1	-78.6	0.1	0.1	0.1	0.1	0.5	0.6	0.5	0.6	0.5	0.3	0.5	0.4
Generic Substitution %	99.5		99.6		99.9	99.9	99.9	99.9	99.5	99.4	99.5	99.4	99.5	99.7	99.5	99.6

**Flutamide (Eulexin)
CAP, 125 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	18	-2.7	55	-4.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	16	-4.5	47	-6.2												
1 TEVA PHARMACEUT	9	-4.5	26	-7.2	56.0	55.2	55.4	54.8	53.9	54.1	56.0	56.1	57.1	54.2	52.0	53.0
2 PAR PHARM	4	-12.1	13	-11.9	26.6	26.7	26.7	26.8	26.5	26.9	26.3	26.2	25.5	29.5	32.9	31.3
3 BARR LABS	3	+10.0	8	+8.0	17.2	18.0	17.9	18.4	19.6	19.0	17.7	17.7	17.4	16.3	15.1	15.7
Brand	2	+12.3	8	+13.0												
1 SANDOZ	2	+14.2	8	+13.6	15.5	14.4	14.6	15.5	16.2	15.4	12.8	13.5	12.2	11.8	12.0	11.3
Generic Substitution %	87.5		86.3		84.5	85.6	85.4	84.5	83.8	84.6	87.2	86.5	87.8	88.2	88.0	88.7

Fluvoxamine Maleate (Fluvoxamine Maleate (was Luvox))

TAB, 25 mg, 50 mg,100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	371	-1.2	858	-3.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	325	+16.4	760	+9.8												
1 APOTEX CORP	137	+181.0	299	+163.6	57.1	56.1	53.0	49.1	44.0	41.5	37.9	34.5	27.2	21.5	20.4	19.3
2 MYLAN	84	-0.5	187	-1.7	23.2	23.0	23.2	23.2	23.5	23.4	24.3	24.5	26.4	27.6	27.4	27.4
3 TEVA PHARMACEUT	74	-36.6	198	-37.2	12.1	13.4	16.0	19.2	23.8	26.2	28.2	30.3	33.4	36.9	38.9	40.9
4 CARACO PHARM	14	+283.4	35	+303.5	5.5	5.5	5.3	5.4	5.2	5.0	4.8	4.6	4.4	3.8	3.2	1.9
5 BARR LABS	15	-37.9	40	-36.0	1.9	2.0	2.4	2.9	3.4	3.8	4.6	5.9	8.4	9.9	9.8	10.2
6 UNIT DOSE LABS	0	-54.0	1	-36.2	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2
Brand	46	-52.4	98	-51.3												
1 SANDOZ	46	-52.5	98	-51.3	4.3	4.6	5.0	5.3	5.8	6.7	8.3	11.9	17.5	21.6	22.0	22.1
Generic Substitution %	87.7		88.6		95.7	95.4	95.0	94.7	94.2	93.3	91.7	88.1	82.5	78.4	78.0	77.9

Decline in Share: Gave up RiteAid, Safeway, GPO's. ABC/Progen demand is decreasing.

Folic Acid (Folic Acid)
TAB, 1 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,514	+4.5	10,387	-0.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,013	+9.9	5,552	+2.3												
1 WEST WARD	976	+1.1	2,980	+0.2	52.0	51.8	52.3	52.5	53.2	53.4	53.9	53.4	54.3	54.5	55.4	57.2
2 CADISTA PHARM	561	+740.3	1,144	+462.8	32.9	32.7	31.3	29.6	27.8	25.5	23.7	19.7	11.5	5.2	4.5	4.7
3 AMNEAL PHARM	190	+203.5	558	+185.4	11.3	11.2	11.5	12.3	12.3	12.7	10.7	10.3	9.5	8.1	6.6	4.7
4 PRASCO LABS	236	-61.6	713	-57.1	1.9	2.2	2.7	3.4	4.3	5.8	8.9	13.7	21.6	28.9	29.7	29.0
5 TEVA PHARMACEUT	12	-28.8	34	-34.7	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.7	0.7	0.8	0.8
6 QUALITEST PRODUCTS	8	-52.2	29	-51.7	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.8
7 CONTRACT PHARM	7	-27.7	24	-29.1	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.6
8 ALLAN PHARM	5	-73.6	15	-77.8	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.3	0.3	0.3
9 MAJOR PHARM	3	+6.2	9	+2.4	0.1	0.2	0.2	0.2	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.2
10 BRECKENRIDGE	3	-83.1	9	-84.8	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.3
11 MUTUAL PHARM	6	-75.4	21	-72.5	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.4	0.4	0.5	0.8	1.1
12 UNIT DOSE LABS	2	-60.0	4	-71.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
13 MCKESSON PKG SERV	1	-80.2	3	-63.7	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
14 AMERICAN HLTH PKG	1	+16.1	4	+26.5	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
15 URL PHARMA	1	-73.4	3	-76.5	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
16 NATIONAL VITAMIN C	0	+5.2	1	+51.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	1,502	-2.0	4,835	-3.4												
1 WATSON LABS	1,502	-2.0	4,835	-3.4	47.6	47.3	47.2	47.3	47.0	46.7	46.4	46.4	46.4	45.7	45.5	45.2
Generic Substitution %	57.3		53.5		52.4	52.7	52.8	52.7	53.0	53.3	53.6	53.6	53.6	54.3	54.5	54.8

Fosinopril Sodium (Monopril)
TAB, 10 mg, 20 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	764	-14.0	2,661	-14.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	746	-13.4	2,590	-13.4												
1 TEVA PHARMACEUT	411	-4.1	1,390	-3.5	53.9	54.9	54.2	54.6	54.7	55.4	55.4	53.7	52.1	51.6	52.7	51.8
2 SANDOZ	139	-14.8	535	-13.0	22.5	21.9	21.7	20.8	20.6	20.1	19.9	20.2	20.2	20.8	20.2	19.5
3 RANBAXY PHARM	108	-33.3	390	-34.6	13.9	13.8	14.0	14.4	13.9	14.6	14.8	14.9	16.0	16.4	15.8	17.5
4 APOTEX CORP	80	-1.4	245	-2.3	9.3	8.9	9.5	9.4	9.7	8.5	8.1	9.5	10.2	9.9	10.1	10.3
5 GLENMARK PHARMA	7	-71.7	29	-67.1	0.4	0.5	0.6	0.8	1.1	1.4	1.7	1.7	1.5	1.3	1.1	1.0
Brand	18	-33.0	72	-31.0												
1 BRISTOL-M SQ US PH	18	-33.0	72	-31.0	2.5	2.5	2.5	2.6	2.5	2.5	2.7	2.7	2.8	3.0	2.9	3.0
Generic Substitution %	97.6		97.3		97.5	97.5	97.5	97.4	97.5	97.5	97.3	97.3	97.2	97.0	97.1	97.0

Furosemide (Lasix)
TAB, 20 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	14,411	+0.4	40,258	-0.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	14,287	+0.6	39,875	-0.5												
1 MYLAN	7,216	+5.1	19,399	+4.9	48.5	49.0	49.0	49.2	48.9	48.5	48.4	48.3	48.5	48.8	48.4	48.4
2 TEVA PHARMACEUT	3,113	-6.4	8,168	-10.7	20.0	19.8	19.9	20.0	20.5	20.9	21.3	21.3	21.1	20.4	20.4	20.3
3 SANDOZ	1,692	-13.8	5,445	-12.8	12.9	12.9	12.8	12.8	13.1	13.9	14.0	14.0	14.1	14.3	14.5	14.6
4 WATSON LABS	983	+36.8	3,011	+36.6	8.9	8.8	8.9	8.5	8.0	7.2	6.9	6.8	6.7	6.6	6.6	6.6
5 QUALITEST PRODUCTS	838	+21.6	2,499	+21.7	6.4	6.3	6.2	6.2	6.2	6.4	6.4	6.3	6.3	6.3	6.1	6.1
6 ROXANE	187	-47.2	581	-48.6	1.2	1.2	1.3	1.3	1.4	1.5	1.5	1.5	1.6	1.6	1.7	1.8
7 DAVA PHARM	92	-39.1	307	-28.9	1.0	0.9	0.9	0.8	0.8	0.6	0.4	0.5	0.6	0.8	0.9	1.0
8 EXCELLIUM PHARM	126	+58.3	349	+61.4	0.9	0.9	0.9	0.9	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
9 UNIT DOSE LABS	35	-30.5	101	-35.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.4	0.4
10 MCKESSON PKG SERV	4	-12.9	16	-4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1
Brand	124	-18.8	382	-19.6												
1 SANOFI AVENTIS PHR	124	-18.8	382	-19.6	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.1	1.0	1.1
Generic Substitution %	99.1		99.1		99.1	99.1	99.1	99.1	99.1	99.1	99.1	99.0	99.0	98.9	99.0	98.9

Gabapentin (Neurontin)
CAP, 100 mg, 300 mg, 400 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	7,304	+14.0	16,494	+12.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	7,228	+14.7	16,278	+13.2												
1 TEVA PHARMACEUT	3,306	+11.1	7,061	+11.7	46.5	46.4	46.1	45.2	43.4	42.2	42.0	41.5	41.4	41.7	41.8	41.6
2 GREENSTONE LTD	1,348	+13.5	3,032	+11.9	17.2	17.2	17.3	16.9	17.2	18.8	19.2	19.4	20.0	20.3	20.2	20.4
3 ACTAVIS	1,225	+7.8	3,161	+3.5	17.1	17.3	17.2	18.7	20.3	20.4	20.5	20.6	20.4	20.5	20.3	20.0
4 APOTEX CORP	763	+75.9	1,755	+71.1	13.0	12.9	13.0	12.7	12.3	11.7	10.9	9.7	8.6	8.0	7.9	7.9
5 SANDOZ	466	+2.2	974	-1.9	4.6	4.6	4.7	4.8	4.8	5.0	5.5	6.7	7.6	7.7	8.0	8.4
6 RANBAXY PHARM	53	-38.7	132	-37.6	0.6	0.6	0.6	0.6	0.6	0.7	0.8	0.9	1.0	1.1	1.1	1.2
7 AMNEAL PHARM	25	--	59	--	0.5	0.5	0.6	0.5	0.5	0.5	0.5	0.4	0.2	0.0	0.0	0.0
8 SUN PHARMACEUTICAL	36	+389.4	88	+397.7	0.4	0.4	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.5	0.5	0.4
9 AMERICAN HLTH PKG	3	-42.5	8	-38.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1
10 UNIT DOSE LABS	2	-56.4	3	-64.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
11 MAJOR PHARM	1	+102.4	2	+75.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 MUTUAL PHARM	1	-78.9	2	-72.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	76	-27.2	216	-27.9												
1 PFIZER	76	-27.2	216	-27.9	1.1	1.1	1.2	1.2	1.2	1.2	1.3	1.3	1.4	1.5	1.5	1.6
Generic Substitution %	99.0		98.7		98.9	98.9	98.8	98.8	98.8	98.8	98.7	98.7	98.6	98.5	98.5	98.4

Gabapentin (Neurontin)
TAB, 600 mg, 800 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,969	+8.0	5,074	+6.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,939	+8.7	4,982	+7.6												
1 TEVA PHARMACEUT	1,146	+25.8	2,780	+25.4	56.9	57.0	57.1	56.9	56.5	55.3	55.2	55.1	55.3	55.0	55.0	54.2
2 ACTAVIS	271	+2.0	741	-1.3	14.8	15.2	15.1	15.2	15.1	15.1	14.9	14.7	14.4	14.7	14.7	14.5
3 APOTEX CORP	163	+100.3	411	+111.1	11.2	10.5	9.2	8.5	8.4	8.0	7.8	7.8	7.7	7.3	7.0	5.4
4 GREENSTONE LTD	166	-49.8	459	-48.6	8.0	7.8	7.6	7.6	8.3	9.8	9.9	10.0	10.0	10.2	10.4	11.2
5 GLENMARK PHARMA	111	+0.0	352	+0.7	7.3	6.9	6.8	6.9	6.8	6.8	7.2	7.2	7.3	7.3	7.3	7.3
6 SUN PHARMACEUTICAL	68	+266.6	196	+274.6	1.5	2.3	3.8	4.5	4.5	4.5	4.5	4.4	4.5	4.5	4.3	4.1
7 RANBAXY PHARM	14	-78.4	40	-76.6	0.3	0.3	0.4	0.4	0.4	0.5	0.5	0.5	0.7	0.9	1.3	3.3
8 AMERICAN HLTH PKG	0	-0.9	1	+74.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	30	-23.9	92	-23.4												
1 PFIZER	30	-23.9	92	-23.4	1.6	1.6	1.7	1.7	1.7	1.8	1.8	1.9	1.9	2.0	2.1	2.1
Generic Substitution %	98.5		98.2		98.4	98.4	98.3	98.3	98.3	98.2	98.2	98.1	98.1	98.0	97.9	97.9

Gemfibrozil (Lopid)
TAB, 600 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,860	+1.6	5,987	-0.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,856	+1.7	5,972	-0.1												
1 TEVA PHARMACEUT	1,280	+2.7	3,995	+0.8	67.0	67.4	67.0	67.0	67.2	67.0	67.4	67.4	67.3	66.2	65.9	65.6
2 APOTEX CORP	538	-0.6	1,849	-1.9	30.5	30.1	30.5	30.6	30.3	30.9	31.0	30.8	30.9	31.9	32.1	31.9
3 CAMBER PHARM	10	--	34	--	1.4	1.4	1.3	1.2	1.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0
4 WEST WARD	8	+8461.5	25	+10594.4	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.2
5 WATSON LABS	14	-47.2	48	-51.0	0.3	0.3	0.3	0.4	0.6	0.7	0.8	0.9	1.0	1.1	1.3	1.8
6 ZYDUS PHARM	2	+5.4	8	+12.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1
7 MAJOR PHARM	1	-42.1	4	-45.9	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
8 UNIT DOSE LABS	1	-57.4	4	-43.3	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
9 DAVA PHARM	2	-48.4	5	-50.5	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	4	-23.4	14	-25.9												
1 PFIZER	4	-23.4	14	-25.9	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3
Generic Substitution %	99.8		99.8		99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.7	99.7	99.7

Glimepiride (Amaryl)
TAB, 1 mg, 2 mg, 4 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,002	+1.2	9,235	+5.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,948	+2.7	9,044	+7.1												
1 DR REDDY'S LAB	1,274	+7.8	3,807	+19.8	42.0	42.5	42.5	42.3	42.0	42.1	41.8	41.7	41.3	42.3	42.4	42.2
2 TEVA PHARMACEUT	728	+46.4	2,241	+46.0	26.0	25.6	25.9	25.6	25.3	24.9	24.8	24.7	24.5	23.4	23.3	23.2
3 RANBAXY PHARM	682	+6.6	2,146	+7.4	23.2	23.5	23.5	23.6	23.8	23.4	23.7	23.9	24.0	24.1	24.0	24.1
4 PERRIGO	139	-26.2	449	-22.8	5.3	4.9	4.4	4.6	5.0	5.6	5.6	5.5	5.8	5.4	4.6	2.9
5 PRASCO LABS	91	-60.2	294	-58.5	2.8	3.0	3.1	3.1	3.3	3.3	3.3	3.3	3.3	3.4	3.5	3.5
6 SANDOZ	30	-75.5	102	-74.8	0.5	0.5	0.7	0.7	0.6	0.7	0.8	0.9	1.0	1.3	2.1	3.9
7 UNIT DOSE LABS	1	+63.1	2	+1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
8 PAR PHARM	1	-87.5	3	-90.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1
Brand	55	-42.5	190	-43.5												
1 SANOFI AVENTIS PHR	55	-42.5	190	-43.5	1.7	1.7	1.7	1.8	1.9	1.9	2.0	2.1	2.2	2.5	2.5	2.6
Generic Substitution %	98.2		97.9		98.3	98.3	98.3	98.2	98.1	98.1	98.0	97.9	97.8	97.5	97.5	97.4

Glipizide (Glucotrol)
TAB, 5 mg,10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,687	+2.1	7,963	+2.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,681	+2.2	7,941	+2.3												
1 MYLAN	1,058	+3.9	2,940	+3.0	37.5	37.6	37.3	37.3	37.4	36.9	36.9	36.9	36.7	36.7	36.6	36.3
2 SANDOZ	333	-2.6	1,070	-1.9	14.8	14.7	14.7	14.4	13.5	12.7	12.6	12.7	12.8	13.0	12.9	12.9
3 CARACO PHARM	393	+199.5	1,122	+224.0	14.8	15.1	15.0	15.1	15.1	14.8	14.8	14.5	13.9	13.2	12.4	10.9
4 WATSON LABS	315	-8.8	1,096	-7.6	12.4	12.5	12.6	12.9	13.4	14.2	14.3	14.3	14.5	14.6	14.9	15.0
5 TEVA PHARMACEUT	319	-40.4	952	-39.0	11.1	11.1	11.2	11.2	11.3	11.6	11.8	11.7	12.1	12.8	13.2	14.8
6 APOTEX CORP	259	+7.1	744	+7.5	9.3	8.8	9.0	9.0	9.1	9.6	9.4	9.7	9.6	9.5	9.7	9.7
7 UNIT DOSE LABS	4	-46.8	14	-48.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.3	0.3
8 MAJOR PHARM	1	-37.9	2	-13.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	7	-27.2	22	-24.3												
1 PFIZER	7	-27.2	22	-24.3	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Generic Substitution %	99.8		99.7		99.7	99.8	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7

Glipizide/Metformin HCl (Metaglip)

TAB, 2.5/250 mg, 2.5/500 mg, 5/500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	128	-10.3	382	-6.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	122	-5.5	358	+0.2												
1 SANDOZ	44	-40.4	139	-36.0	35.2	34.0	36.2	38.6	35.0	36.9	38.9	38.4	40.9	44.1	44.6	43.9
2 BARR LABS	41	+80.7	109	+145.3	32.3	32.3	31.1	31.1	30.4	28.0	27.6	30.2	30.5	31.2	30.5	29.9
3 TEVA PHARMACEUT	25	-18.6	75	-18.8	18.0	19.3	18.9	17.0	21.6	23.0	24.0	24.9	23.5	19.7	19.1	21.6
4 MYLAN	11	+1093.7	35	+1093.1	14.4	14.3	13.8	13.4	13.0	12.0	9.4	6.5	5.1	4.9	5.8	4.6
Brand	6	-54.6	24	-52.8												
1 BRISTOL-M SQ US PH	6	-54.6	24	-52.8	4.8	4.9	5.4	5.4	5.8	5.6	6.1	6.4	6.6	7.5	8.1	8.1
Generic Substitution %	95.0		93.7		95.2	95.1	94.6	94.6	94.2	94.4	93.9	93.6	93.4	92.5	91.9	91.9

Glyburide (Diabeta)
TAB, 1.25 mg, 2.5 mg, 5 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	765	-5.5	2,340	-6.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	760	-5.4	2,322	-5.9												
1 TEVA PHARMACEUT	760	-5.4	2,322	-5.9	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Brand	5	-28.2	18	-27.5												
1 SANOFI AVENTIS PHR	5	-28.2	18	-27.5	0.7	0.7	0.7	0.8	0.7	0.7	0.8	0.8	0.8	0.9	0.9	0.9
Generic Substitution %	99.4		99.2		99.3	99.3	99.3	99.2	99.3	99.3	99.2	99.2	99.2	99.1	99.1	99.1

Glyburide (Glynase)
 TAB, 1.5 mg, 3 mg, 6 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	189	-15.6	657	-15.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	186	-15.4	646	-15.5												
1 DAVA PHARM	52	-26.1	200	-24.9	32.9	32.6	32.0	31.1	30.8	30.2	29.9	29.3	29.5	30.6	31.2	31.7
2 MYLAN	47	-5.5	161	-5.1	24.6	24.3	24.6	25.0	24.9	24.4	24.8	25.2	25.1	24.9	25.4	25.7
3 TEVA PHARMACEUT	51	-15.0	152	-16.4	23.9	23.7	23.5	23.6	23.4	23.8	23.7	24.0	23.8	23.2	23.0	22.9
4 WEST WARD	29	+99.8	104	+105.0	16.8	17.2	17.1	16.9	16.9	16.7	16.6	16.2	15.7	15.3	14.5	13.6
5 ACTAVIS	4	+4.9	18	+7.0	1.1	1.4	1.7	2.2	2.8	3.4	3.5	3.5	3.6	3.5	3.4	3.2
6 GREENSTONE LTD	3	-85.7	11	-86.0	0.7	0.9	1.1	1.2	1.3	1.4	1.6	1.9	2.3	2.4	2.4	2.8
Brand	3	-31.1	11	-32.4												
1 PFIZER	3	-31.1	11	-32.4	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.7	1.7	1.8	1.8	1.9
Generic Substitution %	98.5		98.3		98.5	98.5	98.5	98.4	98.4	98.4	98.4	98.3	98.3	98.2	98.2	98.1

Glyburide (Micronase)
 TAB, 1.25 mg, 2.5 mg, 5 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,187	-5.0	6,632	-5.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,181	-4.9	6,613	-5.8												
1 TEVA PHARMACEUT	1,700	+3.7	4,987	+4.2	76.7	76.6	76.8	76.9	77.2	77.3	77.7	77.4	75.9	72.8	70.9	69.7
2 SANDOZ	394	+0.0	1,333	-0.5	20.3	20.4	20.1	20.0	19.6	19.3	18.6	18.4	19.5	22.0	21.8	21.6
3 GREENSTONE LTD	84	-66.9	283	-67.6	2.9	2.9	3.0	3.0	3.1	3.3	3.6	4.0	4.4	5.0	7.1	8.5
4 UNIT DOSE LABS	2	-48.9	8	-51.5	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2
5 MCKESSON PKG SERV	1	-51.7	2	-41.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0
Brand	6	-25.3	19	-30.2												
1 PFIZER	6	-25.3	19	-30.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.4	0.4	0.4
Generic Substitution %	99.7		99.7		99.8	99.8	99.8	99.8	99.8	99.8	99.7	99.7	99.7	99.6	99.6	99.6

Gain in Share: Increase due to the addition of ESI, Drug Mart, R&S and Meijer. Wal-Mart increased due to \$4 prescription program.

Glyburide/Metformin HCl (Glucovance)
TAB, 1.25/250 mg, 2.5/500 mg, 5/500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,695	-11.5	5,137	-9.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,660	-10.8	5,016	-9.1												
1 TEVA PHARMACEUT	824	+12.9	2,527	+11.6	49.1	49.5	49.7	48.8	51.1	51.4	51.3	51.5	51.2	50.7	50.3	49.9
2 ACTAVIS	764	+30.3	2,247	+42.2	48.2	47.6	47.4	48.3	45.7	45.0	44.7	43.5	43.1	42.6	41.9	40.6
3 SANDOZ	30	-85.2	99	-84.0	1.4	1.4	1.4	1.4	1.5	1.6	1.7	1.9	2.1	2.5	2.9	3.8
4 PAR PHARM	42	-87.8	141	-86.6	1.3	1.5	1.5	1.5	1.8	2.0	2.3	3.1	3.5	4.2	4.9	5.7
Brand	35	-34.6	121	-33.7												
1 BRISTOL-M SQ US PH	35	-34.6	121	-33.7	2.0	2.0	2.1	2.2	2.1	2.2	2.3	2.4	2.5	2.7	2.7	2.9
Generic Substitution %	97.9		97.6		98.0	98.0	97.9	97.8	97.9	97.8	97.7	97.6	97.5	97.3	97.3	97.1

Granisetron HCl (Kytrel)
TAB, 1 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	45	-21.5	75	-23.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	26		42													
1 TEVA PHARMACEUT	14	--	22	--	33.9	35.2	45.8	54.0	57.2	59.0	60.4	61.5	67.0	0.0	0.0	0.0
2 ROXANE	8	--	13	--	32.3	33.7	32.2	28.6	30.9	30.6	29.1	29.2	28.5	0.0	0.0	0.0
3 COREPHARMA	3	--	5	--	22.6	19.9	12.6	9.6	8.4	8.6	9.8	9.1	4.5	0.0	0.0	0.0
4 NORTHSTAR RX	1	--	1	--	6.5	6.2	4.5	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5 BARR LABS	1	--	1	--	3.5	3.2	2.8	3.1	2.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0
Brand	19	-67.6	33	-66.0												
1 ROCHE	19	-67.6	33	-66.0	9.6	11.6	12.4	13.2	15.5	18.9	22.8	34.3	64.8	100.0	100.0	100.0
Generic Substitution %	58.8		55.8		90.4	88.4	87.6	86.8	84.5	81.1	77.2	65.7	35.2	0.0	0.0	0.0

Griseofulvin Microcrystalline (Grifulvin V)
LIQ, 125mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	368	-3.1	437	-3.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	359	-0.7	426	-1.3												
1 PATRIOT PHARMA	247	+0.4	292	-0.4	67.7	68.7	68.5	67.7	69.3	68.6	69.0	68.9	68.3	67.8	67.9	67.7
2 PERRIGO	90	-21.5	109	-21.6	15.5	19.6	22.4	24.0	23.2	26.1	27.6	28.3	28.8	29.6	30.1	30.6
3 ACTAVIS	15	+4578.0	18	+5134.3	13.0	8.0	4.7	3.8	3.9	3.5	3.0	2.8	2.9	2.6	2.1	1.7
4 TEVA PHARMACEUT	7	-	8	-	3.8	3.8	4.3	4.4	3.7	1.8	0.5	0.0	0.0	0.0	0.0	0.0
Brand	9	-50.4	11	-52.0												
1 ORTHO DERM	9	-50.4	11	-52.0	4.0	3.7	3.7	3.7	1.9	2.0	2.0	1.5	2.0	2.3	1.2	1.7
Generic Substitution %	97.5		97.6		96.0	96.3	96.3	96.3	98.1	98.0	98.0	98.5	98.0	97.7	98.8	98.3

Guanabenz Acetate (Guanabenz Acetate (formerly Wytensin))

TAB, 4 mg, 8 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3	-30.6	11	-37.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3	-30.5	11	-36.9												
1 TEVA PHARMACEUT	3	-30.4	11	-36.9	99.7	100.0	99.8	99.8	99.3	99.8	99.9	99.8	99.9	99.9	99.9	99.9
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Haloperidol Lactate Conc (Haldol)

LIQ, 2 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	62	+21.4	87	+9.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	62	+21.8	87	+9.7												
1 TEVA PHARMACEUT	41	-1.0	58	-11.1	74.6	76.1	73.5	72.5	70.9	66.4	63.7	64.4	62.6	62.7	59.8	57.1
2 PHARMACEUT ASSOC	19	+130.2	25	+121.5	23.5	21.2	23.5	24.1	24.7	29.2	32.5	31.8	33.0	32.2	34.3	35.8
3 QUALITEST PRODUCTS	2	+77.4	3	+73.8	1.3	2.0	1.9	2.3	3.0	3.1	2.9	2.9	3.5	4.2	5.1	5.4
4 SILARX PHARM INC	1	+33.4	1	+22.8	0.6	0.7	1.1	1.1	1.3	1.2	0.9	0.8	0.7	0.9	0.7	1.7
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: Product was temporarily unavailable from June 2007 to Sep 2007 due to a potent API issue.

Hydralazine HCl (Hydralazine (was Apresoline))

TAB, 10 mg, 25 mg, 50 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,013	+13.6	2,653	+12.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	521	+42.0	1,280	+39.9												
1 PAR PHARM	489	+37.9	1,188	+34.5	88.0	88.5	89.3	90.4	92.6	94.9	95.4	95.2	95.4	95.3	95.3	95.1
2 HERITAGE PHARMACAL	27	+1151.1	78	+1035.2	11.4	10.6	10.0	8.8	6.7	4.3	3.6	3.4	3.2	3.0	2.9	3.0
3 TEVA PHARMACEUT	6	-47.2	14	-44.1	0.5	0.8	0.7	0.8	0.7	0.8	1.0	1.4	1.4	1.6	1.8	1.9
Brand	492	-6.2	1,373	-5.1												
1 BARR LABS	492	-6.2	1,373	-5.1	49.5	49.6	50.4	50.9	51.9	52.8	52.5	51.9	51.3	52.1	53.3	54.9
Generic Substitution %	51.5		48.3		50.5	50.4	49.6	49.1	48.1	47.2	47.5	48.1	48.7	47.9	46.7	45.1

Hydrochlorothiazide (Hydrochlorothiazide (was Hydrodiuril))
 TAB, 25 mg, 50 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	11,966	-6.9	37,894	-2.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	11,966	-6.9	37,893	-2.7												
1 TEVA PHARMACEUT	7,808	+18.2	24,171	+29.7	64.8	64.7	64.6	64.3	63.7	63.3	63.3	63.7	63.9	63.5	63.2	62.5
2 QUALITEST PRODUCTS	2,851	+0.4	9,506	+0.2	23.4	23.6	23.8	24.2	25.0	25.6	25.8	25.8	25.8	25.9	26.0	26.1
3 ACTAVIS	834	-42.4	2,502	-42.2	6.8	6.7	6.6	6.8	6.7	6.6	6.4	6.4	6.3	6.5	6.7	6.7
4 CARACO PHARM	170	+1373.3	662	+1664.0	2.4	2.4	2.3	2.2	2.2	2.0	1.9	1.5	1.1	1.1	0.9	1.0
5 DAVA PHARM	85	-92.0	297	-91.2	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.7	0.9	1.0	1.1	1.3
6 HERITAGE PHARMACAL	33	--	112	--	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.1	0.0	0.0
7 BARR LABS	117	-86.6	449	-85.3	0.5	0.6	0.7	0.8	0.9	1.0	1.2	1.3	1.5	1.6	1.8	2.2
8 EXCELLIUM PHARM	38	+6609.8	108	+9115.5	0.3	0.4	0.4	0.5	0.4	0.3	0.2	0.2	0.2	0.2	0.1	0.1
9 RANBAXY PHARM	8	--	18	--	0.3	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 LANNETT	12	+64822.2	33	+87689.5	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0
11 AUROBINDO PHARM	1	--	3	--	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 APOTEX CORP	4	--	12	--	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 MCKESSON PKG SERV	1	-42.3	2	-51.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
14 MYLAN	1	+456.1	6	+476.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15 LEDERLE SP	1	-42.7	1	-50.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
16 MAJOR PHARM	0	-67.8	1	-69.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
17 UNIT DOSE LABS	0	+183.8	1	+240.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
18 AMERICAN HLTH PKG	1	+1364.6	5	+1097.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Hydrochlorothiazide (Microzide)
CAP, 12.5 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,277	+7.2	9,616	+6.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,271	+7.3	9,597	+6.0												
1 MYLAN	1,848	+3.4	5,329	+2.1	54.0	53.8	54.5	55.3	55.5	55.4	55.7	56.2	56.4	56.5	56.7	56.4
2 WATSON LABS	849	+1.1	2,525	-1.6	27.2	27.5	27.1	26.6	26.5	26.6	26.3	25.9	25.5	25.4	25.5	25.7
3 QUALITEST PRODUCTS	556	+34.0	1,686	+35.9	18.1	17.9	17.7	17.4	17.4	17.4	17.4	17.4	17.6	17.7	17.4	17.6
4 TEVA PHARMACEUT	17	+170.4	51	+152.5	0.6	0.7	0.7	0.6	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.3
5 UNIT DOSE LABS	2	+23.6	5	+18.7	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0
Brand	6	-26.0	19	-25.4												
1 WATSON LABS	6	-26.0	19	-25.4	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3
Generic Substitution %	99.8		99.8		99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.7

Hydrocodone Bitartrate/Ibuprofen (Vicoprofen)
TAB, 7.5mg/200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,944	-2.7	2,408	-2.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,923	-2.3	2,374	-2.3												
1 WATSON LABS	869	+60.2	1,079	+57.1	48.0	47.2	46.8	46.4	45.9	43.8	39.5	56.5	56.4	54.4	34.1	27.8
2 TEVA PHARMACEUT	807	-36.5	983	-36.3	40.7	40.8	40.6	40.3	39.8	39.4	39.2	39.5	39.4	41.3	44.1	51.3
3 AMNEAL PHARM	168	+70.4	210	+64.6	6.6	7.3	8.1	9.2	10.2	12.7	17.3	0.0	0.0	0.0	17.6	16.4
4 QUALITEST PRODUCTS	78	+36.4	99	+37.5	4.3	4.3	4.2	4.0	4.0	4.0	4.0	4.0	4.1	4.3	4.2	4.4
5 BRECKENRIDGE	1	--	1	--	0.2	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
6 CENTRIX PHARM	1	+620.2	1	+705.6	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	21	-30.9	34	-29.6												
1 ABBOTT PHARM PRODS	21	-30.9	34	-29.6	1.2	1.2	1.3	1.4	1.4	1.4	1.4	1.4	1.5	1.6	1.6	1.7
Generic Substitution %	98.9		98.6		98.8	98.8	98.7	98.6	98.6	98.6	98.6	98.6	98.5	98.4	98.4	98.3

Decline in Share: Loss of Wal-Mart, CVS and Kroger.

Hydrocortisone (Cortenema)
REC, 100/60 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	35	-1.8	55	-1.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	34	-3.2	54	-3.0												
1 TEVA PHARMACEUT	26	+0.8	41	+0.5	76.3	75.5	76.2	74.8	76.3	78.3	77.0	77.6	75.9	72.5	71.4	72.4
2 PADDOCK LABS INC	8	-14.5	13	-12.3	23.7	24.5	23.8	25.2	23.7	21.7	23.0	22.4	24.1	27.5	28.6	27.6
Brand	1	+942.3	1	+1121.3												
1 ANI PHARMACEUTICAL	1	+942.3	1	+1121.3	1.8	2.8	2.4	2.5	1.4	1.7	1.7	1.0	0.6	0.2	0.0	0.3
Generic Substitution %	98.4		98.6		98.2	97.2	97.6	97.5	98.6	98.3	98.3	99.0	99.4	99.8	100.0	99.7

Hydroxychloroquine Sulfate (Plaquenil)

TAB, 200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,191	+5.8	3,538	+4.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,165	+6.2	3,462	+5.3												
1 WATSON LABS	517	+10.9	1,467	+8.9	40.9	40.8	41.0	41.2	42.6	43.7	43.9	43.9	43.6	42.4	42.3	42.3
2 MYLAN	289	+15.1	866	+14.8	20.8	20.9	20.7	21.0	21.0	21.5	22.9	26.1	31.1	31.8	31.7	31.3
3 SANDOZ	185	-20.0	612	-17.3	18.4	18.5	18.7	18.3	17.8	16.8	16.7	16.6	16.8	17.8	17.8	17.9
4 ZYDUS PHARM	70	--	210	--	9.1	9.9	10.0	10.0	9.6	9.4	8.6	5.4	0.5	0.0	0.0	0.0
5 TEVA PHARMACEUT	93	-27.2	271	-31.3	7.5	7.5	7.5	7.6	7.7	7.8	7.8	7.9	7.9	8.0	8.2	8.4
6 RANBAXY PHARM	8	--	27	--	2.3	1.7	1.8	1.6	1.1	0.5	0.1	0.0	0.0	0.0	0.0	0.0
7 MALLINCKRODT	2	--	6	--	0.9	0.6	0.2	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0
8 WINTHROP	1	-96.2	3	-95.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	25	-8.5	76	-9.2												
1 SANOFI AVENTIS PHR	25	-8.5	76	-9.2	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.3	2.3	2.3
Generic Substitution %	97.9		97.9		97.9	97.9	97.9	97.9	97.9	97.9	97.9	97.9	97.8	97.7	97.7	97.7

Ibuprofen (Motrin)

TAB, 400 mg, 600 mg, 800 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	20,950	+3.1	27,424	+2.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	20,934	+3.3	27,399	+2.4												
1 AMNEAL PHARM	7,105	+143.6	9,201	+138.0	36.2	34.4	34.4	34.3	34.6	34.8	33.9	33.6	32.8	31.8	31.3	30.9
2 WATSON LABS	6,412	-6.5	7,988	-8.0	26.1	28.4	29.5	29.4	29.4	29.3	29.5	29.5	29.6	30.0	29.7	29.5
3 PAR PHARM	3,831	-36.7	5,581	-33.3	21.8	21.8	21.2	19.8	19.4	19.4	19.2	19.3	20.0	20.2	21.0	21.3
4 PERRIGO	3,334	+0.3	4,245	+0.7	15.0	14.3	13.7	15.3	15.6	15.3	16.2	16.1	15.9	16.3	16.1	16.1
5 QUALITEST PRODUCTS	92	-28.2	132	-29.2	0.5	0.5	0.5	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5
6 MAJOR PHARM	38	+19.7	55	+11.9	0.2	0.3	0.5	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.1
7 DR REDDY'S LAB	53	-93.3	94	-91.8	0.1	0.1	0.1	0.3	0.3	0.3	0.3	0.3	0.4	0.5	0.6	0.9
8 URL PHARMA	19	-28.3	28	-29.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
9 GREENSTONE LTD	38	-68.5	52	-67.9	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.3	0.3	0.4
10 TEVA PHARMACEUT	7	-30.1	11	-32.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
11 MCKESSON PKG SERV	2	-71.0	4	-65.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 UNIT DOSE LABS	2	-40.1	3	-36.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 AMERICAN HLTH PKG	1	-24.3	3	-26.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	16	-68.3	25	-69.3												
1 PFIZER	16	-68.3	25	-69.3	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2
Generic Substitution %	99.9		99.9		100.0	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.8	99.8

Indomethacin (Indocin)
CAP, 25 mg, 50 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,806	+0.0	2,569	+0.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,806	+0.0	2,568	+0.1												
1 MYLAN	1,551	-7.5	2,195	-7.6	74.4	75.2	76.5	77.6	79.8	82.4	85.7	90.3	95.0	97.0	97.1	96.6
2 TEVA PHARMACEUT	174	+120.1	258	+118.1	17.2	16.9	16.0	15.5	14.7	13.2	10.7	7.2	3.1	1.3	1.4	1.9
3 SANDOZ	61	--	85	--	7.6	7.1	6.6	5.9	4.6	3.4	2.4	1.3	0.2	0.0	0.0	0.0
4 UNIT DOSE LABS	20	-59.1	30	-57.0	0.7	0.8	0.8	1.0	1.0	1.0	1.1	1.2	1.7	1.6	1.4	1.5
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: Increase is due to the re-introduction of the Emcure product.

Isosorbide Mononitrate (Monoket)

TAB, 20 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	87	-10.3	293	-13.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	87	-10.2	292	-12.9												
1 KREMERS URBAN	41	+5.9	139	-2.6	56.9	54.7	52.5	48.1	46.6	46.2	46.0	46.7	46.8	44.4	42.5	42.9
2 ACTAVIS	32	-11.1	103	-9.1	26.7	29.4	31.8	36.1	37.7	37.1	37.6	36.9	36.8	37.2	36.8	36.2
3 TEVA PHARMACEUT	12	-37.3	44	-35.6	14.3	13.9	13.9	13.9	13.8	14.7	14.3	14.3	14.3	16.2	18.4	18.4
4 WEST WARD	1	-41.0	4	-46.1	1.4	1.3	1.0	1.1	1.2	1.1	1.3	1.2	1.2	1.3	1.4	1.6
5 PROMIUS PHARMA	1	-45.6	2	-42.5	0.7	0.8	0.8	0.8	0.8	0.9	0.8	0.9	0.9	0.9	0.8	0.9
Brand	0	-43.7	1	-43.1												
1 SCHWARZ PHARMA	0	-43.7	1	-43.1	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4
Generic Substitution %	99.8		99.7		99.8	99.7	99.8	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.6

Ketoconazole (Nizoral)

CRM, 2 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,703	+3.4	2,212	+3.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,703	+3.5	2,212	+3.3												
1 TEVA PHARMACEUT	1,207	+13.8	1,530	+13.3	71.5	71.7	71.3	70.6	69.4	68.1	67.8	67.7	67.8	67.8	68.0	67.8
2 FOUGERA	307	-9.0	403	-6.5	21.9	21.3	20.5	19.8	19.1	17.7	16.5	16.1	16.0	16.2	16.1	16.2
3 TARO PHARM	185	-23.7	273	-22.8	6.4	6.8	8.0	9.4	11.2	14.0	15.5	15.9	15.9	15.8	15.6	15.7
4 JSJ PHARMACEUTICAL	4	-26.3	5	-23.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.2	0.2	0.3	0.3	0.3
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Ketoconazole (Nizoral)
TAB, 200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	564	-3.5	702	-3.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	564	-3.4	702	-3.0												
1 TEVA PHARMACEUT	242	+0.9	302	+1.5	43.2	43.5	43.8	43.5	42.7	43.2	42.5	42.3	42.6	42.7	42.7	42.8
2 APOTEX CORP	203	+135.9	247	+143.1	38.3	37.9	37.1	36.9	36.9	35.7	35.1	34.3	33.2	32.3	31.7	30.6
3 MYLAN	43	-68.3	58	-66.0	7.0	6.9	7.1	7.3	7.7	8.0	8.6	8.5	8.9	9.0	9.8	10.6
4 MUTUAL PHARM	37	-19.5	46	-19.6	6.5	6.4	6.5	6.6	6.7	6.5	6.3	6.4	6.7	6.5	6.6	6.6
5 TARO PHARM	24	-39.8	32	-40.1	3.0	3.3	3.4	3.5	3.7	4.2	5.0	5.5	5.7	6.3	6.0	5.8
6 BARR LABS	11	-46.4	14	-47.0	1.6	1.7	1.9	1.7	1.9	2.0	2.1	2.3	2.2	2.2	2.2	2.3
7 URL PHARMA	3	-76.9	4	-77.6	0.2	0.2	0.3	0.4	0.4	0.5	0.4	0.7	0.8	1.0	1.1	1.3
Brand	1	-60.8	1	-64.1												
1 JANSSEN PHARM	1	-60.8	1	-64.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	99.9		99.9		99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9

**Ketoprofen (Orudis)
CAP, 50 mg, 75 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	218	-13.5	330	-12.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	217	-13.4	330	-12.8												
1 MYLAN	144	-13.1	209	-12.7	64.3	64.0	64.1	64.0	64.1	62.7	62.8	63.0	62.2	63.0	62.7	63.9
2 TEVA PHARMACEUT	74	-14.2	121	-12.8	35.6	36.0	35.9	35.9	35.8	37.2	37.1	37.0	37.8	36.9	37.2	36.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Ketorolac Tromethamine (Toradol)
TAB, 10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,078	+0.6	1,180	+0.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,077	+0.7	1,179	+0.6												
1 TEVA PHARMACEUT	464	-0.9	503	-1.2	42.7	43.0	42.7	42.6	42.3	42.0	42.7	42.8	42.6	43.1	42.6	42.7
2 MYLAN	317	+7.0	346	+7.3	29.4	29.1	29.4	29.2	29.6	29.2	29.5	29.7	29.8	29.4	29.4	28.9
3 ETHEX CORP	269	+1.1	300	+1.0	25.9	25.8	25.7	25.8	25.6	26.1	25.2	25.0	25.0	24.9	25.2	25.2
4 BARR LABS	27	-31.5	30	-31.4	2.0	2.1	2.1	2.3	2.5	2.7	2.6	2.6	2.6	2.6	2.9	3.2
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Labetalol HCl (Normodyne)
TAB, 100 mg, 200 mg, 300 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,060	+1.3	3,029	+0.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,058	+1.3	3,021	+0.8												
1 SANDOZ	677	+24.0	1,868	+25.1	64.2	63.6	63.3	62.9	62.4	61.5	61.1	61.4	61.4	61.0	60.1	59.3
2 TEVA PHARMACEUT	318	+3.3	959	+2.3	30.9	31.0	31.1	31.5	31.8	32.1	32.3	31.8	31.7	31.8	32.1	32.5
3 WATSON LABS	59	-67.3	182	-66.2	4.7	5.0	5.3	5.2	5.5	6.0	6.2	6.3	6.4	6.7	7.3	7.5
4 MUTUAL PHARM	2	-59.5	6	-59.5	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3
5 UNIT DOSE LABS	1	-55.3	4	-54.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2
6 URL PHARMA	1	-60.6	2	-58.3	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
7 WARRICK PHARM	0	-35.1	1	-33.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	2	-11.7	8	-15.4												
1 PROMETHEUS PRODUCT	2	-11.5	8	-15.4	0.2	0.2	0.2	0.2	0.3	0.3	0.2	0.2	0.3	0.3	0.3	0.3
Generic Substitution %	99.8		99.8		99.8	99.8	99.8	99.8	99.7	99.7	99.8	99.8	99.7	99.7	99.7	99.7

Lactulose (Constulose (previously Chronulac))
LIQ, 10gm/15ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	757	+1.3	1,572	-1.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	692	+0.9	1,425	-1.9												
1 HI-TECH PHARMACAL	390	+106.9	732	+109.5	53.8	53.2	53.1	53.5	54.1	52.5	51.2	50.6	51.2	50.5	48.2	45.3
2 QUALITEST PRODUCTS	136	+60.1	328	+82.2	23.8	24.1	23.4	21.6	23.6	24.8	25.0	24.2	23.5	22.2	21.6	18.6
3 APOTEX CORP	79	-56.6	177	-62.8	10.2	10.1	10.8	11.8	9.9	10.2	11.1	11.8	12.4	13.7	16.2	20.1
4 PHARMACEUT ASSOC	29	+95.4	60	+106.4	5.4	5.4	5.2	5.1	4.5	4.2	4.1	4.0	3.3	3.2	3.2	3.3
5 MORTON GROVE PHARM	37	-77.2	81	-74.1	4.2	4.6	4.7	4.9	4.9	5.1	5.3	5.6	6.0	6.8	7.4	8.8
6 TEVA PHARMACEUT	11	+7.8	25	+23.9	1.5	1.7	1.8	1.8	1.9	1.8	1.9	1.9	1.7	1.5	1.6	1.9
7 WATSON LABS	7	-81.1	15	-81.2	0.4	0.5	0.6	0.6	0.8	1.0	1.1	1.4	1.4	1.6	1.5	1.6
8 ROXANE	2	-15.4	5	-11.9	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.4	0.4	0.4	0.3	0.3
9 ANI PHARMACEUTICAL	0	--	1	--	0.2	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 ACTAVIS	1	-38.2	1	-53.4	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	65	+6.5	148	+7.1												
1 ACTAVIS	65	+6.5	148	+7.1	9.0	9.2	9.4	9.9	9.6	9.4	8.9	8.9	9.3	9.7	9.8	9.8
Generic Substitution %	91.4		90.6		91.0	90.8	90.6	90.1	90.4	90.6	91.1	91.1	90.7	90.3	90.2	90.2

Lactulose Oral/Rectal (Enulose (previously Cephulac))
LIQ, 10g/15mL

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,127	+17.8	2,435	+16.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	442	+58.6	850	+56.8												
1 HI-TECH PHARMACAL	390	+106.9	732	+109.5	88.5	88.1	87.3	87.2	86.7	86.2	85.9	85.1	85.5	85.1	84.7	83.1
2 MORTON GROVE PHARM	34	-18.9	78	-17.0	8.3	8.3	8.8	8.8	9.1	9.2	9.2	9.3	9.3	9.7	10.0	10.4
3 TEVA PHARMACEUT	11	+7.8	25	+23.9	2.5	2.8	3.0	3.0	3.0	3.0	3.1	3.3	2.9	2.6	2.8	3.5
4 WATSON LABS	7	-81.1	15	-81.2	0.7	0.8	0.9	1.0	1.3	1.6	1.8	2.3	2.4	2.7	2.6	3.0
Brand	685	+1.1	1,585	+2.9												
1 ACTAVIS	685	+1.1	1,585	+2.9	64.5	64.5	64.6	64.7	64.6	65.3	65.2	65.5	65.3	66.2	65.4	65.4
Generic Substitution %	39.2		34.9		35.5	35.5	35.4	35.3	35.4	34.7	34.8	34.5	34.7	33.8	34.6	34.6

Lamotrigine (Lamictal CD)
CHEW, 5 mg,25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	93	+16.8	206	+20.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	80	+23.0	174	+28.8												
1 TEVA PHARMACEUT	80	+23.0	174	+28.8	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Brand	13	-11.4	32	-9.3												
1 GSK PHARM	13	-11.4	32	-9.3	15.5	12.5	13.2	14.9	15.1	15.6	15.3	15.9	16.5	17.5	18.2	18.8
Generic Substitution %	86.4		84.4		84.5	87.5	86.8	85.1	84.9	84.4	84.7	84.1	83.5	82.5	81.8	81.2

Leflunomide (Arava)
 TAB, 10 mg, 20 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	245	+0.4	607	+5.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	240	+1.8	592	+7.2												
1 APOTEX CORP	46	-17.4	109	-1.0	24.2	25.0	24.3	22.9	20.0	19.6	18.4	17.2	15.6	11.0	10.3	11.4
2 BARR LABS	57	+203.4	125	+225.1	22.5	21.1	20.5	20.6	20.2	20.5	21.1	22.1	22.8	21.6	20.9	19.1
3 PRASCO LABS	52	+4.1	130	+5.0	20.4	20.5	20.6	20.4	20.4	20.5	20.9	20.9	21.4	23.0	26.6	27.8
4 SANDOZ	30	-9.1	86	-9.3	15.3	15.1	14.8	14.5	15.0	14.4	14.7	14.7	14.2	13.8	14.0	14.1
5 TEVA PHARMACEUT	28	-34.7	72	-24.3	11.5	11.5	11.6	11.3	11.6	11.8	11.8	11.6	12.0	15.8	13.0	12.5
6 PAR PHARM	26	-23.8	70	-22.1	6.2	6.8	8.2	10.3	12.8	13.1	13.1	13.5	14.1	14.8	15.1	15.0
Brand	5	-39.8	14	-38.5												
1 SANOFI AVENTIS PHR	5	-39.8	14	-38.5	1.7	1.8	1.9	2.1	2.2	2.2	2.5	2.5	2.6	2.8	2.9	3.0
Generic Substitution %	97.9		97.7		98.3	98.2	98.1	97.9	97.8	97.8	97.5	97.5	97.4	97.2	97.1	97.0

Lidocaine HCl Jelly (Xylocaine)

TOP, 2 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	230	+4.9	310	+6.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	227	+5.7	305	+7.1												
1 AKORN, INC	163	+33.8	212	+33.7	68.7	68.8	69.1	69.0	70.1	69.3	69.8	69.3	69.3	69.7	70.1	68.9
2 TEVA PHARMACEUT	62	-31.8	89	-26.9	29.7	29.6	29.6	29.6	28.4	29.1	28.5	29.0	29.0	28.6	28.3	29.7
3 INTL MED SYSTEM	2	-7.1	5	-7.1	1.5	1.7	1.3	1.4	1.5	1.6	1.7	1.7	1.7	1.6	1.5	1.5
Brand	3	-30.2	5	-27.0												
1 APP	3	-30.2	5	-27.0	1.5	1.5	1.5	1.3	1.6	1.4	1.5	1.8	1.8	1.7	1.6	2.2
Generic Substitution %	98.5		98.4		98.5	98.5	98.5	98.7	98.4	98.6	98.5	98.2	98.2	98.3	98.4	97.8

Lisinopril (Zestril, Prinvil)

TAB, 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	23,836	+4.6	74,653	+7.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	23,747	+4.8	74,320	+7.4												
1 LUPIN PHARMA	9,520	+23.7	26,264	+40.7	43.3	43.6	43.7	43.5	42.7	40.1	34.5	32.4	32.6	33.2	33.0	33.0
2 TEVA PHARMACEUT	4,416	-13.6	14,115	-14.2	19.6	19.6	19.7	19.7	19.4	18.6	18.8	18.8	18.6	18.3	18.2	18.6
3 SANDOZ	4,252	-22.6	14,158	-22.9	12.5	12.1	11.9	12.3	13.4	16.9	22.6	25.1	25.6	25.4	25.8	26.0
4 MYLAN	2,622	+49.1	8,479	+49.3	12.1	12.1	12.3	12.3	12.3	12.3	12.4	12.2	12.1	12.2	10.5	3.9
5 WATSON LABS	1,475	+31.3	4,463	+22.4	6.2	6.3	6.4	6.6	6.4	6.2	6.0	5.8	5.6	5.6	5.6	5.3
6 APOTEX CORP	414	-29.9	1,376	-33.4	2.0	1.7	1.2	1.0	1.2	2.1	2.2	2.1	2.1	2.3	2.3	2.1
7 RANBAXY PHARM	221	+40.1	707	+28.9	1.6	1.6	1.6	1.5	1.4	0.6	0.5	0.5	0.5	0.5	0.5	0.6
8 WOCKHARDT AMERICA	262	+26580.6	975	+36985.5	1.4	1.7	2.0	1.9	1.9	1.7	1.6	1.4	1.1	0.6	0.3	0.1
9 AUROBINDO PHARM	487	-16.2	1,503	-19.3	1.1	1.1	1.1	1.0	1.0	1.1	1.1	1.2	1.3	1.6	3.1	9.8
10 WEST WARD	18	-1.5	59	-5.5	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
11 PAR PHARM	38	-64.5	136	-62.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.3	0.3	0.3	0.3
12 AMERICAN HLTH PKG	9	+16.5	34	+10.4	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0
13 UNIT DOSE LABS	13	-20.8	47	-23.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1
14 MAJOR PHARM	0	-58.2	1	-57.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15 MCKESSON PKG SERV	0	+27.4	1	+39.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	89	-22.9	333	-23.2												
1 ASTRAZENECA	64	-21.6	238	-22.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4
2 MERCK & COMPANY	26	-25.8	95	-25.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	99.6		99.6		99.6	99.6	99.6	99.6	99.6	99.6	99.6	99.5	99.5	99.5	99.5	99.5

Lisinopril/HCTZ (Prinzide/Zestoretic)
 TAB, 10mg/12.5 mg, 20mg/12.5 mg, 20mg/25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	5,949	+9.8	18,630	+12.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	5,920	+10.1	18,522	+13.4												
1 LUPIN PHARMA	1,401	+76.9	4,677	+83.3	26.9	26.8	26.5	26.3	25.9	25.5	24.4	23.9	24.2	24.6	24.0	23.7
2 WATSON LABS	1,551	+1.4	4,409	+17.1	23.7	23.9	23.4	23.6	23.7	23.8	23.9	24.0	23.9	23.9	24.1	23.9
3 TEVA PHARMACEUT	1,532	+1.8	4,824	-0.7	23.2	24.8	26.8	27.0	26.9	26.7	26.6	26.4	26.3	26.2	26.0	25.8
4 AUROBINDO PHARM	519	+98.8	1,755	+104.6	10.7	10.6	10.9	10.7	10.0	9.2	9.0	8.7	8.5	8.4	8.3	8.3
5 SANDOZ	497	-34.3	1,522	-39.7	5.8	5.7	5.9	6.1	6.8	8.2	9.6	10.4	10.5	9.6	10.3	10.6
6 APOTEX CORP	113	+17.2	371	+8.1	4.1	2.5	0.7	0.7	1.3	2.0	2.0	2.1	2.1	2.4	2.1	2.1
7 MYLAN	227	-40.4	696	-43.5	3.4	3.4	3.3	3.5	3.5	3.6	3.6	3.8	3.8	4.2	4.4	4.9
8 RANBAXY PHARM	75	+76.8	247	+61.9	2.3	2.3	2.2	2.1	1.9	0.9	0.6	0.6	0.7	0.7	0.7	0.7
9 WEST WARD	4	-51.5	15	-48.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10 ACTAVIS	1	-76.7	5	-78.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Brand	29	-31.2	108	-31.2												
1 ASTRAZENECA	23	-24.7	87	-23.1	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.6	0.6
2 MERCK & COMPANY	6	-48.5	22	-51.7	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
Generic Substitution %	99.5		99.4		99.5	99.5	99.5	99.5	99.5	99.4	99.4	99.4	99.4	99.3	99.3	99.3

Loperamide HCl (Imodium)
CAP, 2 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	622	-3.5	969	-3.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	622	-3.5	969	-3.2												
1 MYLAN	485	-4.8	736	-6.0	75.5	75.5	75.1	75.1	75.9	76.1	76.1	76.4	76.6	76.6	76.3	76.4
2 TEVA PHARMACEUT	122	+15.0	213	+18.0	23.6	23.1	23.4	23.0	22.1	21.8	21.4	21.2	20.8	21.1	21.4	21.4
3 UNIT DOSE LABS	14	-49.0	20	-47.5	0.9	1.3	1.5	1.9	2.0	2.1	2.5	2.4	2.6	2.3	2.3	2.2
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Lorazepam (Ativan)
 TAB, 0.5 mg, 1 mg, 2 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	14,903	+3.8	25,112	+3.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	14,764	+4.0	24,855	+3.3												
1 WATSON LABS	3,856	+20.2	6,606	+19.5	27.9	27.6	27.7	27.5	26.7	26.0	25.9	26.0	26.0	26.0	25.8	25.7
2 RANBAXY PHARM	4,723	-5.4	7,551	-5.8	22.8	31.4	31.6	31.8	31.7	31.6	31.2	31.1	30.5	30.3	30.2	30.5
3 SANDOZ	2,708	-1.1	4,964	-0.7	18.4	18.4	18.5	18.7	19.6	20.4	20.7	20.5	20.6	21.0	21.4	21.4
4 MYLAN	2,425	-1.0	4,073	-1.9	16.2	16.0	16.0	16.2	16.2	16.1	16.4	16.5	16.8	16.8	16.7	16.8
5 ACTAVIS	937	+32.3	1,469	+22.0	13.6	5.7	5.3	5.1	5.2	5.1	5.1	5.2	5.2	5.1	5.2	5.0
6 MUTUAL PHARM	60	+26.1	102	+15.1	0.5	0.3	0.3	0.3	0.3	0.4	0.4	0.5	0.6	0.4	0.4	0.4
7 EXCELLIUM PHARM	19	--	32	--	0.4	0.3	0.2	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0
8 UNIT DOSE LABS	16	-18.2	23	-10.6	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
9 MAJOR PHARM	5	+84.3	8	+72.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 TEVA PHARMACEUT	6	+345.8	10	+321.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0
11 MCKESSON PKG SERV	6	-74.3	13	-64.7	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1
12 URL PHARMA	2	-50.9	2	-58.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 AMERICAN HLTH PKG	1	+124.3	1	+143.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
14 ALTURA PHARM	0	+306.7	1	+399.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	139	-14.5	257	-15.1												
1 BIOVAIL PHARMACEUT	139	-14.5	257	-15.1	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1
Generic Substitution %	99.1		99.0		99.1	99.1	99.0	99.0	99.0	99.0	99.0	99.0	98.9	98.9	98.9	98.9

Lovastatin (Mevacor)

TAB, 10 mg, 20 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	4,745	-1.7	15,169	-4.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	4,740	-1.7	15,150	-4.7												
1 ACTAVIS	1,593	-30.0	5,306	-25.4	27.3	27.8	28.1	28.4	29.2	30.7	31.7	33.7	41.2	46.9	46.6	45.8
2 LUPIN PHARMA	957	--	2,241	--	24.5	25.1	25.0	24.1	22.1	19.1	18.0	15.7	7.4	0.2	0.0	0.0
3 SANDOZ	679	-11.8	2,528	-3.8	17.0	16.9	17.1	16.9	16.3	14.7	14.5	14.2	15.0	18.8	19.3	19.1
4 MYLAN	636	-3.0	2,253	-2.3	12.7	12.5	12.5	12.9	14.0	16.3	16.6	16.7	16.7	16.0	15.3	15.9
5 PAR PHARM	335	-15.1	981	-21.2	7.2	6.9	6.9	6.9	6.9	6.7	6.6	6.7	6.5	5.4	5.5	5.6
6 TEVA PHARMACEUT	351	-34.2	1,164	-38.7	7.2	7.1	7.1	7.5	7.9	8.3	8.0	8.0	7.9	7.7	7.8	7.7
7 MUTUAL PHARM	134	+0.8	482	-3.4	1.7	1.8	1.9	2.1	2.4	3.2	3.5	3.9	4.1	4.1	4.4	4.6
8 APOTEX CORP	18	+1226.0	64	+1179.7	1.6	1.1	0.6	0.4	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
9 WATSON LABS	34	-35.6	122	-34.0	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	1.0
10 UNIT DOSE LABS	2	-26.7	6	-31.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
11 MAJOR PHARM	1	-46.0	2	-44.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 AMERICAN HLTH PKG	0	+52.6	1	+119.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	5	-27.8	20	-27.1												
1 MERCK & COMPANY	5	-27.8	20	-27.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	99.9		99.9		99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9

Mebendazole (Vermox)
CHEW, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	471	+2.7	490	+2.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	471	+2.7	490	+2.8												
1 TEVA PHARMACEUT	471	+2.7	490	+2.8	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Megestrol Acetate (Megace)

LIQ, 40 mg/ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	622	+13.2	1,171	+10.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	621	+13.3	1,169	+10.1												
1 MORTON GROVE PHARM	241	+4.3	500	+3.9	40.2	41.0	41.0	42.0	43.6	44.3	44.5	43.7	43.7	43.0	43.1	43.0
2 ROXANE	165	+43.5	265	+34.0	29.0	28.3	28.5	27.7	25.6	23.3	21.0	18.0	16.7	17.4	17.0	17.8
3 PAR PHARM	163	+8.3	315	+4.7	28.0	27.8	27.2	26.3	26.1	26.9	27.5	27.6	26.4	26.4	26.6	26.6
4 TEVA PHARMACEUT	15	-31.2	33	-19.4	2.0	1.9	2.0	2.4	3.1	3.0	3.1	3.0	3.4	3.5	3.4	3.3
5 APOTEX CORP	36	+24.1	56	+39.6	0.7	1.0	1.3	1.6	1.6	2.4	3.9	7.7	9.8	9.7	9.9	9.4
Brand	1	-17.1	2	-24.0												
1 BRISTOL-MYERS ONCO	1	-17.1	2	-24.0	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.2
Generic Substitution %	99.8		99.8		99.8	99.8	99.8	99.8	99.8	99.9	99.9	99.8	99.8	99.8	99.8	99.8

Megestrol Acetate (Megace)
TAB, 40 mg



	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08	Aug 08	Jul 08	Jun 08	May 08	Apr 08	Mar 08	Feb 08	Jan 08	Dec 07	Nov 07	Oct 07
					%	%	%	%	%	%	%	%	%	%	%	%
Megestrol Acetate (Megace)	222.561	+5.5	481.657	+4.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	222.493	+5.5	481.559	+4.7												
1 PAR PHARM	124.052	+31.7	276.373	+27.8	58.8	58.4	58.1	57.3	57.8	57.3	57.7	57.2	57.4	56.0	56.4	56.1
2 BARR LABS	94.051	-16.2	195.697	-16.2	39.8	39.9	39.9	40.7	40.0	40.6	40.4	40.4	40.6	41.8	41.5	42.0
3 ROXANE	2.734	+20.1	5.923	+11.8	1.0	1.1	1.4	1.4	1.3	1.3	1.2	1.3	1.2	1.3	1.2	1.1
4 UNIT DOSE LABS	1.006	-19.8	2.065	-18.2	0.3	0.4	0.4	0.5	0.6	0.5	0.4	0.5	0.4	0.5	0.4	0.4
5 MAJOR PHARM	0.509	-34.9	1.244	-37.4	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.5	0.3	0.3	0.4	0.4
6 TEVA PHARMACEUT	0.083	-22.4	0.148	-28.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
7 MCKESSON PKG SERV	0.050	+42.9	0.091	+44.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
8 QUALITEST PRODUCTS	0.006	-45.5	0.014	-77.0				0.0			0.0	0.0		0.0	0.0	0.0
9 REPACKAGER		--		--												
10 WATSON LABS	0.002	-75.0	0.004	-80.0						0.0		0.0	0.0			0.0
Brand	0.068	-28.4	0.098	-7.5												
1 BRISTOL-MYERS ONCO	0.068	-28.4	0.098	-7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.9	100.0	100.0

Meloxicam (Mobic)
TAB, 7.5 mg,15 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	5,774	+32.0	11,198	+27.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	5,715	+34.3	11,048	+30.8												
1 LUPIN PHARMA	2,719	+175.7	4,659	+147.3	45.6	45.4	45.1	44.5	42.5	41.4	41.4	41.1	41.0	40.9	40.0	35.3
2 APOTEX CORP	840	+824.4	1,655	+859.2	20.4	20.2	19.5	18.4	17.4	16.2	15.0	12.8	10.2	9.5	8.9	7.8
3 ZYDUS PHARM	508	+32.4	1,072	+32.8	11.2	10.9	10.7	10.2	10.1	9.6	9.4	9.4	9.0	8.4	8.5	8.4
4 TEVA PHARMACEUT	438	-68.0	1,072	-58.7	9.3	9.4	9.4	9.7	9.8	9.4	9.5	9.3	9.0	8.6	9.5	13.6
5 ROXANE	219	+19.3	426	+14.0	2.8	3.1	3.8	4.2	4.2	4.0	4.1	4.1	4.1	4.0	4.0	4.0
6 CARACO PHARM	80	+203.2	171	+202.4	2.8	2.0	1.7	1.6	1.7	1.5	1.4	1.4	1.2	1.0	0.9	0.9
7 WATSON LABS	217	-12.9	467	-16.2	2.7	3.1	3.3	3.4	3.8	4.1	4.2	4.6	5.0	5.3	5.6	6.6
8 GLENMARK PHARMA	76	+38.1	132	+41.1	1.2	1.3	1.3	1.3	1.3	1.2	1.1	1.1	1.1	1.1	1.1	1.2
9 BRECKENRIDGE	95	-19.5	217	-15.5	1.0	1.2	1.3	1.6	1.9	2.0	2.1	2.3	2.4	2.6	2.7	2.8
10 SANDOZ	179	+17.8	402	+27.7	1.0	1.1	1.3	1.5	1.8	2.3	3.1	4.7	7.1	7.3	7.1	7.5
11 MYLAN	197	-56.6	418	-54.6	0.8	0.9	1.1	1.7	3.1	5.1	5.3	5.4	5.6	5.6	5.9	6.5
12 LANNETT	29	+1093.1	60	+1246.9	0.5	0.5	0.5	0.5	0.5	0.4	0.5	0.6	0.7	0.7	0.8	0.6
13 ACTAVIS	36	-24.0	86	-21.5	0.2	0.3	0.4	0.6	0.9	1.1	1.0	1.0	1.0	1.0	1.0	1.0
14 PAR PHARM	30	-73.7	68	-73.4	0.2	0.2	0.3	0.3	0.4	0.4	0.5	0.6	0.7	1.1	1.3	1.5
15 MALLINCKRODT	12	+356.7	25	+376.0	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.2	0.2	0.1
16 DR REDDY'S LAB	36	+104.6	110	+194.9	0.1	0.1	0.2	0.3	0.4	0.8	0.9	1.2	1.6	2.5	2.4	2.0
17 UNIT DOSE LABS	1	+6.8	2	+3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
18 MUTUAL PHARM	3	-26.2	7	-20.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Brand	58	-50.7	150	-53.6												
1 BOEHRINGER INGEL	58	-50.7	150	-53.6	1.0	1.0	1.1	1.1	1.1	1.2	1.3	1.4	1.5	1.8	1.8	1.9
Generic Substitution %	99.0		98.7		99.0	99.0	98.9	98.9	98.9	98.8	98.7	98.6	98.5	98.2	98.2	98.1

Mercaptopurine (Purinethol)
TAB, 50 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	177	-6.0	504	-2.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	173	-4.9	489	-0.5												
1 MYLAN	65	+39.9	175	+79.7	36.9	37.2	37.1	37.4	36.5	36.3	36.2	35.6	35.0	34.6	33.8	31.6
2 ROXANE	59	-12.6	173	-13.1	35.0	35.0	34.4	34.6	34.9	35.0	35.1	35.0	35.7	36.2	36.6	37.2
3 PAR PHARM	46	-20.8	132	-19.8	25.4	25.4	25.7	25.4	26.1	26.6	27.0	28.7	28.7	27.5	27.9	28.9
4 TEVA PHARMACEUT	3	-66.5	10	-68.9	2.6	2.4	2.8	2.6	2.5	2.2	1.7	0.7	0.6	1.7	1.7	2.2
Brand	4	-37.6	14	-36.7												
1 GATE PHARM	4	-37.6	14	-36.7	2.4	2.5	2.6	2.5	2.5	2.8	2.8	3.0	3.0	3.3	3.3	3.5
Generic Substitution %	97.7		97.2		97.6	97.5	97.4	97.5	97.5	97.2	97.2	97.0	97.0	96.7	96.7	96.5

Mesalamine Enema (Rowasa)

REC, 4 gm/60 ml g

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	78	-1.2	135	-0.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	74	+2.0	127	+3.3												
1 TEVA PHARMACEUT	39	-6.4	65	-6.6	49.3	51.9	51.3	51.7	51.9	51.3	51.1	51.3	51.1	51.3	51.4	52.0
2 PERRIGO	33	+11.3	58	+13.9	46.7	44.7	44.8	45.0	44.8	45.3	45.9	45.7	45.8	45.5	45.0	44.7
3 PRASCO LABS	2	+48.1	4	+62.4	4.1	3.4	4.0	3.4	3.3	3.4	3.0	2.9	3.0	3.2	3.6	3.3
Brand	3	-41.2	8	-41.2												
1 ALAVEN PHARM	3	-41.2	8	-41.2	4.4	4.1	5.0	5.1	5.6	5.6	5.5	5.9	5.9	6.9	6.2	6.8
Generic Substitution %	95.7		94.4		95.6	95.9	95.0	94.9	94.4	94.4	94.5	94.1	94.1	93.1	93.8	93.2

Metformin HCl (Glucophage)
TAB, 500 mg, 850 mg, 1000 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	13,750	+1.5	41,453	+4.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	13,672	+1.7	41,190	+4.8												
1 TEVA PHARMACEUT	5,704	-2.8	15,978	+1.8	38.4	38.8	38.8	38.7	38.6	38.7	39.1	39.1	39.2	38.9	38.8	38.5
2 ZYDUS PHARM	2,567	+120.4	8,289	+128.3	20.3	20.5	20.5	20.4	20.1	19.8	19.8	19.7	19.9	20.2	20.2	20.2
3 APOTEX CORP	2,130	+18.7	6,541	+26.3	15.7	15.4	15.9	15.8	16.2	16.1	15.8	15.8	15.8	15.9	15.9	16.1
4 AUROBINDO PHARM	1,005	+66.9	3,061	+58.0	7.5	7.2	6.8	7.4	7.8	8.0	8.1	7.9	7.7	7.6	7.3	5.8
5 SANDOZ	719	+1.3	2,173	-6.7	5.3	5.4	5.4	5.6	5.4	5.4	5.3	5.2	5.0	5.1	5.0	5.0
6 WATSON LABS	482	-24.9	1,687	-22.1	3.7	3.8	3.9	4.0	4.0	4.0	4.1	4.2	4.3	4.3	4.4	4.6
7 CARACO PHARM	378	-48.1	1,218	-43.6	3.4	2.8	2.7	2.6	2.6	2.6	2.5	2.7	2.8	2.9	3.2	4.6
8 MALLINCKRODT	208	+130.4	709	+125.7	2.0	2.1	2.1	2.1	2.0	1.8	1.8	1.7	1.4	1.2	1.2	1.2
9 MUTUAL PHARM	271	-42.1	848	-43.5	1.9	1.9	1.9	1.9	1.9	2.0	2.0	2.1	2.2	2.2	2.3	2.3
10 MYLAN	109	-91.6	368	-91.0	0.8	0.8	0.9	0.9	0.8	0.9	0.9	0.9	0.9	0.9	1.0	1.0
11 PROVIDENT PHARM	74	+619.5	225	+704.4	0.6	1.1	1.0	0.5	0.5	0.4	0.4	0.4	0.4	0.5	0.4	0.3
12 MAJOR PHARM	8	-75.9	27	-74.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1
13 BARR LABS	5	-27.6	19	-27.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1
14 UNIT DOSE LABS	5	-38.8	18	-32.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1
15 AMERICAN HLTH PKG	2	+108.5	7	+92.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
16 PAR PHARM	3	-77.3	9	-77.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
17 WOCKHARDT AMERICA	3	-65.5	8	-66.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
18 ACTAVIS	1	-72.8	4	-73.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	78	-24.3	263	-23.4												
1 BRISTOL-M SQ US PH	78	-24.3	263	-23.4	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.7	0.7
Generic Substitution %	99.4		99.4		99.4	99.4	99.4	99.4	99.4	99.4	99.4	99.4	99.3	99.3	99.3	99.3

Metformin HCl (Glucophage XR)

MR TAB, 500 mg, 750 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,668	-0.4	8,093	+2.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,605	+0.5	7,880	+4.1												
1 TEVA PHARMACEUT	1,382	+8.0	4,163	+14.4	52.5	51.9	50.7	47.2	50.8	52.8	53.8	54.8	54.9	54.9	54.9	54.9
2 SUN PHARMACEUTICAL	310	+212.2	996	+234.9	14.7	13.7	13.6	15.2	14.1	12.9	12.3	11.4	11.4	11.1	10.7	10.4
3 APOTEX CORP	361	+42.3	1,128	+42.0	12.0	13.4	14.0	16.4	15.4	14.7	14.7	14.2	13.9	14.7	14.4	14.0
4 WATSON LABS	288	-28.3	740	-30.5	10.2	9.9	10.3	9.9	9.6	9.7	9.5	9.4	9.2	8.2	8.4	8.5
5 RANBAXY PHARM	116	-0.5	353	+3.1	4.6	4.7	4.8	4.7	4.3	4.4	4.2	4.3	4.2	4.3	4.5	4.7
6 SANDOZ	46	+150.6	149	+240.7	2.6	2.6	2.6	2.5	2.1	1.5	1.4	1.4	1.5	1.5	1.4	1.5
7 BARR LABS	47	+9.3	157	+12.4	2.2	2.2	2.2	2.1	2.0	2.0	2.0	1.9	1.9	1.9	1.9	1.9
8 PAR PHARM	44	-85.7	157	-84.8	0.7	1.1	1.3	1.5	1.4	1.5	1.7	2.2	2.6	3.1	3.4	3.6
9 AMNEAL PHARM	1	--	3	--	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 MYLAN	6	-91.0	22	-89.4	0.2	0.3	0.3	0.3	0.3	0.2	0.3	0.2	0.3	0.3	0.3	0.4
11 ACTAVIS	3	+8.3	10	+7.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
12 UNIT DOSE LABS	0	-39.9	1	-37.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	63	-26.0	212	-27.1												
1 BRISTOL-M SQ US PH	63	-26.0	212	-27.1	2.3	2.4	2.4	2.6	2.4	2.5	2.6	2.6	2.8	2.9	3.0	3.1
Generic Substitution %	97.6		97.4		97.7	97.6	97.6	97.4	97.6	97.5	97.4	97.4	97.2	97.1	97.0	96.9

Methazolamide (Neptazone)
TAB, 25 mg, 50 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	58	-1.1	151	-3.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	58	-1.1	151	-3.9												
1 SANDOZ	28	+28.6	73	+18.0	59.7	58.7	57.9	56.6	53.4	49.6	43.7	41.4	41.2	41.5	41.2	40.3
2 TEVA PHARMACEUT	21	-24.6	50	-25.9	21.1	22.4	23.4	24.4	27.8	31.3	37.4	40.2	41.1	42.3	41.8	42.1
3 QUALITEST PRODUCTS	9	-1.3	27	+1.3	19.1	18.8	18.5	18.9	18.8	19.0	18.7	18.2	17.5	16.0	16.8	17.4
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Decline in Share: Lost Walgreens and ESI due to supply issues.

Methyldopa (Aldomet)
TAB, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	244	-9.8	620	-6.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	244	-9.8	620	-6.4												
1 MYLAN	140	-12.4	336	-8.6	53.6	53.7	53.8	53.5	53.9	53.8	54.1	54.8	54.5	54.7	55.3	55.3
2 TEVA PHARMACEUT	104	-5.8	282	-3.6	46.3	46.1	46.0	46.3	45.9	45.9	45.6	44.9	45.3	45.0	44.5	44.5
3 UNIT DOSE LABS	0	-26.2	1	-20.9	0.1	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Metoclopramide HCl (Reglan)
TAB, 5 mg,10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,909	+2.3	7,126	+2.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,900	+2.4	7,107	+2.3												
1 BARR LABS	1,287	-17.4	2,684	-16.4	33.2	33.3	33.9	36.7	38.0	38.6	38.4	38.5	39.3	39.9	40.9	42.5
2 TEVA PHARMACEUT	1,382	+30.6	2,368	+37.3	33.0	33.6	34.5	34.3	34.4	34.1	34.1	34.0	33.5	32.7	31.7	30.0
3 ACTAVIS	1,084	+6.8	1,764	+6.4	24.6	24.9	24.9	24.9	25.1	24.9	25.0	24.9	24.6	24.8	24.7	24.5
4 NORTHSTAR RX	57	--	103	--	6.1	5.3	4.1	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5 QUALITEST PRODUCTS	51	+165.3	102	+174.8	2.2	2.0	1.7	1.5	1.4	1.4	1.3	1.3	1.2	1.1	1.1	1.0
6 MUTUAL PHARM	29	-79.6	60	-78.3	0.6	0.6	0.7	0.7	0.7	0.8	0.8	0.8	0.9	1.0	1.1	1.4
7 MAJOR PHARM	3	-34.9	7	-29.6	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
8 UNIT DOSE LABS	4	-33.7	10	-40.9	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2
9 URL PHARMA	2	-47.8	5	-47.9	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
10 MCKESSON PKG SERV	1	-16.1	3	+5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
11 ESI PHARMA INC	1	-44.2	2	-52.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	9	-20.6	19	-19.2												
1 ALAVEN PHARM	9	-20.6	19	-19.2	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Generic Substitution %	99.8		99.7		99.8	99.8	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.7

Metoprolol Tartrate (Lopressor)

TAB, 50 mg,100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	6,716	-1.2	21,667	-2.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	6,672	-1.0	21,513	-2.7												
1 MYLAN	3,549	+4.7	11,296	+5.2	52.1	52.7	53.2	53.4	53.5	53.0	52.9	52.3	52.5	52.4	51.3	51.0
2 CARACO PHARM	1,986	-8.1	6,232	-11.3	23.8	23.8	24.0	25.1	27.6	28.8	29.7	31.1	31.6	32.3	34.2	34.8
3 SANDOZ	538	-13.0	2,021	-14.3	6.5	6.2	7.9	10.9	11.5	11.6	11.2	10.5	9.8	9.4	8.7	8.5
4 TEVA PHARMACEUT	129	-16.7	429	-27.4	6.1	5.7	5.2	3.8	1.1	0.5	0.3	0.3	0.3	0.3	0.4	0.4
5 AUROBINDO PHARM	75	--	275	--	5.5	5.6	3.7	0.6	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0
6 MUTUAL PHARM	309	+19.2	985	+10.4	5.0	4.9	4.9	5.0	4.9	4.8	4.6	4.4	4.2	4.2	4.1	4.1
7 WATSON LABS	58	-39.5	182	-35.4	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.8	0.8
8 MAJOR PHARM	12	+62.1	41	+64.3	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.2	0.1	0.1
9 UNIT DOSE LABS	12	-25.1	34	-31.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.2	0.2
10 URL PHARMA	4	-88.9	18	-87.9	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
11 MCKESSON PKG SERV	0	+139.8	1	+98.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	43	-21.7	154	-20.1												
1 NOVARTIS RX	43	-21.7	154	-20.1	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.8
Generic Substitution %	99.4		99.3		99.3	99.3	99.3	99.3	99.3	99.3	99.3	99.3	99.3	99.2	99.2	99.2

Gain in Share: Picked up McKesson(OneStop).

Metronidazole (Flaygl)
TAB, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	6,972	+3.3	7,276	+3.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	6,963	+3.4	7,266	+3.3												
1 TEVA PHARMACEUT	3,031	+0.8	3,153	+0.7	47.3	45.3	44.4	43.5	43.1	42.9	42.8	42.7	42.4	42.3	42.1	41.8
2 BARR LABS	3,402	+68.4	3,556	+67.7	45.9	48.5	48.8	48.3	48.4	49.6	49.7	49.7	49.9	49.6	49.6	49.5
3 MUTUAL PHARM	191	+2.0	200	+2.0	4.0	3.1	2.9	2.8	2.8	2.5	2.5	2.4	2.5	2.5	2.5	2.5
4 WATSON LABS	317	-78.6	332	-78.5	2.4	2.8	3.7	5.2	5.4	4.8	4.8	4.9	4.9	5.2	5.4	5.8
5 UNIT DOSE LABS	8	-29.6	8	-27.7	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
6 MCKESSON PKG SERV	1	+9360.0	1	+9780.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
7 URL PHARMA	8	-65.3	9	-64.8	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1
8 AMNEAL PHARM	2	+11.5	2	+8.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
9 MAJOR PHARM	3	-33.4	3	-31.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Brand	9	-27.5	10	-26.2												
1 PFIZER	9	-27.5	10	-26.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2
Generic Substitution %	99.9		99.9		99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.8	99.9	99.8

Gain in Share: Picked up HEB, NC Mutual and Progressive Dist.

Mexiletine HCl (Mexitil)
CAP, 150 mg, 200 mg, 250 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	39	+1.6	118	+0.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	39	+1.6	118	+0.7												
1 TEVA PHARMACEUT	39	+4.0	117	+3.3	99.6	99.6	99.6	99.6	99.4	99.1	98.9	98.5	98.3	97.9	97.9	98.4
2 WATSON LABS	0	-65.8	1	-67.5	0.3	0.2	0.3	0.2	0.4	0.7	0.9	1.2	1.2	1.6	1.5	0.9
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Minocycline HCl (Minocin)
CAP, 50 mg, 75 mg,100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,043	-3.2	4,111	-4.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,038	-3.1	4,100	-3.9												
1 TEVA PHARMACEUT	975	-25.4	1,875	-25.6	41.0	41.3	41.5	41.4	41.5	41.6	41.9	43.2	45.3	50.9	58.8	59.4
2 RANBAXY PHARM	657	+76.9	1,337	+64.1	37.0	36.8	36.3	36.7	36.8	36.9	37.0	35.7	33.8	27.7	19.4	18.3
3 WATSON LABS	260	-0.8	585	+0.4	14.5	14.9	16.1	15.9	14.5	14.0	13.7	13.6	13.2	13.4	13.6	14.1
4 GLOBAL PHARM CORP	145	-8.2	302	-11.0	7.5	7.0	6.0	6.0	7.2	7.5	7.4	7.5	7.7	7.9	8.2	8.2
5 MEDICIS DERM	0	-93.2	1	-95.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	5	-20.4	11	-24.9												
1 TRIAX PHARM	5	-20.4	11	-24.9	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.3
Generic Substitution %	99.7		99.7		99.8	99.8	99.8	99.8	99.8	99.7	99.8	99.7	99.7	99.7	99.7	99.7

Decline in Share: Gave up CVS/Caremark.

Mirtazapine (Remeron)

TAB, 15 mg, 30 mg, 45 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,064	+3.7	7,442	+4.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,047	+3.9	7,399	+4.2												
1 TEVA PHARMACEUT	1,250	-5.3	2,580	-4.4	36.0	36.0	35.8	35.2	35.1	34.6	34.1	34.4	34.3	34.4	34.5	34.1
2 CARACO PHARM	839	+14.7	2,360	+11.4	30.2	30.5	30.9	31.6	31.9	31.9	32.4	32.6	32.6	32.8	32.8	32.5
3 AUROBINDO PHARM	253	+16.3	751	+17.6	11.2	11.6	12.2	11.0	9.9	9.8	9.2	9.3	9.3	9.5	9.6	9.4
4 MYLAN	402	+19.8	812	+20.9	10.9	11.0	11.0	10.9	10.9	10.9	10.9	10.9	11.1	11.0	10.8	11.4
5 SANDOZ	129	-13.0	368	-17.7	4.7	5.2	5.5	5.3	4.7	5.2	5.0	4.9	4.9	4.8	4.8	4.7
6 APOTEX CORP	39	+1969400.0	129	+6425350.0	4.6	3.1	1.9	2.9	3.8	2.3	0.7	0.4	0.3	0.4	0.3	0.1
7 WATSON LABS	49	-37.1	112	-39.5	1.7	1.7	1.5	1.5	1.5	1.4	1.3	1.3	1.4	1.5	1.6	1.7
8 ACTAVIS	30	+30.6	70	+7.4	0.3	0.6	0.8	0.9	1.2	1.3	1.2	1.2	1.2	0.9	0.8	1.0
9 UNIT DOSE LABS	7	-36.8	19	-48.1	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.3
10 AMERICAN HLTH PKG	44	+53.1	182	+38.6	0.2	0.2	0.3	0.4	0.6	2.3	4.8	4.4	4.3	4.0	4.0	4.1
11 PAR PHARM	3	-65.9	9	-62.6	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.4
12 ROXANE	2	-91.3	6	-90.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.2	0.2
13 WOCKHARDT AMERICA	0	-95.4	1	-94.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	17	-21.5	43	-20.6												
1 ORGANON	17	-21.5	43	-20.6	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Generic Substitution %	99.5		99.4		99.5	99.5	99.5	99.4	99.4	99.4	99.4	99.4	99.4	99.4	99.4	99.4

Mirtazapine (Remeron SolTab)

ODT, 15 mg, 30 mg, 45 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	238	-24.3	647	-28.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	227	-23.5	618	-27.6												
1 PRASCO LABS	118	-30.5	386	-34.1	60.5	59.5	59.0	60.2	59.9	60.9	63.1	63.9	64.9	65.4	65.5	64.6
2 BARR LABS	50	-20.2	114	-18.5	20.6	19.9	19.8	19.2	19.3	18.7	17.7	17.3	17.9	17.7	17.5	17.3
3 TEVA PHARMACEUT	38	+76.9	73	+55.4	14.0	15.7	16.3	15.8	14.9	13.6	12.3	10.7	8.8	8.8	8.1	6.9
4 AUROBINDO PHARM	8	-30.5	18	-32.6	4.2	4.0	3.7	3.3	2.6	2.0	1.9	2.0	2.2	3.0	3.1	3.1
5 ACTAVIS	14	-57.0	26	-51.4	0.7	0.9	1.2	1.5	3.4	4.8	5.1	6.1	6.2	5.1	5.8	8.1
Brand	10	-38.8	28	-39.2												
1 ORGANON	10	-38.8	28	-39.2	4.5	4.1	4.2	4.3	4.2	4.3	4.2	4.3	4.5	4.7	4.6	4.6
Generic Substitution %	95.7		95.6		95.5	95.9	95.8	95.7	95.8	95.7	95.8	95.7	95.5	95.3	95.4	95.4

Gain in Share: Picked up Walgreens and Medco.

Misoprostol (Cytotec)
 TAB, 100 mcg, 200 mcg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	292	+19.4	460	+10.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	289	+21.4	454	+12.2												
1 TEVA PHARMACEUT	185	-4.8	295	-8.8	58.6	59.8	60.8	61.5	61.6	62.1	63.8	64.9	66.8	70.4	74.5	77.8
2 GREENSTONE LTD	104	+140.2	159	+97.0	41.4	40.2	39.2	38.5	38.4	37.8	36.1	35.1	33.2	29.6	25.4	22.2
Brand	3	-54.2	6	-48.0												
1 PFIZER	3	-54.2	6	-48.0	1.1	1.2	1.0	1.2	1.2	1.3	1.2	1.3	1.5	1.7	1.9	2.0
Generic Substitution %	99.0		98.6		98.9	98.8	99.0	98.8	98.8	98.7	98.8	98.7	98.5	98.3	98.1	98.0

Decline in Share: Lost ESI, Wal-Mart and Walgreens due to supply issues (October 2007).

Moexipril HCl (Univasc)
TAB, 7.5 mg,15 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	117	-29.0	450	-20.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	103	+8.6	385	+40.3												
1 PADDOCK LABS INC	42	-7.9	150	+29.8	37.7	37.5	38.4	38.5	38.9	39.5	39.9	40.3	40.5	38.7	39.3	39.6
2 TEVA PHARMACEUT	13	+516.3	50	+815.7	26.3	25.1	22.5	20.1	16.1	11.9	8.1	7.0	6.2	6.4	4.7	3.4
3 COBALT LABS	9	--	35	--	25.1	23.4	21.1	18.4	13.6	8.1	2.1	0.2	0.0	0.0	0.0	0.0
4 KREMERS URBAN	39	-16.6	150	-1.9	10.9	14.0	17.9	23.0	31.4	40.5	49.9	52.5	53.4	54.9	55.9	57.0
Brand	15	-79.2	65	-77.7												
1 SCHWARZ PHARMA	15	-79.2	65	-77.7	10.3	10.7	11.4	11.7	11.6	13.0	14.0	14.4	15.8	17.9	18.9	20.6
Generic Substitution %	87.5		85.6		89.7	89.3	88.6	88.3	88.4	87.0	86.0	85.6	84.2	82.1	81.1	79.4

Gain in Share: Picked up CVS.

Moexipril HCl/HCTZ (Uniretic)

TAB, 7.5/12.5 mg, 15/12.5 mg, 15/25 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	130	-28.9	475	-19.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	114	+52.8	407	+109.8												
1 TEVA PHARMACEUT	63	+55.5	218	+136.8	63.4	62.0	60.2	57.4	55.7	53.7	51.6	50.3	49.8	47.7	46.4	44.9
2 COBALT LABS	10	--	36	--	24.7	23.2	21.0	18.8	13.7	7.0	1.5	0.2	0.0	0.0	0.0	0.0
3 KREMERS URBAN	40	+19.9	153	+49.8	12.0	14.8	18.7	23.8	30.6	39.3	46.9	49.6	50.2	52.3	53.6	55.1
Brand	16	-85.2	68	-82.9												
1 SCHWARZ PHARMA	16	-85.2	68	-82.9	9.3	9.6	10.4	11.3	11.8	12.0	13.5	14.6	15.8	18.2	19.6	21.4
Generic Substitution %	87.7		85.8		90.7	90.4	89.6	88.7	88.2	88.0	86.5	85.4	84.2	81.8	80.4	78.6

Gain in Share: Picked up CVS and ESI (Feb 2008). Market Share gain off-set slightly by loss of RiteAid to preserve market (Feb 2008).

Mupirocin (Bactroban)
OINT, 2 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	4,288	+19.1	4,873	+17.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	4,263	+19.4	4,840	+18.1												
1 TEVA PHARMACEUT	2,988	+17.3	3,358	+16.0	70.9	70.9	71.1	71.0	70.3	68.5	67.5	64.5	65.8	69.1	71.0	70.6
2 PERRIGO	955	+24.4	1,119	+22.5	21.4	21.5	21.5	21.4	22.0	23.8	25.0	27.4	26.6	23.7	22.1	22.5
3 TARO PHARM	262	+20.1	296	+19.5	6.0	6.0	5.9	6.2	6.3	6.1	6.1	6.4	6.3	6.2	6.0	6.1
4 FOUGERA	58	+60.4	67	+59.2	1.6	1.6	1.6	1.4	1.4	1.5	1.4	1.7	1.4	1.1	0.9	0.9
Brand	25	-21.0	33	-21.6												
1 GSK PHARM	25	-21.0	33	-21.6	0.5	0.6	0.6	0.7	0.7	0.7	0.7	0.8	0.8	0.7	0.7	0.7
Generic Substitution %	99.4		99.3		99.5	99.4	99.4	99.3	99.3	99.3	99.3	99.2	99.2	99.3	99.3	99.3

Nabumetone (Relafen)
TAB, 500 mg, 750 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,368	-10.2	4,371	-9.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,367	-10.2	4,370	-9.6												
1 TEVA PHARMACEUT	1,545	-16.1	2,682	-16.1	55.0	55.4	56.2	58.9	62.6	63.3	63.4	63.6	64.2	64.1	64.3	64.4
2 SANDOZ	564	-12.0	1,179	-10.6	24.3	24.2	24.8	25.2	26.8	28.6	28.5	28.3	27.9	28.3	28.1	28.0
3 PAR PHARM	253	+68.3	501	+59.6	20.0	19.8	18.6	15.7	10.5	8.0	8.1	8.0	7.8	7.5	7.5	7.5
4 GLENMARK PHARMA	3	--	7	--	0.7	0.5	0.4	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5 UNIT DOSE LABS	1	-53.1	2	-50.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0
Brand	1	-64.6	1	-67.4												
1 GSK PHARM	1	-64.6	1	-67.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Decline in Share: Gave up RiteAid.

Naproxen (Naprosyn)
TAB, 250 mg, 375 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	9,616	-3.3	13,718	-2.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	9,603	-3.2	13,697	-2.8												
1 TEVA PHARMACEUT	4,485	+11.0	6,604	+11.4	47.4	46.9	46.8	46.8	46.5	46.4	48.9	50.1	50.0	49.7	49.6	49.6
2 GLENMARK PHARMA	3,163	+160.6	4,162	+136.4	32.4	32.4	32.0	31.8	31.8	31.7	31.2	30.7	29.7	30.5	29.4	21.6
3 AMNEAL PHARM	574	-24.0	809	-23.5	8.0	8.5	8.9	8.8	8.4	7.3	4.7	3.4	3.3	3.3	3.2	3.3
4 WEST WARD	416	+75.9	636	+83.2	4.2	4.0	3.9	4.2	4.2	4.3	4.4	4.6	5.7	4.6	4.7	6.7
5 DAVA PHARM	343	-85.7	530	-82.9	2.5	2.5	2.6	2.7	2.9	3.1	3.3	3.5	3.6	4.1	5.0	10.3
6 DR REDDY'S LAB	232	-33.9	366	-33.0	1.7	1.8	1.9	1.9	2.5	3.2	3.2	3.2	3.1	3.2	3.2	3.2
7 SANDOZ	156	-12.9	235	-5.6	1.6	1.7	1.7	1.7	1.6	1.6	1.6	1.7	1.8	1.8	1.8	2.0
8 MYLAN	132	-77.0	198	-76.2	1.3	1.3	1.2	1.2	1.3	1.4	1.4	1.5	1.6	1.6	1.7	1.8
9 PERRIGO	91	-35.5	139	-37.0	0.8	0.8	0.8	0.8	0.8	0.9	1.1	1.1	1.1	1.2	1.2	1.4
10 MAJOR PHARM	4	-51.0	7	-46.7	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1
11 UNIT DOSE LABS	3	-49.6	6	-51.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1
12 WATSON LABS	3	-77.2	4	-78.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Brand	13	-21.5	22	-22.5												
1 ROCHE	13	-21.5	22	-22.5	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2
Generic Substitution %	99.9		99.8		99.9	99.9	99.9	99.9	99.9	99.9	99.8	99.8	99.8	99.8	99.8	99.8

Naproxen DR (EC-Naprosyn)

MR TAB, 375 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	698	-6.2	976	-7.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	696	-6.1	972	-7.0												
1 TEVA PHARMACEUT	362	-20.2	493	-19.0	43.5	43.6	44.2	44.3	44.2	44.4	44.3	52.2	62.1	61.6	61.5	61.6
2 ETHEX CORP	236	-3.0	359	-3.8	36.1	36.2	36.0	36.8	37.5	38.4	40.7	38.8	35.6	36.0	36.0	35.9
3 SANDOZ	97	+140.2	118	+107.6	20.3	20.1	19.7	18.8	18.2	17.1	14.9	9.0	2.2	2.3	2.3	2.4
4 BARR LABS	0	-89.1	1	-89.7	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Brand	2	-33.6	4	-37.8												
1 ROCHE	2	-33.6	4	-37.8	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5	0.5	0.5
Generic Substitution %	99.7		99.6		99.7	99.7	99.7	99.7	99.7	99.7	99.7	99.6	99.6	99.5	99.5	99.5

Decline in Share: Lost Walgreens due to supply issues.

Naproxen Sodium (Anaprox)
TAB, 275 mg, 550 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,671	-7.7	2,113	-7.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,665	-7.6	2,102	-7.8												
1 TEVA PHARMACEUT	1,373	-8.5	1,716	-8.5	80.1	80.3	80.5	80.6	81.0	81.0	81.8	82.5	82.8	82.6	82.9	83.0
2 WEST WARD	133	-41.0	179	-40.5	8.8	8.6	7.9	6.8	5.7	6.0	6.8	8.1	10.2	10.7	10.8	11.2
3 GLENMARK PHARMA	95	+1908.2	124	+1930.8	7.4	7.3	7.3	7.5	7.5	7.4	6.6	5.5	4.1	3.9	3.7	3.3
4 AMNEAL PHARM	47	+7905.1	61	+8471.6	2.7	2.9	3.5	4.1	4.7	4.7	4.0	3.1	1.9	1.5	1.3	0.9
5 DR REDDY'S LAB	3	--	4	--	0.5	0.4	0.4	0.5	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0
6 WATSON LABS	11	-83.6	15	-83.6	0.3	0.4	0.4	0.4	0.5	0.6	0.7	0.7	0.9	1.0	1.1	1.4
7 SANDOZ	1	-59.2	2	-57.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	6	-29.1	11	-25.1												
1 ROCHE	6	-29.1	11	-25.1	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.6
Generic Substitution %	99.6		99.5		99.6	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.4	99.4	99.4

Nefazodone HCl (Serzone)

TAB, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	152	-10.5	418	-11.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	151	-10.4	418	-11.9												
1 TEVA PHARMACEUT	151	-10.1	416	-11.6	99.8	99.7	99.7	99.6	99.6	99.6	99.5	99.5	99.5	99.3	99.5	99.4
2 SANDOZ	0	-25.8	1	-37.6	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.2
3 PAR PHARM	0	-61.4	1	-52.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Neomycin Sulfate (Neomycin Sulfate)
 TAB, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	166	-7.3	196	-6.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	166	-7.3	196	-6.8												
1 TEVA PHARMACEUT	165	-7.2	195	-6.7	99.4	99.4	99.2	99.3	99.5	99.4	99.2	99.4	99.4	99.2	99.3	99.3
2 UNIT DOSE LABS	1	-26.1	1	-21.6	0.6	0.6	0.8	0.7	0.5	0.6	0.8	0.6	0.6	0.8	0.7	0.7
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Nicardipine HCl (Cardene)
CAP, 20 mg, 30 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	18	-4.3	57	-6.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	18	-2.8	57	-5.2												
1 MYLAN	12	-8.4	41	-5.0	66.9	68.1	67.6	69.7	69.4	70.1	71.4	72.3	75.7	76.7	77.5	74.9
2 TEVA PHARMACEUT	5	+72.8	14	+45.4	31.8	30.3	30.7	28.6	28.8	27.4	25.7	24.6	20.7	19.3	18.4	20.4
3 PAR PHARM	0	-84.5	1	-86.8	0.8	0.8	1.0	1.0	0.9	1.5	1.7	1.4	1.3	1.5	1.4	1.7
4 GENPHARM INC	0	-17.6	1	+11.9	0.4	0.6	0.5	0.5	0.7	0.8	0.8	1.4	2.0	2.0	2.1	2.2
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: Picked up Walgreens.

Nifedipine (Adalat CC)
MR TAB, 30 mg, 60 mg, 90 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	769	-10.7	2,618	-11.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	756	-10.2	2,565	-10.9												
1 TEVA PHARMACEUT	582	-7.8	1,942	-8.8	72.8	72.8	72.4	72.2	72.4	72.8	74.2	75.4	78.4	80.5	81.4	79.5
2 WATSON LABS	112	-46.7	415	-44.7	14.2	14.2	14.7	15.4	15.7	16.1	16.1	16.7	16.9	16.3	16.7	19.7
3 ACTAVIS	62	+29522.5	208	+40694.9	13.0	13.0	12.8	12.4	11.9	11.1	9.7	7.8	4.7	3.1	1.9	0.8
Brand	13	-33.2	53	-31.2												
1 SCHERING	13	-33.2	53	-31.2	1.9	1.9	2.0	2.0	2.0	2.0	1.9	2.1	2.0	2.0	2.0	2.2
Generic Substitution %	98.3		98.0		98.1	98.1	98.0	98.0	98.0	98.0	98.1	97.9	98.0	98.0	98.0	97.8

Decline in Share: Gave up ABC (Progen) and some smaller customers purchasing through the wholesalers.

Nifedipine (Procardia XL)
MR TAB, 30 mg, 60 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,880	+2.7	5,867	+2.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,849	+3.4	5,756	+3.8												
1 TEVA PHARMACEUT	860	-13.7	2,507	-14.9	45.0	44.3	44.3	44.3	44.2	43.6	43.9	45.3	44.9	40.9	40.6	40.9
2 MYLAN	793	+23.4	2,615	+23.4	42.7	43.4	43.6	43.7	44.4	45.2	45.4	44.5	45.4	48.4	49.0	49.4
3 KREMERS URBAN	162	+11.9	520	+9.9	9.4	9.4	9.3	9.2	8.8	8.7	8.4	8.3	8.5	9.7	9.6	9.2
4 ACTAVIS	33	+23010.6	109	+33308.6	2.8	2.8	2.8	2.7	2.6	2.5	2.2	1.7	1.0	0.8	0.5	0.3
5 UNIT DOSE LABS	2	-45.5	6	-38.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
Brand	31	-26.6	111	-27.3												
1 PFIZER	31	-26.6	111	-27.3	1.6	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.9	2.1	2.2	2.3
Generic Substitution %	98.4		98.1		98.4	98.3	98.3	98.3	98.2	98.2	98.2	98.2	98.1	97.9	97.8	97.7

Nitrofurantoin, Macrocrystalline (Macrochantin)
CAP, 50 mg,100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,628	-26.2	2,681	-19.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,614	-26.2	2,653	-19.7												
1 TEVA PHARMACEUT	666	+3.0	1,202	+1.7	45.2	44.7	45.5	45.5	45.5	45.7	45.6	46.1	46.1	45.9	45.4	42.8
2 MYLAN	476	-7.9	885	-3.4	33.8	33.6	33.8	33.7	33.2	33.1	32.9	32.8	32.7	33.1	32.8	34.4
3 WATSON LABS	468	-52.7	555	-51.9	20.6	21.2	20.3	20.3	20.9	20.8	21.1	20.6	20.8	20.6	21.4	22.4
4 UNIT DOSE LABS	4	+41.6	11	+70.9	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Brand	14	-25.8	28	-23.1												
1 PROCTER & G MED PH	14	-25.8	28	-23.1	0.9	1.0	1.0	0.9	0.9	1.0	1.0	1.0	1.0	1.2	1.2	1.3
Generic Substitution %	99.2		99.0		99.1	99.0	99.0	99.1	99.1	99.0	99.0	99.0	99.0	98.8	98.8	98.7

Nizatidine (Axid)
CAP, 150 mg, 300 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	133	-15.1	387	-16.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	130	-14.9	378	-16.4												
1 DR REDDY'S LAB	36	+760.5	88	+767.1	31.9	31.9	30.9	30.6	29.7	29.5	28.0	25.9	21.6	15.2	6.9	6.4
2 MYLAN	36	-20.3	109	-18.8	28.7	28.8	29.1	29.0	28.9	28.5	28.8	29.0	29.4	29.2	29.3	28.3
3 TEVA PHARMACEUT	33	-52.0	95	-50.5	20.5	19.8	19.6	19.7	19.4	19.7	21.0	22.0	24.8	28.4	40.5	41.8
4 SANDOZ	11	-18.6	40	-15.5	10.2	10.3	10.7	10.4	11.0	10.7	10.5	10.8	11.1	10.5	10.6	10.7
5 APOTEX CORP	4	-24.4	12	-22.4	3.3	3.4	3.5	3.4	3.2	3.1	3.1	3.4	3.2	3.3	3.2	3.5
6 PAR PHARM	6	-41.3	21	-43.0	3.2	3.6	4.0	4.4	4.8	5.5	5.6	5.3	6.7	10.4	6.4	6.0
7 WATSON LABS	3	-23.0	11	-21.5	2.1	2.2	2.1	2.5	2.8	2.9	2.8	3.5	3.0	3.0	3.2	3.2
Brand	3	-27.3	9	-29.6												
1 GSK PHARM	3	-27.3	9	-29.6	2.2	2.2	2.1	2.1	2.2	2.2	2.3	2.4	2.3	2.5	2.6	2.5
Generic Substitution %	98.0		97.7		97.8	97.8	97.9	97.9	97.8	97.8	97.7	97.6	97.7	97.5	97.4	97.5

Decline in Share: Lost RiteAid, ESI and Walgreens due to supply issues (Q4 2007).

Nortriptyline HCl (Pamelor)
CAP, 10 mg, 25 mg, 50 mg, 75 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,278	-3.1	3,163	-3.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,272	-2.9	3,147	-3.6												
1 WATSON LABS	813	-2.8	2,034	-3.2	59.4	60.2	61.7	64.1	66.8	67.0	66.8	66.9	66.6	65.7	65.3	65.0
2 TEVA PHARMACEUT	450	-1.9	1,090	-2.9	40.3	39.4	38.0	35.3	32.6	32.5	32.7	32.6	32.8	33.0	33.3	33.5
3 MYLAN	5	-55.8	13	-58.7	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.6	0.6
4 UNIT DOSE LABS	1	-48.5	2	-55.7	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
5 TARO PHARM	2	+215.0	6	+195.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.8	0.7	0.8
Brand	6	-32.6	16	-31.2												
1 MALLINCKRODT	6	-32.6	16	-31.2	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.5	0.5
Generic Substitution %	99.6		99.5		99.6	99.6	99.6	99.5	99.5	99.5	99.5	99.5	99.5	99.4	99.5	99.5

Gain in Share: Picked up McKesson(OneStop).

Nystatin (Mycostatin)
TAB, 500000 units

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	69	+0.5	119	-0.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	69	+0.5	119	-0.6												
1 MUTUAL PHARM	40	-8.1	67	-10.5	52.2	53.7	52.0	52.4	53.1	55.3	56.6	57.6	58.0	59.0	59.9	61.7
2 TEVA PHARMACEUT	28	+33.3	50	+35.1	47.0	45.5	46.9	46.3	45.6	42.8	41.5	39.9	39.2	38.3	36.7	34.4
3 URL PHARMA	1	-67.6	2	-70.9	0.8	0.8	1.0	1.2	1.2	1.8	1.9	2.6	2.7	2.7	3.2	3.8
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: Picked up CVS.

Ofloxacin (Floxin)

TAB, 200 mg, 300 mg, 400 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	59	-33.4	64	-33.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	59	-33.1	64	-32.8												
1 RANBAXY PHARM	47	-36.7	51	-36.6	70.6	72.7	75.7	79.0	81.5	81.8	83.2	83.0	82.5	82.9	81.6	83.7
2 TEVA PHARMACEUT	9	-26.9	10	-25.6	17.4	16.0	14.7	14.9	15.0	14.8	13.9	14.5	15.2	15.4	16.1	14.1
3 DR REDDY'S LAB	2	+2922.5	3	+2913.8	11.7	10.9	9.4	5.8	3.1	2.7	2.3	2.0	1.8	1.3	1.6	1.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Omeprazole (Prilosec)
MR CAP, 10 mg, 20 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	11,590	+27.2	32,939	+32.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	11,552	+27.5	32,808	+32.8												
1 SANDOZ	3,585	+65.8	9,609	+68.1	28.1	28.6	28.3	28.1	28.3	28.8	29.4	29.6	30.0	31.2	30.9	30.9
2 APOTEX CORP	2,867	+36.3	8,076	+39.3	25.0	25.1	25.3	25.7	25.7	25.9	25.2	25.0	24.6	22.7	22.5	22.0
3 MYLAN	2,882	+28.5	8,305	+32.3	24.1	24.1	24.3	24.6	24.6	25.4	26.4	26.3	26.3	26.2	26.1	25.9
4 KREMERS URBAN	2,062	+65.8	6,326	+70.2	19.6	19.4	19.5	19.6	20.0	18.7	18.1	18.2	18.4	19.2	20.0	20.6
5 DR REDDY'S LAB	102	--	302	--	2.1	1.7	1.7	1.4	1.2	0.9	0.6	0.5	0.3	0.1	0.0	0.0
6 UNIT DOSE LABS	18	+56.8	87	+175.9	0.9	0.8	0.6	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
7 TEVA PHARMACEUT	33	-97.4	95	-97.0	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.4	0.5
8 AMERICAN HLTH PKG	3	+12.2	6	+7.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	38	-29.7	132	-30.7												
1 ASTRAZENECA	38	-29.7	132	-30.7	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.6
Generic Substitution %	99.7		99.6		99.7	99.7	99.7	99.7	99.6	99.6	99.6	99.6	99.6	99.5	99.5	99.4

Ondansetron (Zofran ODT)
ODT, 4 mg, 8 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,144	+59.4	1,372	+54.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,123	+122.8	1,343	+119.5												
1 GLENMARK PHARMA	347	+6918.6	398	+6155.7	46.6	44.9	43.7	43.0	41.2	36.7	30.8	16.3	10.6	10.3	9.0	7.3
2 MYLAN	303	+1521.7	367	+1513.8	29.4	29.4	29.6	29.1	28.7	28.3	27.7	27.0	26.4	25.2	23.4	20.8
3 SANDOZ	180	-19.1	226	-17.5	14.6	14.9	14.7	14.8	14.8	15.1	15.8	16.9	18.2	19.5	21.6	25.2
4 BARR LABS	254	-0.7	300	-1.6	5.1	6.5	7.6	9.0	11.0	15.2	21.5	36.2	41.4	42.1	43.2	44.0
5 ETHEX CORP	32	+1390.8	41	+1315.0	3.1	3.2	3.2	3.1	3.5	3.9	3.4	2.9	2.7	2.5	2.5	2.5
6 SUN PHARMACEUTICAL	2	--	3	--	0.7	0.5	0.4	0.3	0.2	0.2	0.1	0.1	0.1	0.0	0.0	0.0
7 TEVA PHARMACEUT	5	+1090.5	7	+1097.0	0.6	0.6	0.6	0.7	0.6	0.6	0.7	0.6	0.4	0.3	0.2	0.3
Brand	21	-90.3	30	-89.3												
1 GSK PHARM	21	-90.3	30	-89.3	1.4	1.5	1.6	1.8	1.8	1.8	1.8	1.9	2.4	3.1	3.7	4.3
Generic Substitution %	98.2		97.8		98.6	98.5	98.4	98.2	98.2	98.2	98.2	98.1	97.6	96.9	96.3	95.7

Ondansetron HCl (Zofran)
 TAB, 4 mg, 8 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,470	+44.0	2,097	+41.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,442	+98.6	2,049	+100.0												
1 DR REDDY'S LAB	1,025	+91.0	1,441	+92.5	68.6	69.1	69.0	69.6	70.3	70.4	71.1	71.1	71.3	71.7	71.6	71.3
2 MYLAN	180	+1705.6	260	+1606.3	15.2	15.2	15.1	14.6	14.4	14.0	12.1	11.3	10.5	9.7	9.3	8.4
3 SANDOZ	192	+8.3	280	+8.7	11.6	11.4	11.9	12.0	11.8	12.2	13.6	14.7	15.6	16.3	16.9	18.3
4 RANBAXY PHARM	13	+2173.7	20	+2518.6	1.4	1.4	1.3	1.1	1.1	1.0	0.9	0.8	0.7	0.7	0.6	0.5
5 SUN PHARMACEUTICAL	10	+3041.6	14	+3344.0	1.3	1.1	0.9	0.7	0.7	0.6	0.6	0.5	0.4	0.4	0.3	0.3
6 ACTAVIS	10	+812.9	16	+846.8	0.8	0.8	0.9	0.9	0.8	0.8	0.9	0.9	0.8	0.7	0.7	0.6
7 TEVA PHARMACEUT	7	+2593.6	10	+2576.2	0.5	0.5	0.5	0.6	0.6	0.6	0.5	0.5	0.3	0.3	0.3	0.3
8 AUROBINDO PHARM	1	--	2	--	0.3	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
9 WEST WARD	0	--	1	--	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 GLENMARK PHARMA	1	+2456.5	2	+2283.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
11 PERRIGO	3	+1153.6	4	+1275.8	0.1	0.1	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2
Brand	28	-90.4	48	-89.4												
1 GSK PHARM	28	-90.4	48	-89.4	1.6	1.7	1.7	1.8	1.8	1.9	2.0	2.3	2.6	3.1	3.5	4.1
Generic Substitution %	98.1		97.7		98.4	98.3	98.3	98.2	98.2	98.1	98.0	97.7	97.4	96.9	96.5	95.9

**Oxaprozin (Daypro)
TAB, 600 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	540	-13.0	1,007	-12.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	536	-12.8	998	-12.1												
1 DR REDDY'S LAB	339	+9.5	602	+11.0	72.4	72.3	71.2	69.7	64.9	58.4	53.5	53.4	53.4	52.7	52.5	52.4
2 SANDOZ	108	-34.9	207	-31.4	11.0	11.3	12.2	13.6	16.8	22.4	26.6	26.3	26.2	26.1	26.8	26.9
3 APOTEX CORP	37	+40.1	78	+36.5	8.6	8.0	7.8	7.4	7.9	7.7	7.9	8.1	7.9	8.0	7.8	7.4
4 CARACO PHARM	35	-26.1	71	-27.2	6.1	6.3	6.6	7.0	7.5	7.6	7.7	7.4	7.6	7.6	6.7	6.9
5 TEVA PHARMACEUT	11	-78.0	27	-74.8	1.2	1.2	1.2	1.4	1.9	2.7	3.1	3.3	3.3	3.8	4.3	4.4
6 PAR PHARM	6	-53.0	12	-52.7	0.6	0.8	0.9	0.8	0.9	1.0	1.1	1.4	1.5	1.7	1.7	1.8
7 GREENSTONE LTD	0	-74.9	1	-76.6	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	4	-29.2	9	-29.2												
1 PFIZER	4	-29.2	9	-29.2	0.8	0.8	0.8	0.9	0.9	1.0	1.0	0.9	1.0	1.1	1.0	1.1
Generic Substitution %	99.3		99.1		99.2	99.2	99.2	99.1	99.1	99.0	99.0	99.1	99.0	98.9	99.0	98.9

Oxazepam (Serax)
CAP, 10 mg, 15 mg, 30 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	272	-8.4	558	-8.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	272	-8.4	558	-8.1												
1 ACTAVIS	138	-2.7	286	-1.8	51.4	51.4	51.1	51.1	51.3	51.7	51.9	51.2	51.3	51.0	51.5	50.9
2 SANDOZ	87	+1.0	179	+1.4	33.2	32.9	33.2	33.2	32.3	31.4	31.3	31.7	31.8	32.1	31.6	31.5
3 TEVA PHARMACEUT	46	-31.9	92	-33.4	15.4	15.6	15.7	15.7	16.4	16.9	16.8	17.1	16.8	16.9	16.9	17.5
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Oxcarbazepine (Trileptal)
 TAB, 150 mg, 300 mg, 600 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,444	+2.1	3,028	-2.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,138		2,278													
1 GLENMARK PHARMA	724	--	1,393	--	45.7	47.0	49.0	51.8	57.0	63.6	67.8	70.3	71.6	72.6	76.4	87.0
2 SUN PHARMACEUTICAL	222	--	502	--	22.9	22.8	22.7	22.5	22.1	22.4	23.8	23.5	23.1	21.8	17.9	6.5
3 ROXANE	145	--	284	--	22.6	21.9	20.4	18.3	14.1	9.0	6.3	5.5	5.3	5.6	5.7	6.5
4 BRECKENRIDGE	24	--	54	--	4.0	3.9	4.1	4.0	3.7	3.1	2.0	0.7	0.0	0.0	0.0	0.0
5 ASCEND LABS	16	--	30	--	2.5	2.4	2.6	2.5	2.6	1.7	0.0	0.0	0.0	0.0	0.0	0.0
6 APOTEX CORP	5	--	12	--	2.0	1.8	1.1	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
7 TEVA PHARMACEUT	1	--	2	--	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
8 AMERICAN HLTH PKG	0	--	1	--	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	306	-78.4	750	-75.8												
1 NOVARTIS RX	306	-78.4	750	-75.8	14.0	14.6	15.5	16.5	17.0	17.4	17.9	19.4	21.8	26.2	35.7	79.2
Generic Substitution %	78.8		75.2		86.0	85.4	84.5	83.5	83.0	82.6	82.1	80.6	78.2	73.8	64.3	20.8

Oxybutynin Chloride (Ditropan XL)
MR TAB, 5 mg,10 mg, 15 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	944	-7.6	2,988	+5.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	903	+13.7	2,835	+38.0												
1 MYLAN	608	-9.5	2,035	+14.1	71.0	71.0	71.3	71.7	71.2	71.8	72.0	71.8	71.8	72.2	72.4	73.3
2 TEVA PHARMACEUT	292	+140.0	788	+193.6	28.9	28.9	28.6	28.1	28.6	28.0	27.6	27.7	27.6	27.0	26.6	25.8
3 UNIT DOSE LABS	4	+153.1	12	+389.3	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.6	0.6	0.8	1.0	0.9
Brand	41	-82.0	154	-80.6												
1 MCNEIL PHARM	41	-82.0	154	-80.6	3.5	3.6	3.9	4.1	4.1	4.5	4.9	5.3	5.9	6.7	7.2	8.0
Generic Substitution %	95.7		94.9		96.5	96.4	96.1	95.9	95.9	95.5	95.1	94.7	94.1	93.3	92.8	92.0

Paroxetine HCl (Paxil)
TAB, 10 mg, 20 mg, 30 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	5,797	-7.3	15,548	-6.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	5,746	-7.2	15,421	-6.1												
1 APOTEX CORP	3,599	+3.0	9,494	+2.6	53.4	53.1	52.9	53.0	53.8	56.7	65.0	70.1	70.0	69.8	70.0	69.6
2 AUROBINDO PHARM	581	--	1,509	--	20.0	19.9	19.7	19.2	18.2	15.1	6.5	0.3	0.1	0.0	0.0	0.0
3 TEVA PHARMACEUT	687	-51.1	1,797	-48.5	11.3	11.5	11.6	11.6	11.8	11.8	11.9	11.9	11.8	11.6	11.2	11.8
4 PAR PHARM	421	-54.5	1,209	-52.8	6.7	7.1	7.5	7.7	7.7	7.9	8.0	8.0	8.1	8.4	8.6	8.5
5 ZYDUS PHARM	278	+282.5	906	+307.6	5.8	5.6	5.5	5.4	5.2	5.3	5.4	6.4	6.5	6.5	6.5	6.4
6 WATSON LABS	127	-49.4	356	-52.3	1.5	1.7	1.8	2.1	2.4	2.4	2.4	2.4	2.6	2.7	2.8	2.9
7 MALLINCKRODT	41	+600.7	118	+560.6	1.0	1.0	0.9	0.9	0.8	0.7	0.7	0.7	0.7	0.7	0.6	0.5
8 CARACO PHARM	3	--	8	--	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
9 MYLAN	0	--	1	--	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 AMERICAN HLTH PKG	5	-84.8	17	-85.5	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2
11 MAJOR PHARM	3	-20.4	6	-23.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 UNIT DOSE LABS	1	-8.6	1	-3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	51	-15.6	127	-12.7												
1 GSK PHARM	51	-15.6	127	-12.7	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.8	0.9	0.8
Generic Substitution %	99.1		99.2		99.2	99.2	99.2	99.2	99.2	99.2	99.2	99.2	99.1	99.2	99.1	99.2

Penicillin V Potassium (V-Cillin-K)
 POS, 125 mg/5ml, 250 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	519	-9.6	623	-8.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	519	-9.6	623	-8.0												
1 TEVA PHARMACEUT	466	-6.1	557	-4.7	89.7	89.8	89.6	89.9	90.0	89.9	89.5	89.7	88.8	89.1	88.5	88.0
2 DAVA PHARM	51	-25.4	64	-21.8	10.1	10.0	10.1	9.8	9.7	9.7	10.1	9.9	10.6	10.5	10.9	11.4
3 SANDOZ	2	-80.0	2	-79.3	0.2	0.2	0.2	0.3	0.3	0.3	0.4	0.3	0.5	0.4	0.6	0.6
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Penicillin V Potassium (V-Cillin-K)
 TAB, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	7,662	-7.9	8,022	-7.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	7,662	-7.9	8,022	-7.9												
1 TEVA PHARMACEUT	5,233	+8.4	5,449	+8.3	66.6	66.8	67.1	67.4	68.1	68.2	68.7	68.7	68.5	68.8	68.2	67.7
2 SANDOZ	1,634	-34.0	1,729	-33.7	22.4	22.1	22.1	22.1	21.6	21.4	21.2	21.1	21.1	21.0	21.3	21.4
3 DAVA PHARM	794	-21.6	843	-21.3	11.0	11.1	10.8	10.6	10.3	10.4	10.1	10.2	10.4	10.1	10.5	10.9
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Pentoxifylline (Trental)

MR TAB, 400 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	389	-8.3	1,148	-7.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	386	-8.1	1,135	-7.5												
1 TEVA PHARMACEUT	227	-0.5	640	-1.2	58.3	58.3	57.9	57.3	56.2	56.0	55.5	55.8	55.4	55.7	55.6	55.2
2 APOTEX CORP	103	-3.8	319	+2.8	26.9	26.7	27.2	27.7	28.3	28.8	29.2	28.8	28.7	28.1	28.0	28.3
3 MYLAN	51	-16.8	157	-16.1	13.8	14.0	13.8	13.6	13.9	13.5	13.6	13.6	13.9	14.1	14.2	14.3
4 UPSHER-SMITH	2	-28.7	6	-27.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.7	0.6
5 ACTAVIS	3	-85.3	8	-85.8	0.3	0.3	0.3	0.5	0.7	0.9	0.8	0.8	1.0	1.0	1.1	1.1
6 BARR LABS	1	-81.0	1	-82.8	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.2	0.2
7 MAJOR PHARM	0	-38.5	1	-34.5	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
8 UNIT DOSE LABS	0	-56.4	1	-54.8	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	4	-24.2	13	-22.7												
1 SANOFI AVENTIS PHR	4	-24.2	13	-22.7	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.1	1.2	1.2	1.2	1.2
Generic Substitution %	99.0		98.8		98.9	98.9	98.9	98.9	98.9	98.9	98.8	98.9	98.8	98.8	98.8	98.8

**Piroxicam (Feldene)
CAP, 10 mg, 20 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	950	-9.6	1,849	-10.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	947	-9.6	1,842	-10.0												
1 TEVA PHARMACEUT	681	+15.6	1,304	+18.1	72.5	72.6	72.2	71.7	71.5	71.5	70.9	70.8	70.2	69.3	68.8	67.8
2 MYLAN	263	-41.3	531	-42.4	27.3	27.1	27.5	28.0	28.2	28.2	28.8	28.8	29.4	30.2	30.6	31.5
3 RANBAXY PHARM	1	-75.9	2	-74.8	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2
4 MARTEC PHARM	1	-69.8	2	-68.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2
5 UNIT DOSE LABS	1	-18.3	2	-11.7	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
Brand	3	-28.4	7	-26.2												
1 PFIZER	3	-28.4	7	-26.2	0.3	0.3	0.3	0.3	0.4	0.3	0.4	0.4	0.4	0.4	0.4	0.4
Generic Substitution %	99.7		99.6		99.7	99.7	99.7	99.7	99.6	99.7	99.6	99.6	99.6	99.6	99.6	99.6

Gain in Share: Picked up ABC, Omnicare, Cardinal and Kroger due to Mylan supply problems.

Potassium Chloride (K-Dur)

MR TAB, 10 meq, 20 meq

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	6,875	+1.5	19,133	+1.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	6,872	+1.8	19,128	+1.9												
1 UPSHER-SMITH	2,912	+19.8	7,991	+19.0	40.9	41.5	42.1	42.3	42.4	43.4	42.7	42.1	41.8	41.2	41.4	39.5
2 TEVA PHARMACEUT	1,183	-35.7	3,851	-30.7	20.2	20.0	19.5	19.6	18.7	18.5	19.1	20.4	20.6	21.1	21.3	22.6
3 SCHERING	1,352	+122.1	3,708	+126.9	20.1	19.9	20.6	19.9	20.0	20.0	19.9	16.7	19.0	18.7	18.6	19.1
4 WATSON LABS	1,297	-3.5	3,182	-3.4	17.5	17.3	16.5	16.7	17.1	16.2	16.3	18.5	16.0	16.1	15.7	15.6
5 ETHEX CORP	96	-42.6	292	-40.5	1.1	1.1	1.1	1.2	1.3	1.4	1.6	1.8	1.9	1.9	2.0	2.1
6 WARRICK PHARM	27	-92.1	93	-90.9	0.2	0.2	0.2	0.3	0.4	0.4	0.4	0.5	0.6	0.8	0.9	1.0
7 PAR PHARM	2	-88.4	6	-88.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1
8 MCKESSON PKG SERV	2	+74.9	3	+51.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
9 QUALITEST PRODUCTS	1	-50.4	3	-57.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	3	-87.9	5	-92.4												
1 KEY PHARMACEUTICAL	3	-87.9	5	-92.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Pravastatin Sodium (Pravachol)

TAB, 10 mg, 20 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,646	+24.9	11,055	+21.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3,592	+27.5	10,866	+24.4												
1 TEVA PHARMACEUT	1,699	+21.1	4,986	+18.8	44.4	44.7	44.9	45.8	46.2	46.1	47.2	48.0	46.5	45.8	45.8	45.7
2 APOTEX CORP	1,100	+98.0	3,255	+100.4	32.6	32.2	32.2	31.8	31.6	31.2	30.1	28.9	27.8	26.4	26.5	26.4
3 DR REDDY'S LAB	437	+116.4	1,400	+106.4	14.6	14.7	14.7	14.4	13.9	13.7	13.0	11.5	10.8	10.8	10.6	10.4
4 GLENMARK PHARMA	56	+2857.7	178	+3060.3	2.7	2.4	2.3	2.1	1.7	1.5	1.4	1.2	1.1	1.0	0.9	0.7
5 RANBAXY PHARM	34	--	111	--	2.5	2.4	2.0	1.4	1.3	0.9	0.6	0.4	0.1	0.0	0.0	0.0
6 WATSON LABS	158	-69.6	568	-68.2	1.5	1.7	2.0	2.2	2.6	3.8	5.0	7.1	9.2	9.9	10.1	10.5
7 PAR PHARM	21	-1.3	73	+9.3	0.4	0.5	0.6	0.7	0.9	0.8	0.7	0.7	0.7	0.7	0.7	0.8
8 COBALT LABS	9	+102.3	29	+82.0	0.4	0.4	0.4	0.4	0.5	0.4	0.3	0.1	0.1	0.1	0.1	0.1
9 MYLAN	6	--	23	--	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.2	0.0	0.0	0.0	0.0
10 BARR LABS	16	+37.1	52	+59.6	0.3	0.4	0.4	0.4	0.4	0.5	0.5	0.6	0.6	0.6	0.6	0.5
11 SANDOZ	54	-45.1	186	-43.3	0.2	0.3	0.3	0.3	0.5	0.7	0.9	1.5	3.1	4.7	4.8	4.8
12 UNIT DOSE LABS	1	+89.1	2	+55.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 AMERICAN HLTH PKG	0	+5100.0	2	+9116.7	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
14 MARLEX PHARM	0	+1193.9	1	+1104.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	54	-46.7	189	-49.3												
1 BRISTOL-M SQ US PH	54	-46.7	189	-49.3	1.3	1.3	1.4	1.5	1.4	1.5	1.6	1.7	2.0	2.2	2.3	2.5
Generic Substitution %	98.5		98.3		98.7	98.7	98.6	98.5	98.6	98.5	98.4	98.3	98.0	97.8	97.7	97.5

Prazosin HCl (Minipress)
CAP, 1 mg, 2 mg, 5 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	168	+4.7	460	-1.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	166	+5.0	453	-1.4												
1 MYLAN	93	-0.0	247	-7.4	54.1	54.1	53.9	54.1	54.6	53.9	54.2	54.3	55.0	55.2	55.2	55.0
2 TEVA PHARMACEUT	73	+12.4	206	+7.2	45.9	45.9	46.1	45.8	45.3	46.0	45.7	45.6	44.8	44.7	44.6	44.9
Brand	2	-13.9	7	-19.5												
1 PFIZER	2	-13.9	7	-19.5	1.3	1.3	1.3	1.6	1.5	1.5	1.5	1.6	1.7	1.9	1.7	2.0
Generic Substitution %	98.8		98.4		98.7	98.7	98.7	98.4	98.5	98.5	98.5	98.4	98.3	98.1	98.3	98.0

Prednisolone (Prelone)
LIQ, 15 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,600	+7.4	1,629	+7.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,600	+7.5	1,629	+7.3												
1 HI-TECH PHARMACAL	677	-1.2	688	-1.2	44.3	44.6	42.3	41.7	42.1	42.4	42.3	41.7	42.3	42.1	41.7	40.8
2 TEVA PHARMACEUT	492	+12.7	502	+12.4	38.1	33.5	30.5	30.1	30.2	29.2	28.7	28.6	29.0	30.5	31.1	32.3
3 ETHEX CORP	243	-13.7	248	-13.8	14.8	14.7	14.3	14.7	14.3	15.4	15.6	16.3	15.8	15.0	15.3	15.4
4 PHARMACEUT ASSOC	163	+235.9	165	+233.4	1.5	6.0	11.8	12.2	12.0	11.6	11.9	11.9	11.2	10.8	10.1	9.5
5 DEXO US	21	-23.4	21	-23.4	0.8	0.8	0.8	1.0	1.3	1.3	1.4	1.4	1.5	1.5	1.5	1.6
6 QUALITEST PRODUCTS	2	+6412.5	2	+6533.3	0.4	0.3	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
7 ACTAVIS	2	-73.4	2	-73.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.2	0.2	0.3	0.3
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: Picked up RiteAid.

Prednisone (Deltasone/Meticorten)

TAB, 5 mg,10 mg, 20 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	18,907	+4.7	24,410	+3.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	16,032	+1.4	20,561	-0.2												
1 WATSON LABS	9,535	-14.2	11,982	-17.6	51.4	52.1	54.3	57.9	59.1	59.5	59.8	60.5	60.9	61.3	61.6	61.8
2 WEST WARD	3,187	+184.4	4,396	+180.7	22.0	22.2	22.8	23.2	22.3	21.9	21.8	21.0	20.6	19.9	19.6	19.1
3 QUALITEST PRODUCTS	1,716	+52.0	2,200	+56.5	18.1	17.2	13.9	9.3	9.1	9.2	9.1	8.9	8.6	8.1	7.8	8.0
4 MUTUAL PHARM	1,113	+11.7	1,395	+9.5	6.4	6.4	6.6	7.2	7.3	7.2	7.0	6.9	6.7	6.7	6.7	6.5
5 PERRIGO	267	+42.8	284	+45.3	1.2	1.2	1.4	1.3	1.0	0.9	0.9	1.2	1.5	1.9	2.1	2.1
6 CADISTA PHARM	24	+2420600.0	34	+3384900.0	0.5	0.4	0.3	0.3	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0
7 URL PHARMA	181	-85.3	258	-83.8	0.4	0.5	0.6	0.7	0.9	1.2	1.2	1.4	1.7	2.0	2.1	2.5
8 TEVA PHARMACEUT	6	+7.0	9	-3.2	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
9 MERZ PHARM	1	-41.3	1	-43.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 BRECKENRIDGE	1	-93.1	1	-93.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	2,875	+27.3	3,849	+29.9												
1 ROXANE	2,875	+27.4	3,849	+29.9	7.5	9.1	13.1	17.9	18.8	18.8	18.7	18.1	17.9	17.1	15.8	15.4
Generic Substitution %	84.8		84.2		92.5	90.9	86.9	82.1	81.2	81.2	81.3	81.9	82.1	82.9	84.2	84.6

Prochlorperazine Maleate (Prochlorperazine Maleate (was Compazine))

TAB, 5 mg,10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,655	-0.8	2,111	-1.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,377	+6.9	1,738	+6.3												
1 CADISTA PHARM	270	+3660.9	316	+3094.0	30.8	30.3	29.7	28.6	26.4	23.6	18.9	11.3	7.0	7.5	1.3	0.6
2 TEVA PHARMACEUT	484	-20.4	618	-18.8	29.8	29.6	29.6	29.9	30.0	30.8	34.4	40.1	40.7	33.9	45.3	53.2
3 MYLAN	417	-3.6	528	-3.0	28.2	28.1	27.7	27.7	28.6	29.6	30.8	31.8	33.6	36.2	33.6	29.6
4 BARR LABS	83	-2.6	112	-2.8	6.4	6.2	6.4	6.1	6.3	6.3	6.0	6.2	6.6	7.4	6.8	6.4
5 BRECKENRIDGE	78	-25.5	104	-23.9	3.3	3.7	3.9	4.4	5.2	6.1	6.2	6.7	7.9	10.2	8.6	6.5
6 PRASCO LABS	29	-17.4	41	-16.1	1.1	1.4	1.6	2.1	2.4	2.4	2.5	2.7	2.9	3.4	3.2	2.8
7 UNIT DOSE LABS	12	+23.6	15	+23.7	0.4	0.6	0.9	0.9	0.9	1.0	1.0	0.9	0.9	1.2	0.9	0.6
8 PAR PHARM	3	-42.5	4	-43.4	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3
Brand	278	-26.8	373	-26.1												
1 SANDOZ	278	-26.8	372	-26.1	13.2	13.6	13.8	14.2	15.4	16.4	17.2	19.0	21.8	26.0	23.0	17.5
Generic Substitution %	83.2		82.4		86.8	86.4	86.2	85.8	84.6	83.6	82.8	81.0	78.2	74.0	77.0	82.5

Decline in Share: Gave up Walgreens.

**Propoxyphene HCl (Darvon)
CAP, 65 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	317	-2.8	495	-4.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	313	-2.5	487	-3.8												
1 QUALITEST PRODUCTS	225	+43.6	345	+37.3	79.4	78.1	77.1	76.8	76.4	75.8	74.7	73.2	69.8	59.2	56.2	55.5
2 PAR PHARM	36	+6.3	67	+9.1	13.4	14.1	13.7	14.1	14.1	13.7	14.1	14.1	13.3	13.4	13.3	13.0
3 TEVA PHARMACEUT	47	-62.0	69	-62.7	6.1	6.7	8.0	8.0	8.3	9.2	9.9	11.4	15.3	25.6	28.7	29.6
4 MYLAN	4	-29.9	7	-30.3	1.0	1.2	1.1	1.1	1.1	1.3	1.2	1.3	1.5	1.9	1.8	2.0
Brand	4	-22.5	8	-21.7												
1 XANODYNE PHARMA	4	-22.5	8	-21.7	1.3	1.5	1.4	1.4	1.6	1.6	1.5	1.7	1.7	1.8	1.7	1.7
Generic Substitution %	98.8		98.4		98.7	98.5	98.6	98.6	98.4	98.4	98.5	98.3	98.3	98.2	98.3	98.3

Decline in Share: Gave up Brooks-Eckerd volume as part of the RiteAid acquisition. Lost Walgreens due to supply.

Quinapril HCl (Accupril)
TAB, 5 mg,10 mg, 20 mg, 40 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,085	-4.8	6,681	-12.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,025	-3.5	6,463	-11.0												
1 GREENSTONE LTD	1,088	-11.2	3,788	-12.1	57.4	57.9	57.5	59.5	59.1	58.5	58.5	58.7	58.8	58.2	59.2	59.8
2 APOTEX CORP	226	+271.6	575	+177.6	11.7	12.0	9.5	6.4	6.4	7.7	8.7	10.4	10.0	8.3	8.0	7.9
3 TEVA PHARMACEUT	266	+1119.1	545	+572.0	11.2	10.9	12.8	16.3	16.5	15.1	11.9	6.0	1.7	0.8	0.3	0.3
4 LUPIN PHARMA	154	+144.4	600	+151.0	11.1	10.9	10.5	10.4	9.7	8.9	8.8	8.5	8.3	8.4	8.3	8.1
5 PAR PHARM	242	-66.5	773	-67.9	6.1	5.5	6.3	4.0	4.8	6.3	8.7	13.0	18.1	21.9	22.5	22.6
6 DR REDDY'S LAB	5	--	18	--	1.2	0.7	0.4	0.3	0.2	0.2	0.2	0.1	0.1	0.0	0.0	0.0
7 WATSON LABS	41	+884.5	160	+795.8	1.0	1.9	2.8	3.1	3.2	3.2	3.1	3.2	2.9	2.5	1.7	1.2
8 RANBAXY PHARM	1	--	3	--	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
9 MYLAN	0	+78.0	1	+56.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	61	-34.3	218	-36.4												
1 PFIZER	61	-34.3	218	-36.4	2.7	2.8	2.8	3.0	3.0	3.1	3.2	3.3	3.5	3.8	3.7	3.8
Generic Substitution %	97.1		96.7		97.3	97.2	97.2	97.0	97.0	96.9	96.8	96.7	96.5	96.2	96.3	96.2

Gain in Share: Picked up Walgreens.

**Quinidine Sulfate (Quinidex)
MR TAB, 300 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3	-24.1	10	-22.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	3	-24.1	10	-22.1												
1 TEVA PHARMACEUT	3	-23.9	10	-22.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.9	100.0	99.8	99.9	99.9
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Ramipril (Altace)

CAP, 2.5 mg, 5 mg,10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	3,750	+0.7	11,163	-9.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,935		5,476													
1 COBALT LABS	1,581	--	4,405	--	52.1	55.9	64.9	89.6	99.8	99.8	99.8	99.9	100.0	100.0	0.0	0.0
2 LUPIN PHARMA	328	--	993	--	43.6	40.8	33.6	10.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
3 DR REDDY'S LAB	16	--	51	--	2.9	2.4	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
4 SANDOZ	4	--	10	--	0.7	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5 ROXANE	1	--	3	--	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
6 TEVA PHARMACEUT	1	--	3	--	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
7 APOTEX CORP	1	--	2	--	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
8 AMERICAN HLTH PKG	3	--	9	--	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.1	0.0	0.0	0.0	0.0
Brand	1,815	-51.3	5,687	-53.8												
1 KING PHARM	1,815	-51.3	5,687	-53.8	10.7	12.4	13.9	22.9	30.9	36.1	40.8	51.2	78.9	99.9	100.0	100.0
Generic Substitution %	51.6		49.1		89.3	87.6	86.1	77.1	69.1	63.9	59.2	48.8	21.1	0.1	0.0	0.0

Ranitidine HCl (Zantac)
 TAB, 150 mg, 300 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	4,471	-4.2	11,763	-2.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	4,451	-4.1	11,703	-2.4												
1 TEVA PHARMACEUT	2,434	+13.7	5,827	+18.8	50.4	50.3	50.2	50.0	49.9	49.5	49.7	49.8	49.8	49.6	49.4	49.0
2 PAR PHARM	951	-12.6	2,934	-10.4	23.5	25.4	25.5	25.1	24.8	24.7	24.6	24.8	25.1	25.6	25.7	26.1
3 WOCKHARDT AMERICA	524	+109.0	1,430	+102.1	17.2	16.5	16.5	16.8	16.7	15.1	11.6	9.0	7.5	6.9	6.8	6.8
4 APOTEX CORP	314	-40.6	904	-37.4	5.9	5.4	5.6	5.5	5.6	6.0	6.8	8.8	10.2	10.6	10.8	10.9
5 SANDOZ	49	-87.2	138	-85.8	1.2	1.0	1.0	1.1	1.1	1.1	1.1	1.2	1.2	1.3	1.3	1.4
6 AMNEAL PHARM	30	+1255.3	71	+978.7	1.1	0.7	0.5	0.6	0.6	0.6	0.6	0.6	0.5	0.6	0.5	0.5
7 RANBAXY PHARM	19	-69.3	51	-68.0	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.6
8 MAJOR PHARM	5	-33.1	21	-24.2	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.2	0.2	0.2
9 MCKESSON PKG SERV	2	+117.7	6	+139.9	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
10 GENPHARM INC	114	-25.9	302	-28.0	0.0	0.1	0.1	0.3	0.6	2.2	4.7	4.8	4.5	4.5	4.5	4.4
11 GSMS INC.	0	-5.9	1	-3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 UNIT DOSE LABS	3	-57.3	7	-73.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1
13 DR REDDY'S LAB	4	+123.0	8	+48.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0
14 AMERICAN HLTH PKG	0	-24.8	1	-5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15 WATSON LABS	2	-75.8	4	-74.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1
Brand	20	-18.2	60	-20.0												
1 GSK PHARM	20	-18.2	60	-20.0	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.6
Generic Substitution %	99.5		99.5		99.6	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.5	99.4	99.4	99.4

Ribavirin (Copegus)

TAB, 200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	50	-15.0	114	-10.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	49	-11.9	111	-6.0												
1 TEVA PHARMACEUT	15	-21.2	32	-16.9	32.3	28.5	28.6	27.8	29.5	27.7	26.9	27.0	31.7	31.7	29.9	27.1
2 ZYDUS PHARM	12	+38.6	28	+65.3	24.7	24.4	24.8	24.7	23.4	26.5	33.0	31.3	22.9	21.4	22.8	23.5
3 THREE RIVERS PHARM	11	+110.7	23	+57.5	20.2	24.8	23.4	23.7	23.2	22.1	15.2	17.6	21.9	19.8	19.3	20.8
4 SANDOZ	5	+126.5	14	+144.7	12.4	12.3	12.3	12.1	10.5	11.6	13.9	13.1	10.2	13.0	13.0	11.7
5 MALLINCKRODT	5	+4.9	11	+9.8	9.2	8.8	9.8	10.0	11.2	10.2	8.7	8.5	10.4	10.6	10.6	10.5
6 PAR PHARM	1	-91.4	3	-90.8	1.3	1.2	1.2	1.7	2.1	1.9	2.4	2.6	2.9	3.5	4.4	6.4
Brand	2	-60.2	4	-62.2												
1 ROCHE	2	-60.2	4	-62.2	2.7	3.0	3.2	3.3	3.1	3.0	2.8	2.8	3.8	3.5	3.7	4.1
Generic Substitution %	97.0		96.8		97.3	97.0	96.8	96.7	96.9	97.0	97.2	97.2	96.2	96.5	96.3	95.9

Ribavirin (Rebetol)
CAP, 200 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	57	-7.9	138	-5.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	56	-6.0	136	-3.4												
1 SANDOZ	17	-37.7	41	-35.9	30.2	29.8	28.7	29.0	30.1	28.9	27.3	28.5	32.3	33.6	34.4	34.5
2 MALLINCKRODT	12	+65.7	30	+74.9	29.7	28.9	26.0	26.2	24.4	21.9	21.3	20.6	18.0	17.3	16.3	15.5
3 ZYDUS PHARM	16	+122.4	40	+165.9	22.1	22.8	25.5	24.9	25.9	32.2	38.4	35.4	27.9	26.5	27.6	27.1
4 THREE RIVERS PHARM	8	-42.4	18	-46.8	11.8	12.8	14.0	13.7	13.7	11.2	7.6	9.5	15.2	17.2	16.6	17.8
5 TEVA PHARMACEUT	3	+26.1	6	+15.6	5.7	4.9	5.1	5.4	5.1	5.1	4.9	5.2	5.2	3.5	3.4	3.3
6 WARRICK PHARM	0	-79.4	1	-79.6	0.2	0.5	0.5	0.6	0.6	0.7	0.5	0.6	1.2	1.7	1.6	1.8
Brand	1	-58.3	2	-60.7												
1 SCHERING	1	-58.3	2	-60.7	1.7	1.3	1.2	1.2	1.3	1.4	0.9	0.9	2.0	2.2	2.0	2.4
Generic Substitution %	98.4		98.5		98.3	98.7	98.8	98.8	98.7	98.6	99.1	99.1	98.0	97.8	98.0	97.6

Risperidone (Risperdal)

TAB, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	5,390	+1.1	10,895	-2.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,175		2,023													
1 TEVA PHARMACEUT	820	--	1,377	--	67.5	68.5	68.3	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2 PATRIOT PHARMA	355	--	646	--	32.5	31.5	31.7	95.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	4,215	-21.0	8,872	-20.3												
1 JANSSEN PHARM	4,215	-21.0	8,872	-20.3	15.3	18.3	40.7	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Generic Substitution %	21.8		18.6		84.7	81.7	59.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Gain in Share: Launched on June 30, 2008.

Ropinirole HCl (Requip)

TAB, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,831	+7.4	4,555	+8.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	690		1,451													
1 MYLAN	213	--	553	--	39.6	37.7	36.4	37.6	40.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2 TEVA PHARMACEUT	341	--	616	--	35.5	44.3	46.2	44.7	41.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0
3 ROXANE	83	--	195	--	10.5	12.5	14.1	15.4	17.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
4 COREPHARMA	27	--	61	--	7.5	4.9	3.3	2.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
5 WOCKHARDT AMERICA	25	--	26	--	6.9	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	1,141	-33.1	3,103	-26.3												
1 GSK PHARM	1,141	-33.1	3,103	-26.3	9.0	10.9	13.7	20.8	63.4	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Generic Substitution %	37.7		31.9		91.0	89.1	86.3	79.2	36.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Gain in Share: Launched lower 6 strengths on May 7, 2008. Launched 5mg on May 19, 2008.

Selenium Sulfide (Selsun)
TOP, 2.50 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	384	-5.2	527	-4.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	384	-5.2	526	-4.8												
1 PERRIGO	203	-8.2	291	-5.6	56.3	55.0	55.6	56.1	55.0	54.7	56.0	54.4	54.5	55.6	55.1	54.7
2 MORTON GROVE PHARM	111	-3.2	140	-5.7	25.9	27.0	26.5	26.2	26.9	27.3	25.9	26.6	27.1	26.4	26.7	27.0
3 TEVA PHARMACEUT	67	+7.3	91	+6.3	17.2	17.4	17.3	17.0	17.4	17.2	17.2	18.1	17.6	16.9	17.2	17.3
4 PHARMADERM	2	-61.6	3	-59.2	0.5	0.5	0.5	0.5	0.6	0.6	0.7	0.7	0.7	0.9	0.9	0.8
5 ACTAVIS	0	-48.0	1	-54.5	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.1	0.1
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Sertraline HCl (Zoloft)
 TAB, 25 mg, 50 mg, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	13,112	-2.0	33,152	+0.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	12,722	+2.3	32,116	+5.1												
1 GREENSTONE LTD	6,461	-4.1	15,979	-1.9	46.4	47.0	47.1	47.0	47.8	49.1	49.5	50.6	52.4	52.8	53.4	53.8
2 TEVA PHARMACEUT	4,397	-10.5	11,299	-8.2	33.3	33.5	36.6	37.3	37.0	35.7	35.7	35.4	35.2	34.4	34.3	33.8
3 LUPIN PHARMA	510	+143.5	1,292	+143.1	7.3	6.5	3.9	3.4	3.2	3.1	3.1	3.2	3.2	3.8	3.8	3.8
4 APOTEX CORP	639	+83.2	1,666	+91.4	5.7	5.5	5.3	5.4	5.3	5.2	5.2	5.1	5.1	5.0	4.7	4.7
5 MYLAN	238	+29238.6	593	+45603.7	2.7	3.1	3.0	3.0	2.9	2.9	2.6	1.7	0.2	0.0	0.0	0.0
6 COBALT LABS	69	+254.2	194	+242.7	1.0	1.0	1.0	1.0	0.9	0.4	0.3	0.3	0.3	0.3	0.3	0.3
7 AUROBINDO PHARM	68	+2.8	180	+7.7	0.8	0.7	0.4	0.4	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.6
8 RANBAXY PHARM	68	+359.2	181	+360.2	0.6	0.6	0.6	0.7	0.7	0.7	0.6	0.6	0.5	0.4	0.4	0.4
9 WEST WARD	65	+864.5	171	+946.9	0.6	0.6	0.5	0.4	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.4
10 CAMBER PHARM	19	--	45	--	0.5	0.4	0.3	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0
11 ACTAVIS	42	+68.0	117	+71.3	0.4	0.4	0.4	0.3	0.3	0.4	0.4	0.4	0.3	0.4	0.4	0.4
12 TORRENT PHARM	18	--	41	--	0.3	0.4	0.3	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
13 SANDOZ	41	-48.5	128	-26.9	0.1	0.1	0.2	0.2	0.3	0.3	0.3	0.3	0.4	0.5	0.7	1.2
14 BARR LABS	18	+61.8	52	+81.7	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.3	0.3
15 ROXANE	11	+65.9	20	+78.9	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1
16 WATSON LABS	55	+3612.6	153	+3392.2	0.0	0.1	0.1	0.1	0.2	0.8	1.0	0.9	0.9	0.9	0.6	0.2
17 AMERICAN HLTH PKG	3	+697.1	6	+1604.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	390	-58.5	1,036	-57.8												
1 PFIZER	390	-58.5	1,036	-57.8	2.6	2.8	2.8	2.9	2.9	3.0	3.1	3.2	3.3	3.5	3.7	3.8
Generic Substitution %	97.0		96.9		97.4	97.2	97.2	97.1	97.1	97.0	96.9	96.8	96.7	96.5	96.3	96.2

Silver Nitrate ()
TOP, 0.5 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Silver Nitrate ()	0.525	+4.6	0.590	-28.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	0.525	+4.6	0.590	-28.7												
1 TEVA PHARMACEU1	0.525	+4.6	0.590	-28.7	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Simvastatin (Zocor)

TAB, 5 mg,10 mg, 20 mg, 40 mg, 80 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	21,475	+39.9	62,714	+40.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	21,256	+48.1	62,056	+48.6												
1 TEVA PHARMACEUT	9,494	+18.6	27,620	+22.3	31.5	33.7	39.9	45.5	47.3	46.9	47.2	46.4	47.1	51.2	51.5	51.6
2 DR REDDY'S LAB	4,753	+31.1	14,917	+36.7	24.4	24.5	23.9	23.2	23.6	24.4	24.7	24.2	23.8	24.1	24.0	23.7
3 LUPIN PHARMA	2,860	+1825.4	5,725	+1252.2	22.4	20.1	13.6	7.6	6.5	6.6	5.8	5.0	5.0	4.5	4.4	4.3
4 AUROBINDO PHARM	2,092	+240.1	7,026	+257.1	13.1	13.0	13.0	13.3	12.4	11.5	11.6	12.5	11.3	7.6	7.2	7.2
5 RANBAXY PHARM	1,029	+7.3	3,587	+19.3	4.4	4.7	4.9	4.7	4.8	5.1	5.8	7.6	8.0	7.1	6.6	6.6
6 ZYDUS PHARM	624	+96.5	1,862	+139.4	3.1	2.9	3.4	4.2	4.0	3.9	3.0	2.2	2.1	2.0	2.2	2.4
7 COBALT LABS	117	+11.7	383	+19.6	0.5	0.5	0.5	0.4	0.4	0.5	0.6	0.8	0.8	0.8	0.8	0.9
8 MALLINCKRODT	126	-62.9	385	-62.0	0.4	0.5	0.7	0.7	0.7	0.8	0.8	0.6	0.6	0.6	0.6	0.6
9 SANDOZ	132	-37.2	470	-29.6	0.1	0.1	0.1	0.2	0.2	0.3	0.3	0.4	1.0	2.0	2.5	2.6
10 UNIT DOSE LABS	11	+26.7	26	+27.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0
11 PERRIGO	11	-51.7	37	-45.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1
12 BLU PHARM	0	--	1	--	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 AMERICAN HLTH PKG	4	+323.7	14	+304.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0
14 MARLEX PHARM	1	+5106.7	2	+5702.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15 MCKESSON PKG SERV	1	+8200.0	1	+8633.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	219	-77.9	659	-77.4												
1 MERCK & COMPANY	219	-77.9	659	-77.4	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.1	1.5	1.4	1.6
Generic Substitution %	99.0		98.9		99.1	99.1	99.1	99.1	99.1	99.1	99.1	99.0	98.9	98.5	98.6	98.4

Decline in Share: Lost Walgreens and Albertsons/Supervalu due to supply issues.

Sotalol HCl (Betapace)

TAB, 80 mg,120 mg, 160 mg, 240 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	584	-0.6	1,946	+2.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	579	-0.3	1,925	+2.9												
1 SANDOZ	228	+3.7	722	+12.4	37.2	37.1	37.1	37.5	37.8	38.2	38.3	37.7	36.7	37.3	37.6	37.5
2 TEVA PHARMACEUT	188	+5.6	635	+4.1	33.2	33.4	33.4	33.4	33.2	32.7	32.7	32.3	32.7	33.3	33.0	32.7
3 APOTEX CORP	57	+32.7	213	+29.6	12.5	12.1	11.9	11.3	10.7	10.7	10.5	11.6	12.0	10.3	9.8	9.4
4 PAR PHARM	72	-4.2	232	-6.4	11.6	11.7	11.8	11.9	12.2	12.3	12.3	12.2	12.2	12.1	12.1	12.4
5 QUALITEST PRODUCTS	21	+18.5	81	+20.9	3.9	3.9	3.9	4.0	4.2	4.1	3.9	4.0	4.1	4.7	4.8	4.8
6 MYLAN	5	-84.4	17	-82.5	0.7	0.8	0.8	0.8	0.8	0.8	0.9	1.0	1.1	1.0	1.0	1.1
7 UPSHER-SMITH	4	-47.1	18	-40.9	0.6	0.7	0.8	0.9	0.9	0.9	0.9	0.8	0.9	1.0	1.3	1.6
8 GLOBAL PHARM CORP	2	-23.9	5	-23.9	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
9 GSMS INC.	0	+105.0	1	+116.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 URL PHARMA	0	-72.2	1	-75.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Brand	5	-30.0	21	-26.8												
1 BAYER HEALTHCARE P	5	-30.0	21	-26.8	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.2	1.2	1.2	1.2
Generic Substitution %	99.1		98.9		99.0	99.0	99.0	99.0	99.0	99.0	98.9	98.9	98.8	98.8	98.8	98.8

Sucralfate (Carafate)

TAB, 1 g

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	798	+9.7	1,518	+9.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	795	+9.8	1,509	+10.0												
1 TEVA PHARMACEUT	557	+14.2	1,008	+14.1	63.3	63.7	63.8	63.4	64.9	66.5	69.2	69.9	69.9	69.9	69.4	68.9
2 WATSON LABS	174	-14.2	373	-11.3	30.2	31.6	30.3	26.8	23.7	21.8	20.0	19.6	20.2	21.1	23.6	25.9
3 NOSTRUM PHARM	55	+4631.2	109	+5491.5	5.7	3.9	5.1	8.9	10.5	10.5	9.6	9.1	8.4	7.3	5.2	3.1
4 MARTEC PHARM	3	-75.0	8	-74.6	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.7	0.8	0.9
5 UNIT DOSE LABS	1	-32.7	4	-35.2	0.1	0.1	0.2	0.1	0.1	0.3	0.3	0.4	0.3	0.3	0.3	0.3
6 MAJOR PHARM	1	-69.6	3	-70.8	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.3
7 SANDOZ	1	-65.2	1	-61.6	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
8 WARRICK PHARM	1	-77.2	2	-78.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3
9 MCKESSON PKG SERV	0	-64.4	1	-53.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.0
10 AMERICAN HLTH PKG	0	-66.7	1	-62.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1
Brand	4	-16.7	9	-19.4												
1 AXCAN SCANDIPHARM	4	-16.7	9	-19.4	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.7
Generic Substitution %	99.5		99.4		99.5	99.4	99.4	99.4	99.4	99.4	99.4	99.4	99.4	99.3	99.3	99.3

Decline in Share: Lost McKesson(OneStop) due to supply issues.

Sulfamethoxazole/Trimethoprim Susp (Septra)
LIQ, 200/40 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,582	+10.3	2,878	+8.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,582	+10.3	2,878	+8.2												
1 ACTAVIS	1,191	+39.3	1,323	+37.6	48.1	46.5	45.8	46.6	46.3	47.1	46.6	45.0	44.3	45.3	45.1	45.1
2 HI-TECH PHARMACAL	1,037	-26.2	1,163	-27.8	41.1	38.6	39.4	39.2	40.6	43.1	41.5	39.8	40.4	39.7	40.5	41.3
3 TEVA PHARMACEUT	350	+340.8	388	+342.3	10.5	14.8	14.7	14.2	13.1	9.8	11.8	15.0	15.1	14.7	14.3	13.6
4 QUALITEST PRODUCTS	3	+3664.0	3	+3507.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Tamoxifen Citrate (Tamoxifen Citrate (was Nolvadex))
TAB, 10 mg, 20 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	484	+1.2	1,791	-5.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	484	+1.3	1,791	-5.6												
1 TEVA PHARMACEUT	319	+5.6	1,092	-3.8	60.0	61.3	60.6	60.8	60.4	60.4	61.4	61.1	61.2	61.3	61.5	61.3
2 MYLAN	104	-3.3	430	-6.3	25.5	24.3	24.6	24.7	24.7	24.0	23.2	23.6	23.6	23.5	23.5	23.2
3 BARR LABS	60	-7.1	262	-8.1	14.3	14.2	14.5	14.2	14.6	15.2	15.0	14.9	14.8	14.6	14.5	15.0
4 ROXANE	2	-59.3	7	-59.1	0.2	0.2	0.2	0.2	0.3	0.4	0.4	0.4	0.5	0.5	0.5	0.6
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Terbinafine HCl (Lamisil)
TAB, 250 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,315	-2.1	2,144	+0.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,281	+315.3	2,088	+374.8												
1 APOTEX CORP	411	+314.5	668	+354.2	31.0	31.1	31.4	31.4	30.9	30.7	31.8	33.0	33.2	33.3	32.9	34.1
2 GLENMARK PHARMA	343	+231.8	540	+327.4	25.0	25.5	25.4	25.6	25.9	26.1	26.3	26.4	26.3	26.3	26.2	25.8
3 DR REDDY'S LAB	179	+452.2	302	+503.5	16.5	16.5	16.3	16.1	15.3	14.4	13.6	13.2	12.4	12.6	12.4	12.3
4 WOCKHARDT AMERICA	132	+441.2	211	+485.1	11.2	11.1	11.0	10.9	10.8	10.6	9.9	9.1	9.0	9.1	9.2	8.7
5 AUROBINDO PHARM	127	+343.4	215	+354.2	10.1	9.8	10.1	10.1	10.0	10.3	10.4	10.4	10.7	10.6	10.8	10.7
6 TEVA PHARMACEUT	13	+744.8	21	+891.2	1.5	1.3	0.9	0.8	0.9	1.0	1.0	1.0	1.0	0.9	0.9	0.8
7 HARRIS PHARM	16	+382.0	31	+330.7	1.5	1.4	1.4	1.4	1.5	1.4	1.4	1.4	1.6	1.6	1.8	1.8
8 ACTAVIS	25	+248.4	43	+264.6	1.1	1.1	1.1	1.2	2.0	2.7	2.7	2.7	2.8	2.8	2.7	2.7
9 SANDOZ	12	+449.7	20	+541.5	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.9
10 ROXANE	10	+295.8	16	+344.8	0.5	0.6	0.6	0.7	0.7	0.8	0.8	0.9	0.9	0.9	0.9	1.0
11 CAMBER PHARM	1	--	2	--	0.3	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 WATSON LABS	9	+176.3	15	+225.1	0.2	0.2	0.3	0.5	0.9	0.9	1.0	0.9	0.9	0.9	1.0	1.2
13 MYLAN	1	+1492.5	2	+1863.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
14 BARR LABS	1	+539.2	2	+625.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	33	-96.8	56	-96.7												
1 NOVARTIS RX	33	-96.8	56	-96.7	1.5	1.5	1.8	1.9	2.0	2.3	2.4	2.8	3.2	3.8	4.2	5.0
Generic Substitution %	97.5		97.4		98.5	98.5	98.2	98.1	98.0	97.7	97.6	97.2	96.8	96.2	95.8	95.0

Tetracycline HCl (Tetracycline HCl)
CAP, 250 mg, 500 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,192	-8.0	2,024	-9.1	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,192	-8.0	2,024	-9.1												
1 TEVA PHARMACEUT	1,075	-0.6	1,821	-1.6	91.1	91.2	91.2	90.9	90.9	90.5	90.4	90.0	89.7	88.8	88.3	87.3
2 BARR LABS	113	-45.4	196	-45.7	8.7	8.6	8.5	8.8	8.9	9.1	9.3	9.7	10.0	10.8	11.3	12.2
3 MYLAN	3	-50.3	5	-52.0	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.4	0.4
4 MAJOR PHARM	0	-62.6	1	-61.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Ticlopidine HCl (Ticlid)

TAB, 250 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	52	-8.3	169	-6.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	51	-7.7	166	-5.7												
1 TEVA PHARMACEUT	19	-1.6	68	-1.3	42.0	42.3	40.3	40.9	40.9	41.4	41.3	39.8	40.5	40.8	40.6	39.5
2 APOTEX CORP	17	-3.5	58	-2.0	34.9	34.9	35.4	34.8	35.4	34.6	34.2	35.4	34.9	34.4	34.2	35.0
3 CARACO PHARM	10	-8.0	29	-1.3	18.5	17.8	17.3	18.1	17.9	17.9	18.3	17.1	16.2	16.6	16.9	17.6
4 PAR PHARM	2	-45.0	6	-47.7	2.9	3.4	4.3	3.1	3.0	3.1	3.3	3.9	4.9	5.3	4.6	4.2
5 SANDOZ	2	-18.6	4	-24.9	1.5	1.4	2.4	2.8	2.3	2.7	2.5	3.5	3.3	2.6	3.4	3.4
6 MAJOR PHARM	0	-25.3	1	-30.7	0.3	0.3	0.3	0.3	0.4	0.3	0.4	0.3	0.2	0.3	0.3	0.3
Brand	1	-34.2	3	-34.8												
1 ROCHE	1	-34.2	3	-34.8	0.3	0.6	1.1	1.6	1.9	2.1	2.1	2.3	2.0	2.0	2.3	2.1
Generic Substitution %	98.4		98.3		99.7	99.4	98.9	98.4	98.1	97.9	97.9	97.7	98.0	98.0	97.7	97.9

**Tolmetin Sodium (Tolectin DS)
CAP, 400 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	14	-21.4	30	-17.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	14	-21.4	30	-17.5												
1 TEVA PHARMACEUT	13	-10.0	29	-6.2	95.3	94.3	95.6	95.3	95.0	94.0	94.3	94.3	93.0	93.5	92.3	91.9
2 MYLAN	1	-71.9	2	-72.2	4.5	5.4	4.3	4.5	4.7	5.8	5.5	5.5	6.8	6.3	7.4	7.8
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Torsemide (Demadex)
TAB, 5 mg,10 mg, 20 mg, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	751	-3.8	2,132	-4.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	736	-2.9	2,084	-3.8												
1 TEVA PHARMACEUT	334	+9.9	951	+6.6	47.5	47.5	46.7	45.9	46.0	46.1	45.6	45.8	45.8	45.2	43.8	42.1
2 PAR PHARM	132	-25.4	412	-22.7	19.2	19.1	19.4	19.8	19.7	19.0	19.0	19.1	19.2	19.6	19.7	24.0
3 BARR LABS	178	-20.4	470	-18.6	19.2	19.8	20.3	21.1	21.7	22.3	22.8	22.8	23.1	24.4	25.8	27.1
4 APOTEX CORP	78	+78.4	209	+56.7	12.1	11.5	11.3	11.0	10.5	10.5	10.6	10.5	10.1	9.0	8.9	5.0
5 ROXANE	13	+44.3	39	+47.8	2.0	2.0	2.1	2.1	2.0	1.9	1.9	1.7	1.6	1.6	1.8	1.8
6 UNIT DOSE LABS	1	-15.1	2	-12.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Brand	15	-31.8	48	-32.4												
1 ROCHE	15	-31.8	48	-32.4	2.0	2.0	2.1	2.1	2.1	2.1	2.2	2.3	2.4	2.5	2.6	2.6
Generic Substitution %	98.0		97.8		98.0	98.0	97.9	97.9	97.9	97.9	97.8	97.7	97.6	97.5	97.4	97.4

Gain in Share: Picked up Omnicare.

Tramadol HCl (Ultram)

TAB, 50 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	13,210	+16.3	21,243	+14.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	13,121	+16.6	21,047	+14.6												
1 AMNEAL PHARM	5,652	+1056.7	8,456	+904.1	44.4	44.5	44.1	44.0	43.6	42.8	42.1	41.2	40.0	37.3	33.1	23.7
2 TEVA PHARMACEUT	3,467	+23.3	5,395	+23.2	25.9	25.9	26.1	26.1	26.1	25.8	25.1	25.0	25.2	25.6	25.1	25.4
3 CARACO PHARM	1,952	+12.9	3,587	+11.6	14.0	14.1	14.2	14.6	15.2	17.0	17.8	17.4	17.4	19.6	21.9	22.4
4 APOTEX CORP	718	+183.9	1,262	+163.1	9.9	9.6	9.4	8.7	8.1	6.7	4.1	3.1	3.2	2.2	2.8	2.6
5 MYLAN	466	-62.4	792	-60.4	3.6	3.6	3.6	3.6	3.6	3.7	3.7	3.6	3.8	4.0	4.1	4.5
6 MUTUAL PHARM	442	+124.5	790	+124.2	0.9	1.0	1.2	1.4	1.7	2.3	5.1	6.7	6.6	6.5	6.5	6.3
7 MALLINCKRODT	83	-64.8	163	-68.6	0.6	0.6	0.6	0.6	0.7	0.7	0.8	0.8	0.9	1.0	1.0	1.1
8 BARR LABS	208	-94.8	358	-94.1	0.3	0.4	0.4	0.4	0.5	0.6	0.7	0.8	1.0	1.4	2.8	11.4
9 SANDOZ	117	-52.6	212	-55.2	0.2	0.3	0.3	0.3	0.3	0.4	0.5	1.1	1.8	2.2	2.5	2.6
10 UNIT DOSE LABS	5	-66.0	11	-64.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1
11 MAJOR PHARM	3	+20.5	7	+84.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
12 AMERICAN HLTH PKG	3	+45.4	5	+61.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
13 WATSON LABS	1	-86.3	3	-84.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
14 PAR PHARM	1	-68.3	2	-74.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
15 ACTAVIS	2	-64.7	4	-66.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	88	-14.9	195	-12.7												
1 MCNEIL PHARM	88	-14.9	195	-12.7	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9	1.0	1.1	1.0	1.0
Generic Substitution %	99.3		99.1		99.2	99.2	99.2	99.1	99.1	99.1	99.1	99.1	99.0	98.9	99.0	99.0

Trandolapril (Mavik)
TAB, 1 mg, 2 mg, 4 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	194	-25.0	717	-17.5	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	171	+47.4	620	+95.8												
1 TEVA PHARMACEUT	118	+7.4	422	+41.5	66.0	66.2	66.0	65.7	66.1	65.9	66.8	67.2	66.0	70.6	73.5	76.7
2 LUPIN PHARMA	45	+756.3	168	+955.3	29.8	29.6	29.5	29.6	28.8	28.8	27.8	27.4	26.3	25.6	22.9	20.4
3 WEST WARD	2	+912.2	7	+1570.8	1.2	1.3	1.2	1.2	1.1	1.1	1.2	1.2	1.1	0.9	0.9	0.6
4 SANDOZ	4	+578.4	14	+693.3	1.2	1.3	1.7	2.0	2.6	2.9	2.9	3.1	2.9	2.3	2.2	1.9
4 AUROBINDO PHARM	2	+4287.0	6	+5955.1	1.2	1.2	1.1	1.1	1.1	0.9	0.8	0.7	3.3	0.4	0.4	0.3
6 COBALT LABS	0	+2022.7	2	+2340.7	0.3	0.3	0.4	0.4	0.4	0.4	0.5	0.5	0.4	0.1	0.1	0.1
Brand	24	-83.6	97	-82.4												
1 ABBOTT PHARM PRODS	24	-83.6	97	-82.4	8.6	9.1	9.5	10.3	10.7	11.3	12.2	14.3	16.2	18.1	19.1	20.3
Generic Substitution %	87.9		86.4		91.4	90.9	90.5	89.7	89.3	88.7	87.8	85.7	83.8	81.9	80.9	79.7

Decline in Share: Competition entered. Gave up Wal-Mart, CVS and Kroger.

Trazodone HCl (Deseryl)
TAB, 50 mg,100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	6,870	+4.9	15,094	+3.3	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	6,870	+5.0	15,093	+3.3												
1 BARR LABS	4,645	+4.2	10,107	+0.2	63.8	63.8	63.9	64.5	65.5	66.2	66.5	68.0	68.6	68.8	71.2	73.1
2 APOTEX CORP	1,598	+100.1	3,544	+107.8	27.6	27.4	26.8	24.5	23.2	22.9	22.5	22.0	21.7	21.1	20.9	20.8
3 TEVA PHARMACEUT	373	+652.4	893	+713.4	7.2	7.4	7.2	7.2	7.0	6.7	6.7	5.7	5.3	5.8	3.4	1.3
4 WATSON LABS	193	-83.2	415	-83.3	0.6	0.7	1.4	3.0	3.4	3.4	3.4	3.4	3.4	3.4	3.5	3.7
5 MAJOR PHARM	31	+9.5	73	+1.8	0.4	0.3	0.4	0.5	0.4	0.4	0.5	0.6	0.6	0.5	0.6	0.6
6 MUTUAL PHARM	24	-39.1	50	-42.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4
7 MCKESSON PKG SERV	2	-63.8	5	-39.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
8 UNIT DOSE LABS	1	-87.0	2	-92.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
9 ACTAVIS	1	-75.3	2	-77.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
10 URL PHARMA	1	-87.3	2	-86.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
11 SANDOZ	0	-31.5	1	-42.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Gain in Share: Picked up ESI and Omnicare.

Triamcinolone Acetonide (Kenalog)
OINT, 0.1 %, 0.5 %

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	1,393	+9.0	1,860	+8.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	1,167	+9.2	1,537	+8.3												
1 FOUGERA	580	+17.0	769	+15.9	50.0	49.6	50.0	49.8	50.0	50.1	50.0	50.2	50.6	50.3	50.2	49.2
2 ACTAVIS	517	+2.6	668	+1.6	43.6	44.2	43.6	43.9	43.6	43.4	43.4	42.9	42.7	42.8	43.2	44.2
3 TEVA PHARMACEUT	67	+3.5	97	+3.8	6.3	6.1	6.3	6.1	6.2	6.3	6.3	6.7	6.4	6.6	6.4	6.4
4 CAROLINA MED PROD	2	-15.7	2	-11.4	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2
Brand	226	+8.1	322	+6.3												
1 PERRIGO	226	+8.1	322	+6.3	17.8	17.3	17.3	17.2	17.1	17.3	17.1	17.4	17.4	17.4	17.1	17.6
Generic Substitution %	83.8		82.7		82.2	82.7	82.7	82.8	82.9	82.7	82.9	82.6	82.6	82.6	82.9	82.4

Triamterene/HCTZ (Dyazide)
CAP, 25/50 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	161	-11.2	571	-11.9	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	161	-11.2	571	-11.9												
1 SANDOZ	108	-24.4	391	-23.7	68.5	68.6	68.6	68.7	68.7	68.1	68.2	68.5	68.3	68.8	68.6	69.0
2 TEVA PHARMACEUT	54	+36.8	179	+33.0	31.5	31.4	31.4	31.3	31.3	31.9	31.8	31.5	31.7	31.2	31.4	31.0
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

**Trimethoprim (Proloprim)
TAB, 100 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	140	-2.8	342	+0.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	140	-2.8	342	+0.8												
1 TEVA PHARMACEUT	108	+66.7	263	+80.1	73.5	73.6	74.4	75.2	76.7	80.6	82.1	80.8	79.7	77.4	76.6	74.4
2 WATSON LABS	31	-60.3	78	-59.4	26.5	26.4	25.6	24.8	23.3	19.4	17.9	19.2	20.3	22.6	23.4	25.6
Generic Substitution %	100.0		100.0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

**Ursodiol (Actigall)
CAP, 300 mg**

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	213	+5.8	617	+5.2	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	211	+6.1	609	+5.6												
1 TEVA PHARMACEUT	135	+8.7	383	+8.6	60.8	63.8	65.3	65.6	63.3	62.7	62.3	62.3	61.7	62.1	62.0	61.3
2 WATSON LABS	26	-17.8	83	-18.1	20.5	17.0	13.0	11.6	11.8	12.3	12.5	12.4	12.7	12.5	12.9	13.5
3 RISING PHARM	12	+92.7	38	+97.2	12.2	11.2	9.9	6.2	3.1	3.3	3.9	4.7	5.6	5.2	4.8	4.4
4 ACTAVIS	36	+3.6	104	+2.1	6.4	7.8	11.4	16.3	21.6	21.4	21.0	20.3	19.7	19.8	20.0	20.5
5 UNIT DOSE LABS	1	-28.5	2	-17.3	0.1	0.2	0.3	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Brand	2	-19.5	8	-18.4												
1 WATSON LABS	2	-19.5	8	-18.4	1.2	1.4	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.4
Generic Substitution %	99.0		98.7		98.8	98.6	98.8	98.8	98.8	98.8	98.8	98.8	98.7	98.7	98.7	98.6

Valproic Acid (Depakene)
CAP, 250 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	153	+6.3	361	+5.0	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	152	+6.5	357	+5.2												
1 UPSHER-SMITH	66	+3.8	160	+0.7	39.5	40.3	42.1	43.7	45.3	46.5	46.3	46.3	46.1	46.6	46.7	47.2
2 WATSON LABS	48	+6.3	102	+10.0	29.4	30.1	29.9	29.6	28.9	28.2	27.7	28.3	27.7	27.6	27.1	27.2
3 BARR LABS	34	+16.4	86	+14.4	28.9	27.2	25.3	24.0	23.2	22.5	22.9	22.5	23.2	22.8	23.0	22.4
4 TEVA PHARMACEUT	3	-23.1	7	-28.0	1.6	1.7	1.9	2.0	2.0	2.2	2.1	2.0	2.1	2.2	2.1	2.2
5 UNIT DOSE LABS	1	+11.5	3	-14.0	0.5	0.6	0.6	0.5	0.5	0.6	0.8	0.8	0.7	0.8	1.1	0.9
Brand	1	-16.4	4	-12.4												
1 ABBOTT PHARM PRODS	1	-16.4	4	-12.4	1.0	1.0	1.0	1.2	1.1	1.0	1.2	1.1	1.1	1.3	1.1	1.2
Generic Substitution %	99.3		98.9		99.0	99.0	99.0	98.8	98.9	99.0	98.8	98.9	98.9	98.7	98.9	98.8

Valproic Acid (Depakene)
LIQ, 250 mg/5ml

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	187	-1.4	616	-0.7	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	183	-1.1	600	-0.4												
1 MORTON GROVE PHARM	97	-4.9	361	-3.4	60.7	60.7	60.1	60.0	59.1	59.2	59.5	59.5	59.9	60.0	60.8	61.2
2 TEVA PHARMACEUT	35	+22.0	100	+20.8	17.6	17.7	17.6	17.1	17.0	16.8	16.7	16.7	16.5	16.2	15.5	15.4
3 WATSON LABS	26	-4.1	63	-1.9	10.3	10.4	10.6	10.8	10.8	10.7	10.6	10.6	10.7	10.6	10.4	9.9
4 PHARMACEUT ASSOC	14	-16.9	42	-19.5	5.3	5.1	5.4	6.1	6.5	7.0	7.5	8.1	7.9	8.1	8.1	8.2
5 HI-TECH PHARMACAL	8	-17.2	22	-12.0	3.3	3.5	3.6	3.4	3.5	4.3	4.0	3.8	3.6	3.8	3.8	3.9
6 QUALITEST PRODUCTS	3	+122.7	12	+141.6	2.7	2.5	2.5	2.6	3.0	1.9	1.7	1.3	1.4	1.3	1.3	1.3
Brand	4	-12.0	15	-10.7												
1 ABBOTT PHARM PRODS	4	-12.0	15	-10.7	2.3	2.3	2.4	2.5	2.5	2.4	2.5	2.5	2.6	2.7	2.7	2.7
Generic Substitution %	97.7		97.5		97.7	97.7	97.6	97.5	97.5	97.6	97.5	97.5	97.4	97.3	97.3	97.3

Venlafaxine HCl (Effexor)

TAB, 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	932	+19.3	2,126	+22.8	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	907	+27.7	2,071	+31.8												
1 TEVA PHARMACEUT	848	+19.4	1,942	+23.6	70.0	76.5	87.6	99.2	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
2 MYLAN	39	--	80	--	18.8	14.6	7.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
3 DR REDDY'S LAB	12	--	25	--	5.8	4.4	2.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
4 ZYDUS PHARM	8	--	25	--	5.4	4.5	2.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	25	-65.3	55	-65.7												
1 WYETH-AYERST	25	-65.3	55	-65.7	1.7	1.8	1.9	2.1	2.2	2.4	2.5	2.6	3.0	3.6	3.9	4.1
Generic Substitution %	97.4		97.4		98.3	98.2	98.1	97.9	97.8	97.6	97.5	97.4	97.0	96.4	96.1	95.9

Decline in Share: Competition entered June 2008. Gave up ABC(Progen), CVS and Kroger.

Verapamil HCl (Isoptin SR)
MR TAB, 120 mg, 180 mg, 240 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	2,154	-11.5	7,521	-11.4	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	2,152	-11.5	7,515	-11.3												
1 MYLAN	1,174	-18.4	4,026	-17.8	51.8	52.3	52.6	52.9	53.1	53.5	53.5	53.8	53.9	54.7	54.9	55.2
2 TEVA PHARMACEUT	944	+5.4	3,353	+4.2	44.5	44.9	45.2	45.2	45.4	45.3	45.2	45.0	44.7	43.7	43.4	43.0
3 RANBAXY PHARM	9	--	39	--	2.6	1.7	1.1	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
4 PFIZER	19	-28.8	73	-24.4	0.9	1.0	0.9	0.9	1.0	0.9	1.0	1.0	1.0	1.0	1.0	1.0
5 UNIT DOSE LABS	2	-42.7	8	-39.8	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
6 PAR PHARM	4	-94.0	17	-93.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.3	0.4	0.5	0.6
Brand	2	-51.2	6	-59.7												
1 RANBAXY PHARM	2	-51.2	6	-59.7	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Generic Substitution %	99.9		99.9		99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9

Zaleplon (Sonata)
CAP, 5 mg,10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	431	-23.4	734	-23.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	77		124													
1 COREPHARMA	26	--	42	--	42.3	45.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2 ROXANE	26	--	44	--	28.6	28.0	56.2	67.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
3 TEVA PHARMACEUT	24	--	37	--	28.3	26.2	42.8	32.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	354	-37.1	611	-36.4												
1 KING PHARM	354	-37.1	611	-36.4	17.7	20.2	64.7	87.4	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Generic Substitution %	17.9		16.8		82.3	79.8	35.3	12.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Gain in Share: Launched on June 6, 2008.

Zolpidem Tartrate (Ambien)
TAB, 5 mg,10 mg

	NRx MAT (000s)	NRx MAT Chg %	TRx MAT (000s)	TRx MAT Chg %	Sep 08 %	Aug 08 %	Jul 08 %	Jun 08 %	May 08 %	Apr 08 %	Mar 08 %	Feb 08 %	Jan 08 %	Dec 07 %	Nov 07 %	Oct 07 %
Total Market	15,779	+19.9	29,572	+26.6	TRx Market Share (% of Generics for Generics, % of Total for Brand)											
Generic	15,142	+168.2	28,253	+201.1												
1 TEVA PHARMACEUT	6,671	+159.4	11,927	+199.1	42.2	42.6	42.5	42.2	42.1	42.1	42.2	42.3	42.3	42.0	42.1	41.8
2 APOTEX CORP	2,742	+821.0	5,179	+1079.4	22.6	22.7	23.4	23.2	22.4	20.7	20.2	19.6	18.4	13.0	5.2	4.9
3 DR REDDY'S LAB	1,542	+306.8	2,982	+349.6	13.8	13.0	12.1	11.9	11.2	11.3	11.2	10.4	8.0	7.4	7.4	7.5
4 SANDOZ	986	+178.5	1,793	+219.6	6.0	6.2	6.1	6.2	6.4	6.3	6.4	6.5	6.5	6.7	6.5	6.5
5 RANBAXY PHARM	195	+408.3	377	+466.0	4.1	3.4	1.4	0.8	0.7	0.7	0.8	0.8	0.8	0.7	0.7	0.6
6 MYLAN	997	+63.9	2,017	+84.6	3.5	3.9	5.8	6.6	6.7	6.8	7.0	7.3	7.7	8.9	11.4	11.7
7 TORRENT PHARM	49	--	96	--	1.8	1.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
8 CARACO PHARM	420	+55.8	877	+70.4	1.5	1.5	1.8	1.8	2.3	2.2	2.2	2.8	5.0	5.7	5.7	5.7
9 WOCKHARDT AMERICA	126	+483446.2	257	+547095.7	1.4	1.6	1.6	1.5	1.4	1.4	1.1	0.4	0.1	0.0	0.0	0.0
10 PRASCO LABS	766	-0.8	1,457	+3.8	1.4	1.6	2.5	3.2	3.4	3.5	3.6	3.7	4.4	8.8	14.2	14.3
11 ACTAVIS	319	+112.7	622	+133.0	0.8	0.9	1.0	1.1	1.6	3.0	3.1	3.1	3.1	3.1	3.1	3.1
12 ROXANE	51	+185.3	99	+222.2	0.3	0.4	0.4	0.5	0.4	0.4	0.4	0.3	0.3	0.2	0.2	0.3
13 SYNTHON PHARM	43	+1879.0	83	+2134.3	0.2	0.2	0.2	0.2	0.2	0.3	0.4	0.4	0.4	0.4	0.3	0.2
14 AUROBINDO PHARM	42	+306.1	83	+358.2	0.2	0.2	0.2	0.3	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3
15 WATSON LABS	146	+1.2	306	+9.3	0.2	0.2	0.2	0.3	0.3	0.4	0.7	1.6	2.1	2.3	2.6	2.6
16 GENPHARM INC	21	+65.0	44	+90.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
17 MUTUAL PHARM	23	+25.6	45	+39.4	0.0	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2
18 AMERICAN HLTH PKG	1	--	1	+13309.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
19 UNIT DOSE LABS	2	+1400.0	3	+1608.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20 GLENMARK PHARMA	2	--	4	--	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
21 DISPENSING SOLUTIO	0	--	1	--	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brand	637	-91.5	1,319	-90.6												
1 SANOFI AVENTIS PHR	637	-91.5	1,319	-90.6	3.3	3.5	3.6	3.8	3.9	4.1	4.3	4.6	5.0	5.7	5.9	6.2
Generic Substitution %	96.0		95.5		96.7	96.5	96.4	96.2	96.1	95.9	95.7	95.4	95.0	94.3	94.1	93.8

WEEKLY REPORTS

DIVALPROEX
125mg, 250mg & 500mg Delayed-Release Tablets

	NRx July - Sept. 2008	TRx July - Sept. 2008	TRx Market Share (% of Total)													
			Week of 9/26	Week of 9/19	Week of 9/12	Week of 9/05	Week of 8/29	Week of 8/22	Week of 8/15	Week of 8/08	Week of 8/01	Week of 7/25	Week of 7/18	Week of 7/11	Week of 7/04	
DIVALPROEX	564,172	1,122,957														
GENERIC	292,571	466,750	100.0%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
TEVA PHARMACEUTICA	125,923	179,368	37.3%	37.2%	37.7%	37.3%	38.3%	39.0%	39.7%	43.7%	49.3%	0.0%	0.0%	0.0%	0.0%	0.0%
SUN PHARMACEUTICAL	48,380	85,030	19.5%	20.7%	20.6%	19.5%	18.8%	17.4%	14.8%	9.1%	6.8%	0.0%	0.0%	0.0%	0.0%	0.0%
SANDOZ	70,241	113,679	19.9%	21.6%	22.9%	25.1%	24.5%	26.5%	28.6%	30.3%	14.6%	0.0%	0.0%	0.0%	0.0%	0.0%
UPSHER-SMITH	14,496	24,826	7.7%	6.5%	5.1%	4.9%	4.9%	4.5%	3.9%	3.5%	7.0%	0.0%	0.0%	0.0%	0.0%	0.0%
APOTEX CORP	22,118	43,022	9.7%	9.2%	9.2%	8.9%	9.4%	8.8%	9.0%	9.4%	15.7%	0.0%	0.0%	0.0%	0.0%	0.0%
LUPIN PHARMA	10,814	19,568	4.7%	4.3%	4.3%	4.2%	4.1%	3.9%	3.8%	3.9%	6.5%	0.0%	0.0%	0.0%	0.0%	0.0%
DR REDDY'S LAB	598	1,256	1.2%	0.4%	0.2%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
WOCKHARDT AMERICA	1	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
BRAND																
ABBOTT PHARM PRODS	271,601	656,207	21.8%	22.9%	25.1%	28.1%	29.1%	31.4%	36.8%	63.4%	98.5%	100.0%	100.0%	100.0%	100.0%	100.0%
GENERIC SUBSTITUTION	51.9%	41.6%	78.2%	77.1%	74.9%	71.9%	70.9%	68.6%	63.2%	36.6%	1.5%	0.0%	0.0%	0.0%	0.0%	0.0%

DOXYCYCLINE
25mg/5mL for Oral Suspension

	NRx July - Sept. 2008	TRx July - Sept. 2008	TRx Market Share (% of Total)													
			Week of 9/26	Week of 9/19	Week of 9/12	Week of 9/05	Week of 8/29	Week of 8/22	Week of 8/15	Week of 8/08	Week of 8/01	Week of 7/25	Week of 7/18	Week of 7/11	Week of 7/04	
DOXYCYCLINE GENERIC	1,181 311	1,402 341	100.0%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
TEVA PHARMACEUTICA BRAND	311	341	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
PFIZER	870	1,061	43.5%	46.1%	45.8%	48.1%	60.8%	64.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
GENERIC SUBSTITUTION	26.3%	24.3%	56.5%	53.9%	54.2%	51.9%	39.2%	35.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

LAMOTRIGINE
25mg, 100mg, 150mg & 200mg Tablets

	NRx July - Sept. 2008	TRx July - Sept. 2008	TRx Market Share (% of Total)													
			Week of 9/26	Week of 9/19	Week of 9/12	Week of 9/05	Week of 8/29	Week of 8/22	Week of 8/15	Week of 8/08	Week of 8/01	Week of 7/25	Week of 7/18	Week of 7/11	Week of 7/04	
LAMOTRIGINE GENERIC	1,245,953 670,295	2,258,510 1,043,652	100.0%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
TEVA PHARMACEUTICA BRAND	670,295	1,043,652	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%	0.0%
GSK PHARM	575,658	1,214,858	28.7%	28.5%	28.9%	31.0%	31.0%	30.3%	31.6%	38.5%	57.8%	98.3%	100.0%	100.0%	100.0%	100.0%
GENERIC SUBSTITUTION	53.8%	46.2%	71.3%	71.5%	71.1%	69.0%	69.0%	69.7%	68.4%	61.5%	42.2%	1.7%	0.0%	0.0%	0.0%	0.0%